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ABSTRACT 
Osteoarthritis (OA) is the most common joint disease and one of the leading 
causes of disability worldwide. The hallmark of the pathogenesis of OA is 
cartilage degradation, which is driven by an imbalance between the production of 
catabolic, anabolic and inflammatory factors within the joint. Chondrocytes are 
considered to be essential in this reaction, and during OA they produce increased 
amounts of inflammatory and catabolic agents, such as matrix degrading 
enzymes, reactive oxygen species, cytokines and growth factors. There is 
currently no disease-modifying drug treatment available to prevent or retard the 
progression of OA. In order to develop improved treatment modalities, 
identification of novel drug targets, and a better understanding of the molecular 
pathways involved in the pathogenesis of OA are imperative. 
Transient receptor potential ankyrin 1 (TRPA1) is a membrane bound ligand-
gated cation channel, which has primarily been studied in sensory neurons for its 
roles in pain and neurogenic inflammation. TRPA1 was initially found to function 
as a chemosensor for potentially harmful exogenous compounds. However, more 
recent studies indicate that it can possibly also be expressed in tissue cells and be 
activated by endogenous factors formed during inflammation and hypoxia. Due 
to these new findings, we hypothesized that TRPA1 may also be expressed and 
functional in nonneuronal cells, particularly in chondrocytes, within the OA joint. 
The aim of the present study was to examine the expression and effects of 
TRPA1 in chondrocytes and cartilage, in order to produce novel data on the 
factors involved in the pathogenesis of OA, and ultimately to assess the potential 
of TRPA1 as a novel drug target in OA. In addition, the effects of anti-
inflammatory drugs on TRPA1 expression were investigated. We utilized 
cartilage and chondrocytes from OA patients undergoing knee replacement 
surgery, immortalized human T/C28a2 chondrocytes, as well as cartilage and 
chondrocytes from TRPA1 knock-out and corresponding wild-type mice. 
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TRPA1 was discovered to be functionally expressed in human OA 
chondrocytes and an immortalized chondrocyte cell line. The expression of 
TRPA1 was increased following stimulation with OA-related inflammatory 
factors, most notably the cytokine interleukin (IL)-1β, which is traditionally 
considered one of the significant inflammatory mediators driving the 
pathogenesis of OA. TRPA1 was shown to be involved in the upregulation of 
inflammatory and catabolic factors IL-6, IL-11, leukemia inhibitory factor (LIF), 
fibroblast growth factor (FGF)-2, matrix metalloproteinase (MMP)-1, MMP-3, 
MMP-13, and prostaglandin E2 in chondrocytes/cartilage. The effects of FGF-2 
in cartilage and chondrocytes were also examined further, and FGF-2 was shown 
to exert catabolic and anti-anabolic effects, which were reversed by specific FGF 
receptor antagonists. Additionally, the clinically used anti-inflammatory drugs 
dexamethasone and aurothiomalate, as well as inhibition of the transcription 
factor NF-κB, downregulated the expression of TRPA1 in chondrocytes. 
This is the first study to show the expression of a functional TRPA1 channel 
in chondrocytes. The enhanced expression of TRPA1 by OA-related 
inflammatory mediators, and the TRPA1-mediated increase in the production of 
pro-inflammatory and catabolic factors in chondrocytes and cartilage, point to a 
detrimental role for TRPA1 in the pathogenesis of OA. Further, the clinically used 
anti-inflammatory drugs dexamethasone and aurothiomalate decreased the 
expression of TRPA1 in chondrocytes, suggesting that TRPA1 may already be a 
previously unidentified target of anti-inflammatory drug treatment. Taken 
together, this study has produced novel data on the inflammatory factors involved 
in the pathogenesis of OA and presents TRPA1 as a potential novel target for 
future drug development. Additionally, this thesis has produced valuable 
information on the nonneuronal expression of TRPA1, expanding our knowledge 
of this multifunctional ion channel.  
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TIIVISTELMÄ 
Nivelrikko on merkittävä kipua aiheuttava ja toimintakykyä heikentävä sairaus. 
Nivelrikko on koko nivelen sairaus, jossa rusto vaurioituu ja häviää lopulta 
kokonaan erityisesti kantavilta nivelpinnoilta. Tämä johtuu anabolisten, 
katabolisten ja tulehduksellisten tekijöiden epätasapainosta nivelrikkorustossa. 
Rustosolut ovat nivelrikossa merkittävässä osassa tuottaen tulehduksellisia ja 
katabolisia tekijöitä, kuten rustomatriksia hajottavia entsyymejä, reaktiivisia 
happiyhdisteitä, sytokiineja sekä kasvutekijöitä. Nivelrikon etiologia tunnetaan 
huonosti, eikä aktiivisesta tutkimustyöstä huolimatta ole onnistuttu kehittämään 
taudin etenemistä estävää tai hidastavaa lääkehoitoa. Nivelrikon kulkua 
hidastavien lääkeaineiden kehityksen kannalta on tärkeää saada uutta tietoa 
nivelrikkoon johtavista molekyylitason mekanismeista, sekä tunnistaa uusia 
lääkevaikutuskohteita. 
TRPA1 (engl. transient receptor potential ankyrin 1) on solukalvolla ilmentyvä 
ionikanava. TRPA1:tä on pääasiassa tutkittu sensorisissa neuroneissa, joissa se 
välittää kipua ja neurogeenista tulehdusta. TRPA1:n fysiologisena tehtävänä on 
toimia aistinreseptorina useille elimistölle haitallisille kemiallisille ärsykkeille. 
Tämän lisäksi TRPA1:n on hiljattain havaittu aktivoituvan myös joidenkin 
tulehdusreaktioissa ja hypoksiassa syntyvien molekyylien vaikutuksesta. Nämä 
olosuhteet ovat nivelrikkorustolle ominaisia, eikä rustossa ole hermosoluja, joten 
syntyi uusi näkökulma TRPA1 tutkimukseen: voisiko TRPA1 ilmentyä 
hermosolujen lisäksi myös rustosoluissa.  
Tämän tutkimuksen tarkoituksena oli tutkia TRPA1-ionikanavan 
ilmentymistä ja vaikutuksia rustosoluissa sekä rustokudoksessa. Tavoitteena oli 
tuottaa uutta tietoa nivelrikon tautimekanismeihin liittyvistä tekijöistä, sekä 
selvittää TRPA1:n mahdollista roolia lääkevaikutuskohteena nivelrikossa. 
Lisäksi tutkittiin farmakologisten inhibiittorien sekä tulehdusta estävien 
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lääkeaineiden vaikutuksia TRPA1:n ilmentymiseen. Tutkimuksessa 
hyödynnettiin nivelrikkopotilailta tekonivelleikkauksen yhteydessä poistettavaa 
rustokudosta ja siitä eristettyjä rustosoluja, ihmisen rustosolulinjasoluja sekä 
TRPA1 poistogeenisiltä hiiriltä ja vastaavilta villityypin hiiriltä eristettyä 
rustokudosta ja rustosoluja.   
Tutkimuksen tulokset osoittivat funktionaalisen TRPA1-ionikanavan 
ilmentyvän ihmisen nivelrikkorustosoluissa sekä rustosolulinjan soluissa. 
TRPA1:n ilmentyminen lisääntyi, kun soluja stimuloitiin nivelrikon patogeneesin 
kannalta keskeisillä tulehdustekijöillä, kuten interleukiini (IL)-1:llä. TRPA1:n 
havaittiin välittävän usean tulehduksellisen ja kataboliaan liittyvän tekijän tuottoa 
rustosoluissa/rustokudoksessa. TRPA1:n estäminen vähensi sytokiinien IL-6, IL-
11 ja LIF (engl. leukemia inhibitory factor), fibroblastikasvutekijä-2:n (FGF-2:n), 
prostaglandiini E2:n (PGE2:n), sekä rustokudosta hajottavien 
matriksimetalloproteinaasi (MMP)-1, MMP-3 sekä MMP-13 entsyymien tuottoa. 
Tutkittaessa tarkemmin FGF-2:n vaikutuksia rustossa ja rustosoluissa, havaittiin 
sillä olevan rustokudokselle haitallisia katabolisia ja anti-anabolisia vaikutuksia. 
Lisäksi tulehdusta vaimentavat lääkkeet deksametasoni ja aurotiomalaatti estivät 
TRPA1-kanavan ilmentymistä ihmisen rustosoluissa. 
Tämä on ensimmäinen tutkimus, jossa on osoitettu funktionaalisen TRPA1-
ionikanavan ilmentyvän rustosoluissa. Tutkimuksen tulokset osoittivat TRPA1:n 
ilmentymisen lisääntyvän nivelrikkonivelelle tyypillisten tulehdustekijöiden 
vaikutuksesta, sekä TRPA1:n välittävän useiden tulehduksellisten ja katabolisten 
tekijöiden tuottoa rustosoluissa/rustossa. Tulokset viittaavat siihen, että TRPA1 
voi välittää nivelrustovaurioita edistäviä vaikutuksia nivelrikkonivelessä. Tämä 
tutkimus on tuottanut uutta tietoa nivelrikon tautimekanismeista sekä uudesta 
mahdollisesta lääkevaikutuskohteesta. Lisäksi tämän väitöskirjan 
tutkimustulokset tuovat uutta arvokasta tietoa TRPA1:n ilmentymisestä 
hermoston ulkopuolella.  
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1 INTRODUCTION 
Osteoarthritis (OA) is the leading cause of musculoskeletal disability and pain 
worldwide (Hunter et al. 2019; Mobasheri and Batt 2016). OA is traditionally a 
late-onset disease. The incidence of knee OA is reported to peak at around 60 
years of age, affecting around 10% of men and 18% of women over the age of 60 
(Arokoski et al. 2007; Losina et al. 2013). The global prevalence of OA is 
estimated to keep rising due to the world’s aging population, presenting a 
significant and mounting socioeconomic burden on communities (Hunter et al. 
2019; Hunter et al. 2014). 
OA is a slowly progressing disease, which ultimately leads to the degradation 
of cartilage from articular surfaces. According to current knowledge, a key feature 
of OA pathogenesis is the development of an inflammatory and hypoxic state 
within the joint (Berenbaum 2013; Glyn-Jones et al. 2015). Increased production 
of inflammatory mediators drives cartilage degradation by shifting the balance of 
catabolic and anabolic responses towards catabolism. Chondrocytes, the only 
cells expressed in cartilage, are considered to be essential in this reaction. During 
OA progression, the normally quiescent chondrocytes are activated to produce 
increased amounts of inflammatory and catabolic agents, such as cytokines, 
growth factors, matrix degrading enzymes and reactive oxygen species (Goldring 
2012a; Lepetsos and Papavassiliou 2016; van der Kraan and van den Berg 2012). 
There are currently no disease modifying drugs available to prevent or retard 
the progression of OA. Treatment is based on alleviation of pain, improving joint 
function and preventing disability by pharmacological and non-pharmacological 
means. In most severe cases, joint replacement surgery is utilized as the last-line 
treatment. Therefore, there is an urgent need for the development of disease-
modifying OA drugs (DMOADs). Important aspects for the successful 
development of novel therapies are an increased understanding of the mediators 
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and molecular pathways involved in the pathogenesis of OA as well as the 
identification of novel drug targets. 
Transient receptor potential ankyrin 1 (TRPA1) is a membrane-bound ligand-
gated ion channel, which was discovered in 1999 (Jaquemar et al. 1999). Since 
then, the expression and function of TRPA1 has primarily been studied in sensory 
neurons, where it functions as a chemosensor for potentially harmful exogenous 
compounds, and mediates pain, nociception and neurogenic inflammation (Nilius 
et al. 2012; Zygmunt and Högestätt 2014). In addition to its wide expression in 
neurons, the expression of TRPA1 has also been shown in some nonneuronal 
cells, such as keratinocytes and synoviocytes (Jain et al. 2011; Yin et al. 2018). 
Intriguingly, endogenous factors produced in inflammatory and hypoxic 
conditions, such as those found in OA joints, can also activate TRPA1, leading to 
increased production of inflammatory factors by the activated cells. 
Due to its multiple functions in mediating pain and inflammation, TRPA1 has 
attracted considerable interest as a potential drug target for painful and 
inflammatory conditions (Chen, J. and Hackos 2015; Koivisto et al. 2018; Moran 
2018). Very recently, the potential role of TRPA1 as a mediator and drug target 
in inflammatory arthritidies has also began to raise interest (Galindo et al. 2018). 
Accordingly, TRPA1 has been shown to mediate pain, inflammation and cartilage 
degradation in experimental models of OA (Horvath et al. 2016; McGaraughty et 
al. 2010; Moilanen, Hämäläinen, Nummenmaa et al. 2015b), and further studies 
are needed to elucidate the exact mechanisms behind these effects. 
The aim of the present study was to investigate the expression and effects of 
TRPA1 in human osteoarthritic chondrocytes and cartilage, with the ultimate goal 
of expanding our knowledge on the factors involved in the pathogenesis of OA, 
as well as exploring the potential of TRPA1 as a novel drug target in the treatment 
of OA. 
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2 REVIEW OF THE LITERATURE 
2.1 Osteoarthritis 
Osteoarthritis (OA) is the most common joint disease and one of the leading 
causes of disability worldwide (Glyn-Jones et al. 2015; Mobasheri and Batt 
2016). According to the Finnish Health 2000 survey, 5% of men and 7% of 
women over the age of 30 suffer from clinically diagnosed knee OA. The 
prevalence of knee OA increases with age, and at 65-74 years, around 11% of 
men and 18% of women suffer from knee OA (Arokoski et al. 2007). These 
Finnish statistics are similar to global estimates, which state that the incidence of 
knee OA peaks at around 60 years of age, with a prevalence of around 10% for 
men and 18% for women over the age of 60 (Losina et al. 2013; Woolf and Pfleger 
2003). 
The etiology of OA remains partly unknown, but many risk factors have been 
identified. Risk factors are commonly divided into systemic and local factors. 
Systemic risk factors increase the risk of OA to all joints, whereas local factors 
may increase the risk to single joints. The two major systemic risk factors of OA 
are aging and obesity. Obesity contributes to the pathogenesis of OA by 
increasing load on weight-bearing joints. However, obesity has additionally been 
shown to be associated with OA of non-weight bearing joints of the hand and 
fingers (Haara et al. 2003; Kloppenburg and Kwok 2011; Yusuf et al. 2010), 
suggesting that there is also a metabolic link. These systemic effects of obesity 
on OA pathogenesis are currently under intense investigation, and obesity-
associated low-grade inflammation as well as metabolic syndrome are considered 
to have a key role (Berenbaum et al. 2013; Berenbaum et al. 2017). Other 
systemic risk factors include the female sex, genetic predisposition, race, 
nutritional factors, and bone density (Blagojevic et al. 2010; Felson et al. 2000; 
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Firestein et al. 2016). Systemic risk factors may render the articular cartilage more 
susceptible to degradation through local risk factors, which include obesity 
through increased loading, extreme strenuous physical activity, trauma to the 
joint, and congenital malformations of the joint (Blagojevic et al. 2010; Felson et 
al. 2000; Firestein et al. 2016). 
Osteoarthritis can affect any joint, but the most commonly affected joints are 
the knee, hip, hand interphalangeal and carpometacarpal I joints and the spine 
(Firestein et al. 2016; Hunter et al. 2019). The leading symptom of OA is pain. In 
early OA, the pain typically worsens during movement and weight bearing, and 
is alleviated by rest. As the disease progresses, pain may become constant. The 
nature of OA-related pain is mostly considered to be nociceptive, caused by tissue 
injury. However, cumulative data suggests that there may also be a neuropathic 
component to OA pain, and the use of drugs targeting neuropathic pain could be 
beneficial in such cases (Fingleton et al. 2015; Hochman et al. 2011). Distinct 
disease exacerbation phases may occur, which are characterized by excessive 
pain, inflammation, and effusion of the affected joint, and may require 
arthrocentesis along with intra-articular injection of glucocorticoids (Marty et al. 
2009; Parry et al. 2018). Other symptoms of OA include limited range of motion, 
crepitus, swelling, and stiffness after inactivity. In advanced OA, the changes in 
cartilage and bone can ultimately lead to joint deformity (Firestein et al. 2016; 
Knee and hip osteoarthritis: Current Care Guidelines 2018). 
Treatment of OA is based on alleviation of pain through pharmacological and 
non-pharmacological means and maintaining the ability to perform activities of 
daily living. Exercise and physical therapy are the first-line treatments for OA. 
These are accompanied by weight loss of obese patients. Physical therapy can 
include cold therapy of the joint, transcutaneous electrical nerve stimulation 
(TENS) therapy, therapeutic ultrasound or acupuncture. If exercise and physical 
therapy are not effective enough in pain alleviation, analgesic drugs are used. 
Paracetamol (acetaminophen) and nonsteroidal anti-inflammatory drugs 
(NSAIDs) are used as first-line medication, and if they are not effective enough, 
tramadol and possibly other opioids can be considered. Paracetamol is a centrally 
acting analgesic and antipyretic drug. The mechanisms of action of paracetamol 
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are not known in detail but may partially be explained by inhibition of 
cyclooxygenase (COX) enzyme and prostaglandin production in the central 
nervous system, even though it does not inhibit peripheral prostanoid synthesis. 
Paracetamol has also been proposed to modify serotonin, opioid, 
endocannabinoid and TRP pathways in the central nervous system in a manner 
contributing to its analgesic effect. NSAIDs such as ibuprofen exert analgesic, 
antipyretic and anti-inflammatory effects through the inhibition of COX enzymes 
and the resulting inhibition of prostaglandin synthesis (Rang et al. 2019). 
Topical analgesics (NSAIDs, capsaicin) and intra-articular injections of 
glucocorticoids or hyaluronate are also used. Glucocorticoids are potent anti-
inflammatory drugs, which regulate the expression of numerous inflammatory 
genes. Glucocorticoids generally exert their effects by entering the cell, binding 
to intracellular glucocorticoid receptors (GRs), and migrating into the nucleus to 
interact with DNA to modify gene transcription. In this way, glucocorticoids 
activate the expression of innumerable genes, including many anti-inflammatory 
genes. Additionally, glucocorticoids downregulate the expression of an array of 
pro-inflammatory genes by inhibiting the activity of inflammatory transcription 
factors, particularly nuclear factor (NF)-κB and activator protein (AP)-1, through 
various direct and indirect mechanisms (Hartmann et al. 2016; Rang et al. 2019). 
Intra-articular injections of hyaluronic acid are used in the treatment of OA; 
however, evidence of its efficacy is somewhat controversial. According to meta-
analyses, hyaluronate seems to alleviate OA pain and improve joint function 
better than placebo, but more studies are needed to elaborate its clinical 
effectiveness as OA treatment. The mechanisms of action of hyaluronate remain 
unclear and have been speculated to involve changes in the viscosity of synovial 
fluid and reduction of inflammation (Altman et al. 2018; Santilli et al. 2016). 
If none of the other forms of treatment have been effective, or the state of the 
joint has worsened considerably, the last-line treatment is joint replacement 
surgery (Hochberg et al. 2012; Knee and hip osteoarthritis: Current Care 
Guidelines 2018; McAlindon et al. 2014). 
There is currently no treatment that can prevent or retard disease progression 
and cartilage degradation. Therefore, there is an urgent need for novel disease 
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modifying OA drugs (DMOADs) to help prevent, retard or even reverse cartilage 
degradation. In addition, improved analgesic treatment modalities are needed to 
effectively treat the debilitating pain associated with OA. 
 
2.1.1 Pathogenesis of Osteoarthritis 
The etiology and pathogenesis of OA remain unknown in many aspects. 
Previously OA was considered a “wear and tear” disease, in which cartilage 
becomes eroded due to mechanical stress and increased pressure on the joints. 
Now it is known that OA is a more complex inflammatory condition, which 
includes the release of inflammatory mediators from cartilage, bone, and 
synovium as well as characteristics of metabolic syndrome, innate and adaptive 
immunity, chondrosenescense, and inflammaging i.e. changes in the function of 
the immune system during aging (Berenbaum 2013; Glyn-Jones et al. 2015; 
Haseeb and Haqqi 2013; Mobasheri et al. 2019). 
OA is a disease that affects the entire joint structure. Changes associated with 
OA include fibrillation and degradation of articular cartilage, thickening of 
subchondral bone, formation of osteophytes, synovial inflammation, i.e. synovitis 
and degeneration of ligaments and menisci of the joint (Figure 1) (Loeser et al. 
2012; Robinson et al. 2016). The most severe changes in OA are seen in cartilage, 
which is affected by degradative mediators produced in all tissues of the joint. 
Despite this, OA-associated pain, which is the most severe symptom of OA, is 
mediated through other joint tissues, as cartilage is aneural. 
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Figure 1.  Schematic representation of the changes caused by osteoarthritis in the knee joint, 
along with examples of associated factors. ADAMTS - a disintegrin and metalloproteinase with 
thrombospondin motif, BMP - bone morphogenic protein, CGRP - calcitonin gene related peptide, 
FGF - fibroblast growth factor, IGF - insulin-like growth factor, IL - interleukin, MMP - matrix 
metalloproteinase, NGF - nerve growth factor, OC - osteocalcin, TGFβ - Transforming growth factor 
β, TNF - tumor necrosis factor, TRP - transient receptor potential. 
2.1.1.1 Structural changes in OA cartilage 
Articular cartilage is a thin (≤ 7 mm), specialized, connective tissue, which 
provides a smooth, lubricated surface for the bone ends. The tensile and 
viscoelastic properties of articular cartilage enable it to resist shear, tensile and 
compressive forces. Articular cartilage is avascular and aneural and receives its 
nutrition via diffusion form the synovial fluid and vasculature in the subchondral 
bone. Normal mature articular cartilage contains 65-80% water, and most of its 
dry weight consists of collagens and proteoglycans. The extracellular matrix 
(ECM) also contains small amounts of other molecules including lipids, 
phospholipids, noncollagenous proteins and glycoproteins. The most abundant 
 20 
macromolecule in cartilage is collagen, of which 90-95% is type II. Type II 
collagen fibrils form a highly cross-linked network, which interacts with other 
ECM components in cartilage (Firestein et al. 2016; Heinegård and Saxne 2011; 
Fox et al. 2009). Proteoglycans represent the second-largest group of 
macromolecules in the articular cartilage. The major proteoglycan in articular 
cartilage is the large aggregating proteoglycan, or aggrecan, which is composed 
of a core aggrecan (ACAN) protein and multiple chondroitin and keratan sulphate 
glycosaminoglycan side chains. These bottle brush-like molecules are bound to a 
hyaluronan (HA) backbone forming large HA proteoglycan aggregates. 
Negatively charged proteoglycan aggregates attract water into the cartilage tissue, 
which is important for the normal biomechanical function of cartilage. Collagen 
and aggrecan also form a stiff network structure in the ECM, which is resistant to 
deformation (Heinegård and Saxne 2011; Kiani et al. 2002; Fox et al. 2009). 
Chondrocytes, which are the only cells present in cartilage, compose only 1-2% 
of the total volume of cartilage (Fox et al. 2009). 
Normal articular cartilage is composed of four distinct regions: the superficial 
(tangential) zone, the middle (transitional) zone, the deep (radial) zone, and the 
calcified cartilage zone (Figure 2). The superficial zone contains a relatively high 
amount of flattened chondrocytes and thin collagen fibrils, which are tightly 
packed and aligned parallel to the cartilage surface. The middle zone, which 
composes 40 to 60 % of the cartilage volume, contains rounded chondrocytes and 
bundles of thick collagen fibrils that are situated obliquely and radially around 
the chondrocytes. The deep zone contains the highest amount of proteoglycan and 
the lowest amount of collagen. In this zone, the collagen fibers are typically 
arranged perpendicularly to the articular surface, and the chondrocytes are 
arranged in columns or clusters. The deep zone is distinguished from the calcified 
cartilage by a histologically defined tidemark. The calcified zone functions as a 
mechanical buffer between uncalcified cartilage and subchondral bone. The 
chondrocytes in this zone are scarce and typically hypertrophic (Firestein et al. 
2016; Fox et al. 2009). 
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Figure 2.  Structure of normal cartilage and structural and functional changes caused by OA in 
cartilage. Factors commonly produced by osteoarthritic chondrocytes. Normal cartilage is 
divided into superficial, middle, deep and calcified zones, which have characteristic macromolecule 
networks and chondrocyte phenotypes. During osteoarthritis, the cartilage macromolecules start 
to break down leading to reduced compressive stiffness and fibrillation of the cartilage surface. 
Osteoarthritic chondrocytes undergo transient clonal expansion and shift towards a hypertrophic 
phenotype, characterized by increased production of a variety of inflammatory and degradative 
factors. Ultimately, the changes in chondrocyte function and cartilage structure lead to severe 
ulceration and erosion of cartilage. ADAMTS - a disintegrin and metalloproteinase with 
thrombospondin motifs, COX - cyclooxygenase, CSF-G - colony stimulating factor, FGF - fibroblast 
growth factor, H2O2 - hydrogen peroxide, IFNα - interferon α, IL - interleukin, LIF - leukemia 
inhibitory factor, LOX - lipoxygenase, MMP - matrix metalloproteinase, NO - nitric oxide, PAF - 
platelet activation factor, OA – osteoarthritis, OH− - hydroxyl radical, PDGF - platelet derived growth 
factor, PLA - phospholipase A, PTH - parathyroid hormone, RNS - reactive nitrogen species, ROS 
- reactive oxygen species, TGFβ - transforming growth factor β, TNF - tumor necrosis factor, VEGF 
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- vascular endothelial growth factor (Modified from Heinegård and Saxne 2011, Li et al. 2013, Attur 
et al. 2002). 
The initial changes in OA cartilage are seen as a decrease in proteoglycan 
content, length and level of aggregation, followed by a weakening in the collagen 
network. This leads to reduced compressive stiffness of the tissue and is initially 
seen as softening and fibrillation of the cartilage surface. Changes in the cartilage 
surface are accompanied by an increase in water content leading to swelling and 
alterations in the biomechanical properties of cartilage. During the initial stages 
of OA, chondrocytes attempt to repair the cartilage damage by producing 
increased amounts of cartilage matrix components. This however often leads to 
the production of matrix that is inferior in structure and function to normal 
cartilage. At the same time, proteolytic cartilage matrix degradation is increased, 
and, as OA progresses, the degradation eventually exceeds the enhanced matrix 
synthesis. This leads to reduced thickness, as well as increasingly severe 
fibrillation, ulceration, and cleft formation in the cartilage tissue, and may 
ultimately result in the cartilage becoming fully eroded leading to the exposure 
and eburnation of the subchondral bone (Firestein et al. 2016; Goldring and 
Goldring 2010; Heinegård and Saxne 2011; Lorenzo et al. 2004; Tchetina 2011). 
Figure 2 represents common changes seen in OA cartilage. 
The proteolytic degradation of cartilage matrix macromolecules is mediated 
by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase 
with thrombospondin motifs (ADAMTSs). The most important MMPs in the 
pathogenesis of OA include MMP-1 and -13, which cleave fibrillary collagens, 
as well as MMP-3, which mainly cleaves proteoglycans and activates latent 
collagenases (Cawston and Wilson 2006; Troeberg and Nagase 2012). MMP-
enzymes are produced by chondrocytes and synovial cells, and their production 
is increased in OA by inflammatory factors such as IL-1 and TNF-α (Kobayashi 
et al. 2005; Shlopov et al. 1997; Tetlow et al. 2001). Initially, MMP-enzymes 
were thought to be the main aggrecan-degrading enzymes in OA, until it was 
found that aggrecan fragments are mostly cleaved at a site distinct from the MMP 
cleavage site. It was found that aggrecanases, later named ADAMTS-4 and 
ADAMTS-5, cleave aggrecan at a site distinct from that of MMP-enzymes, and 
they are now considered to be important factors in proteoglycan degradation in 
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OA (Malfait et al. 2002; Troeberg and Nagase 2012). Tissue inhibitors of 
metalloproteinases (TIMPs) act as endogenous inhibitors of MMPs and several 
ADAMTSs, and therefore function as key regulators of the matrix degrading 
metalloproteinases (Brew and Nagase 2010). Recently, the breakdown products 
of ECM have gained interest as potential damage associated molecular patterns 
(DAMPs). Once released from the ECM, these DAMPs can activate 
inflammatory receptors such as members of the toll-like receptor (TLR) family in 
surrounding cells and thereby accelerate the inflammation and cartilage 
degradation in OA (Henrotin et al. 2014; Lees et al. 2015; Sokolove and Lepus 
2013). 
2.1.1.2 Chondrocyte 
The chondrocyte is the only cell type present in adult articular cartilage, and it 
constitutes around 1 to 2 % of the total volume of articular cartilage (Firestein et 
al. 2016; Fox et al. 2009). Mature chondrocytes embedded in the ECM of cartilage 
are considered to be terminally differentiated, with a low rate of synthetic activity 
(Firestein et al. 2016; Goldring 2012b). Since cartilage is avascular, chondrocytes 
rely on the exchange of nutrients and metabolites through diffusion from the 
articular surface (Archer and Francis-West 2003; Bhosale and Richardson 2008). 
The oxygen consumption of chondrocytes is low, and their energy metabolism 
relies heavily on glucose. Accordingly, chondrocytes generally contain low 
amounts of mitochondria (Archer and Francis-West 2003; Firestein et al. 2016). 
Chondrocytes also maintain active membrane transport systems for the exchange 
of cations, including Na+, K+, Ca2+, and H+ (Firestein et al. 2016). Chondrocytes 
are responsible for the production of the major components of extracellular 
matrix, including collagen type II and aggrecan, along with several other 
molecules of the ECM (Akkiraju and Nohe 2015; Goldring 2000). Under normal 
conditions, chondrocytes maintain a low turnover rate of cartilage matrix 
components, retaining a stable equilibrium between their synthesis and 
degradation (Goldring 2000). 
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In OA, the activity of chondrocytes increases and becomes aberrant, and their 
phenotype shifts towards hypertrophy (Akkiraju and Nohe 2015; van der Kraan 
and van den Berg 2012). Chondrocytes respond to abnormal environmental 
insults, mechanical stress, alterations in ECM proteins, cartilage degradation 
products and inflammatory mediators derived from cartilage, synovial fluid or 
subchondral bone (Goldring and Otero 2011; Heinegård and Saxne 2011). In 
early OA, structural changes of the surrounding matrix result in a transient 
increase of chondrocyte proliferation, hypertrophy, and the production of 
cartilage matrix components, along with an increase in the production of matrix 
degrading enzymes and inflammatory cytokines (Firestein et al. 2016; Goldring 
2000; van der Kraan and van den Berg 2012). After the initial proliferative 
response of early OA, a decrease in the number of chondrocytes has been reported 
(Haseeb and Haqqi 2013). Increased apoptosis of chondrocytes in OA has been 
attributed to local inflammation and especially IL-1β (Heraud et al. 2000; Lopez-
Armada et al. 2006). During OA, the gene expression profiles of chondrocytes 
become altered causing the overall balance of catabolic and anabolic responses to 
shift to the catabolic side (Aigner et al. 2007; Akkiraju and Nohe 2015; Heinegård 
and Saxne 2011). Figure 2 demonstrates factors commonly produced by OA-
affected chondrocytes. 
2.1.1.3 Inflammation in OA 
Inflammation is a host defense mechanism, which is triggered by numerous 
harmful stimuli, such as invading pathogens and factors released during tissue 
damage. Inflammation is aimed at the removal of harmful agents, the repair of 
damaged tissue, and restoration of host homeostasis. It is commonly divided into 
acute and chronic inflammation. In acute inflammation, there is increased local 
blood flow due to blood vessel dilation, increased capillary permeability resulting 
in leakage of fluids and plasma proteins into the interstitial spaces, and migration 
of neutrophils and monocytes into the affected tissues. This reaction results in the 
cardinal signs of acute inflammation: redness (rubor), swelling (tumor), heat 
(calor) and pain (dolor) (Kumar et al. 2014). These classical signs of 
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inflammation are not generally present in osteoarthritic joints, with the exception 
of specific exacerbation periods that can result in joint effusions, synovial 
swelling, and increased pain (Marty et al. 2009; Parry et al. 2018). Instead, the 
inflammatory reaction in osteoarthritic joints represents a local low-grade chronic 
inflammation, with prolonged production of inflammatory and catabolic 
mediators causing tissue damage in the affected joint (Robinson et al. 2016; 
Sokolove and Lepus 2013). 
It is not yet known what initiates the inflammatory reaction in the OA joint, 
but several tissues and cells of the joint are known to contribute to the 
pathogenesis of the reaction. Synovitis, i.e., inflammation of the synovial 
membrane, is considered to be a significant part of OA pathogenesis. It is 
positively correlated with the severity and progression of OA (Ayral et al. 2005; 
MacFarlane et al. 2019; Roemer et al. 2011) and is considered to be an important 
factor in OA-related pain (Neogi et al. 2016; Wang, X. et al. 2018). Neurons in 
the synovial membrane contribute to inflammation and pain by releasing 
neuropeptides such as bradykinin, substance P (SP) and calcitonin gene-related 
peptide (CGRP) (Henrotin et al. 2014). Synovial cells and infiltrating 
macrophages produce inflammatory factors in the synovium, from which they can 
diffuse into the surrounding synovial fluid. Via the synovial fluid, they can further 
activate cells in the surrounding tissues and contribute to chondrocyte activation 
and cartilage degradation. Inflammatory and catabolic factors are also produced 
by chondrocytes in cartilage, osteoblasts in subchondral bone, adipocytes in the 
infrapatellar fat pad and leukocytes in synovial fluid. The released inflammatory 
mediators can act in a paracrine, juxtacrine or autocrine fashion, and also the 
degradation products of cartilage ECM can further stimulate the inflammatory 
and catabolic reactions in the OA joint (Henrotin et al. 2014; Rahmati et al. 2016; 
Robinson et al. 2016). 
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2.1.2 Inflammatory mediators in osteoarthritis 
During osteoarthritis, increased amounts of inflammatory cytokines and catabolic 
enzymes are produced by chondrocytes and other cells of the joint and found in 
the synovial fluid of OA patients (Beekhuizen et al. 2013; Tsuchida et al. 2014). 
Cartilage degradation, which is the hallmark of pathogenesis in OA, is mediated 
by a complex interplay of inflammatory and catabolic factors released in all parts 
of the joint. The next paragraphs give a brief overview of OA-related 
inflammatory factors that were used in this thesis either as stimulants or as 
measured factors reflecting inflammation in OA. 
The cytokines IL-1β and IL-6 are regarded as major players in OA 
pathogenesis and cartilage degradation. IL-1β production is elevated in OA joints, 
where it stimulates the release of catabolic enzymes MMP-1, -3 and -13 and 
suppresses the expression of type II collagen and aggrecan. It also stimulates the 
production of other inflammatory factors including IL-6, leukemia inhibitory 
factor (LIF), and PGE2 (Kapoor et al. 2011; Rahmati et al. 2016). 
In concert with IL-1β, IL-6 upregulates the expression of MMP-1 and -13 and 
reduces the expression of type II collagen. In addition to IL-6, LIF and IL-11 are 
also members of the IL-6 cytokine family and are implicated in the pathogenesis 
of OA. LIF, which is produced in response to IL-1β and elevated in the synovial 
fluid of OA patients, participates in cartilage matrix destruction by stimulating 
proteoglycan degradation, MMP-enzyme synthesis and nitric oxide (NO) 
production (Jiang, Y. et al. 2014; Kapoor et al. 2011; Lotz et al. 1992). IL-11, 
unlike most cytokines found in OA joints, seems to have both pro- and anti-
inflammatory properties. It has been found to stimulate inflammatory cells, but 
also to induce TIMP production and reduce PGE2 release (Alaaeddine et al. 1999; 
Maier et al. 1993; Wong et al. 2003). 
Prostaglandin PGE2 is a significant mediator of OA-related pain and 
inflammation. It has been reported to promote chondrocyte apoptosis and 
stimulate the production of IL-6 in synergism with IL-1β (Kapoor et al. 2011; 
Lee, AS. et al. 2013). 
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The cytokine IL-17 in part feeds forward the inflammatory and catabolic 
reactions in the OA joint by stimulating the production of IL-1β and IL-6, and by 
upregulating MMP enzymes and downregulating proteoglycan levels (Honorati 
et al. 2002; Kapoor et al. 2011). 
Several growth factors are also involved in the pathogenesis of OA. One of 
these is fibroblast growth factor-2 (FGF-2), which is found at elevated levels in 
the synovial fluid of OA patients, and exerts catabolic and anti-anabolic effects 
in cartilage, especially as a result of cartilage damage (Ellman et al. 2013; Vincent 
et al. 2002). 
In addition, the innate immune system, and particularly the toll-like receptors 
(TLRs), are involved in driving the pathogenesis of OA. TLRs are expressed in 
chondrocytes, and when activated by factors such as bacterial lipopolysaccharide 
(LPS) or DAMPs, they trigger major inflammatory pathways (Bobacz et al. 2007; 
Sillat et al. 2013; Sokolove and Lepus 2013). The adipocytokine resistin, which 
is produced by macrophages and found in OA joints, has also been found to signal 
through TLR4 and induce catabolic responses (Koskinen et al. 2014; Tarkowski 
et al. 2010). 
The next section describes some of these inflammatory mediators considered 
to be essential in the cartilage degradation and pathogenesis of OA in more detail. 
2.1.2.1 Interleukin-1β (IL-1β) 
Interleukin-1β is a proinflammatory cytokine, which is considered to be one of 
the key players in the pathogenesis of OA. IL-1β is produced in the joints by 
chondrocytes, osteoblasts, mononuclear cells and cells of the synovial tissue 
(Farahat et al. 1993; Goto et al. 1988; Keeting et al. 1991; Massicotte et al. 2002; 
Melchiorri et al. 1998; Moos et al. 1999; Smith et al. 1997). Elevated levels of 
IL-1β have been detected in the synovial fluid of OA patients. However, IL-1β is 
not consistently elevated or even detectable in all OA patients (Beekhuizen et al. 
2013; Scanzello and Goldring 2012; Tsuchida et al. 2014; Westacott et al. 1990). 
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IL-1β is originally formed as a cytosolic precursor protein (pro-IL-1β), which 
is intracellularly cleaved by the enzyme Caspase 1 (also known as IL-1β 
converting enzyme, ICE) to the active form of IL-1β, after which the cytokine is 
secreted out of the cell (Wojdasiewicz et al. 2014). The activation of cells by IL-
1β is mediated through a ubiquitously expressed membrane receptor, IL-1 
receptor type I (IL-1R1). The expression of IL-1R1 is increased in human OA 
chondrocytes compared to chondrocytes in the normal state (Martel-Pelletier et 
al. 1992). IL-1β can also bind a type II receptor (IL-1R2). However, this receptor 
is unable to transduce a signal, and is accordingly termed a decoy receptor. 
Several cell types including chondrocytes and synovial fibroblasts produce an IL-
1 receptor antagonist (IL-1Ra), which functions as a natural antagonist of IL-1β. 
IL-1Ra is capable of binding IL-1R1 with similar specificity and affinity as IL-
1β, but does not activate signal transduction (Kapoor et al. 2011; Weber et al. 
2010). 
Binding of IL-1β to IL-1R1 initiates a complex intracellular cascade. Required 
for signal transduction of the IL-1/IL-1R1 complex is the co-receptor IL-1 
receptor accessory protein (IL-1RacP). Binding of IL-1 to IL-1R1 causes the 
recruitment of IL-1RacP and the subsequent assembly of two intracellular 
signaling proteins, myeloid differentiation primary response gene 88 (MYD88) 
and interleukin-1 receptor-activated protein kinase (IRAK), thereby forming an 
active IL-1R signaling complex. IRAK activates tumor necrosis factor- associated 
factor 6 (TRAF6). Oligomerization of TRAF6 results in the activation of the NF-
κB, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase 
(MAPK) pathways eventually leading to modification of the transcription of 
target genes (Weber et al. 2010; Wojdasiewicz et al. 2014). 
IL-1β plays an important role in cartilage degradation in OA by exerting both 
catabolic and anti-anabolic effects. IL-1β stimulates the production of cartilage 
matrix degrading enzymes including MMP-1, MMP-3 and MMP-13, and 
aggrecanases ADAMTS-4 and ADAMTS-5. Additionally, IL-1β stimulates the 
production of proinflammatory factors such as IL-6 and IL-8, along with OA-
related inflammatory enzymes COX-2 and inducible nitric oxide synthase (iNOS) 
leading to the production of PGE2 and nitric oxide (Kapoor et al. 2011; 
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Wojdasiewicz et al. 2014). IL-1β exerts its anti-anabolic responses in 
chondrocytes and cartilage by suppressing the expression of type II collagen and 
aggrecan, which are major cartilage ECM components (Haseeb and Haqqi 2013; 
Kapoor et al. 2011). IL-1β can also induce the production of reactive oxygen 
species (ROS) and downregulate the expression of antioxidant enzymes that 
scavenge ROS (Afonso et al. 2007; Mathy-Hartert et al. 2008), thereby 
contributing to the oxidative stress and cartilage degradation in OA. Additionally, 
IL-1β has been shown to induce the apoptosis of chondrocytes in OA (Heraud et 
al. 2000; Lopez-Armada et al. 2006). 
Since IL-1β is considered one of the key inflammatory mediators in OA, it is 
not surprising that there have been high hopes for anti-IL-1-therapy in the 
treatment of OA. Inhibiting IL-1 with IL-1Ra has produced promising results in 
animal models, where disease activity and progression of structural changes 
associated with OA have been reduced (Jotanovic et al. 2012). However, despite 
these encouraging results, the use of anti-IL-1-therapy in human studies has 
mostly been disappointing, showing only minor symptom-relieving effects 
(Chevalier et al. 2013; Jotanovic et al. 2012; Kapoor et al. 2011). Fortunately, 
there have recently been some progressive advances in this field. Promising 
results were obtained from a Phase 1 clinical trial with the novel human dual 
variable domain immunoglobulin, ABT-981, which simultaneously binds and 
inhibits IL-1α and IL-1β. In the trial, subcutaneous injections of ABT-981 
significantly reduced absolute neutrophil counts and serum IL-1α and IL-1β 
concentrations in knee OA patients, without serious adverse events (Wang, SX. 
et al. 2017). Additionally, the plant-based drug diacerein, which is available in 
some European countries for the treatment of OA, has been shown to have IL-1-
inhibitory activity. Diacerein has been reported to have a modest effect on OA-
related pain, and more research is needed to examine its possible effects on 
disease progression (Panova and Jones 2015; Pelletier et al. 2000). 
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2.1.2.2 Interleukin-6 (IL-6) 
Interleukin-6 is a proinflammatory cytokine involved in rheumatic diseases. It has 
long been investigated as a major factor in rheumatoid arthritis (RA) and has 
recently also raised interest as a key inflammatory factor in OA. IL-6 is produced 
by chondrocytes, synoviocytes, osteoblasts, macrophages and adipocytes in OA 
joints (Wojdasiewicz et al. 2014). The production of IL-6 is predominantly 
stimulated by cytokines IL-1β and TNF-α but can also be upregulated by other 
inflammatory factors including transforming growth factor β (TGF-β) and PGE2 
(Haseeb and Haqqi 2013; Kapoor et al. 2011). IL-6 is found in the serum and 
synovial fluid of OA patients, with the concentration of IL-6 being significantly 
higher in synovial fluid compared to serum (Doss et al. 2007; Laavola et al. 2018). 
IL-6 levels in the synovial fluid of OA patients are reported to correlate positively 
with radiographic disease severity as well as levels of MMP-enzymes and 
bradykinin (Bellucci et al. 2013; Laavola et al. 2018). 
IL-6 mediates its effects through receptor IL-6R, which occurs in 
transmembrane and soluble (sIL-6R) forms. IL-6 signaling via membrane-bound 
IL-6R is termed classical, while signaling via sIL-6R is called trans-signaling. 
Trans-signaling is important as the membrane-bound receptor is only found in a 
small number of cell types such as hepatocytes and some leukocytes (Calabrese 
and Rose-John 2014). In classical signaling IL-6 binds to the transmembrane 
receptor, after which the IL-6–IL-6R complex associates with a second, 
ubiquitously expressed transmembrane glycoprotein gp130, causing its 
dimerization and initiation of intracellular signaling. In trans-signalling, the sIL-
6R is formed either by cleaving the membrane-bound IL-6R or by alternative 
splicing of IL-6R mRNA. IL-6 binds the sIL-6R and the IL-6–sIL-6R complex 
binds to membrane-bound gp130, causing its dimerization (Calabrese and Rose-
John 2014). In both signaling routes, the dimerization of gp130 leads to the 
activation of Janus kinases (JAKs), which are constitutively bound to the gp130 
proteins. Activation of JAKs results in the phosphorylation of tyrosine residues 
in the intracellular portion of gp130 proteins, leading to the recruitment, 
phosphorylation and nuclear translocation of STAT1 and STAT3, and the 
subsequent transcription of IL-6 target genes. IL-6 dependent JAK activation also 
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leads to the activation of MAPK/ERK (extracellular signal-regulated kinase) and 
PI3K (phosphoinositide 3-kinase)/Akt (protein kinase B) pathways (Calabrese 
and Rose-John 2014; Kapoor et al. 2011). 
IL-6 has been shown to induce catabolic effects by upregulating the expression 
of MMP-1 and MMP-13 together with IL-1β and oncostatin M (OSM) in human 
and bovine cartilage explants (Haseeb and Haqqi 2013; Kapoor et al. 2011). It 
has also been shown that mechanical injury can potentiate the effects of IL-6, 
together with TNF-α, on proteoglycan degradation in articular cartilage (Sui et al. 
2009). IL-6 is considered the key cytokine involved in subchondral bone 
remodeling in OA. This is largely attributed to the promotion of osteoclast 
formation and subsequent bone resorption, which is stimulated by IL-6 in 
synergism with IL-1β and TNF-α (Chenoufi et al. 2001; Kwan Tat et al. 2004). 
Ostephyte-derived osteoblasts stimulated with IL-6 also produce elevated 
amounts of MMP-13, which may contribute to cartilage degradation near the 
activated osteoblasts (Sakao et al. 2009). Increased levels of circulating IL-6 
along with high body mass index (BMI) have been reported to predict the 
development of radiographic knee OA in a prospective population study 
conducted in Britain (Livshits et al. 2009). In the same study, IL-6 levels were 
found to correlate positively with the grading of radiographic knee OA (Livshits 
et al. 2009). IL-6 also induces anti-anabolism by inhibiting the expression of type 
II collagen in cartilage (Haseeb and Haqqi 2013; Kapoor et al. 2011). 
Despite being a significant factor in the pathogenesis of OA, the use of IL-6 
or IL-6R inhibitors in the treatment of OA has only recently begun to be 
investigated in clinical trials. The humanized anti-IL-6R antibody tozilicumab is 
currently being investigated in a phase 3 clinical trial for efficacy on pain and 
function in patients with refractory hand OA (NCT02477059). No results have 
been published yet, but there are high hopes as tozilicumab is already effectively 
used in the treatment of RA along with other rheumatic diseases (Rubbert-Roth 
et al. 2018). As discussed earlier, the effects of IL-6 are mediated by the JAK-
STAT signaling pathway. Therefore, certain JAK inhibitors are also used to 
inhibit the effects of IL-6 in rheumatoid diseases. JAK inhibitors, which are orally 
administered targeted synthetic DMARDs (tsDMARDs), are the newest drugs in 
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the treatment of arthritis. Currently in use are the first-generation JAK inhibitors 
tofacitinib and baricitinib, which target a wide range of cytokines through 
multiple JAK subtypes. Research is ongoing to develop new, more selective JAK 
inhibitors. Two second-generation JAK inhibitors upadacitinib and filgotinib, 
with high selectivity for JAK1, are currently in clinical trials for RA and psoriatic 
arthritis (O'Shea and Gadina 2019). 
2.1.2.3 Fibroblast growth factor-2 (FGF-2) 
FGF-2 belongs to a large family of fibroblast growth factors, which have various 
functions in the growth, differentiation, migration and survival of a wide variety 
of cell types. FGF-2 (also called basic FGF or bFGF) has been shown to regulate 
cartilage matrix homeostasis and has therefore attracted interest as a potential 
mediator in OA (Ellman et al. 2008). FGF-2 is produced in the cartilage, where it 
is sequestered by a heparan sulfate proteoglycan perlecan in the ECM (Vincent et 
al. 2002; Vincent et al. 2007). Upon cartilage damage, FGF-2 is released from the 
ECM, and subsequently activates ERK, p38 and JNK signaling pathways (Figure 
3) (Im et al. 2007; Vincent et al. 2002; Yan et al. 2012). FGF-2 is found at elevated 
levels in the synovial fluid and serum of OA patients compared to healthy controls 
(Honsawek et al. 2012; Im et al. 2007). 
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Figure 3.  Schematic representation of FGF-2 signaling pathways in articular chondrocytes. 
FGF-2 binds to FGFR1 and FGFR3 with high affinity. Binding of FGF-2 to FGFR1 results in the 
phosphorylation of the receptor, and the subsequent activation of the signaling molecules Ras and 
PKCδ, which converge on the Raf-MEK1/2-ERK1/2 MAPK pathway. PKCδ also activates MAP 
kinases p38 and JNK. Activation of MAP kinases causes the upregulation of catabolic gene 
expression. Signaling through FGFR3 is associated with anabolism, but more research is needed 
to reveal the connection between FGF-2 and FGFR3-associated anabolic responses. ADAMTS - 
a disintegrin and metalloproteinase with thrombospondin motif, ECM - extracellular matrix, ERK - 
extracellular signal-regulated kinase, FGF - fibroblast growth factor, FGFR - fibroblast growth factor 
receptor, JNK - c-Jun N-terminal kinase, MEK - MAPK/ERK kinase, MMP - matrix 
metalloproteinase, PKC - protein kinase C, Raf - rapidly accelerated fibrosarcoma kinase, Ras - 
rat sarcoma GTPase (Modified from Ellman et al. 2013) 
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The role of FGF-2 in cartilage matrix homeostasis has been investigated in 
various species and cell models, but the results have been somewhat 
contradictory, and the exact role of FGF-2 remains controversial. FGF-2 has been 
shown to have a potent mitogenic effect on growth plate cartilage and adult 
articular cartilage (Ellman et al. 2008). Various studies investigating the role of 
FGF-2 in human articular cartilage and chondrocytes have shown FGF-2 to 
induce catabolism and anti-anabolism. FGF-2 has been shown to trigger 
proteoglycan depletion in cartilage explants and inhibit proteoglycan 
accumulation in articular chondrocytes both in vitro in alginate beads and in vivo 
in cultured human articular cartilage explants (Ellman et al. 2013). FGF-2 also 
inhibits bone morphogenetic protein-7 (BMP-7) and insulin-like growth factor-1 
(IGF-1)-mediated proteoglycan production in human articular cartilage (Loeser 
et al. 2005). In addition, FGF-2 induces the production of cartilage matrix 
degrading enzymes MMP-13 and ADAMTS-5 and downregulates the expression 
of aggrecan in human articular chondrocytes (Im et al. 2007; Wang, X. et al. 2004; 
Yan et al. 2011). 
Surprisingly, FGF-2 seems to have an opposing role in murine cartilage 
compared to human articular cartilage. FGF-2 has exerted anabolic and 
chondroprotective effects in murine models of OA. In these, intra-articular 
injections of FGF-2 reversed the progressive cartilage degradation caused by the 
DMM (destabilization of the medial meniscus) model of OA (Li et al. 2012), and 
FGF-2 deficiency was shown to increase the development of OA, a finding that 
was counteracted by subcutaneous injection of FGF-2 (Chia et al. 2009). 
The discrepancies in the reported effects of FGF-2 have been suggested to 
result from differing receptor expression profiles between species, tissues and/or 
cell types. FGFs signal through four FGF receptor (FGFR) subtypes: FGFR1-4 
(Ornitz and Itoh 2015). Human articular chondrocytes express all four subtypes, 
with the expression of FGFR1 and FGFR3 being significantly higher that FGFR2 
and FGFR4 (Yan et al. 2011). FGF-2 has been shown to signal primarily via 
FGFR1 and FGFR3 in human chondrocytes, and its catabolic properties are 
shown to be mediated selectively by FGFR1 (Yan et al. 2011). Conversely, 
activation of FGFR3 is associated with anabolic effects (Figure 3) (Davidson et 
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al. 2005; Ellman et al. 2013). It has also been shown that in OA cartilage the 
expression of FGFR1 is increased while the expression of FGFR3 is decreased, 
which may contribute to the FGF-2-dependent catabolism seen in OA cartilage 
(Weng et al. 2012; Yan et al. 2011). Unlike in human OA cartilage, FGFR2 and 
4 have been shown to be the most prominent receptors in murine knee articular 
cartilage, although their precise roles are not yet clearly understood (Li et al. 
2012). This predominant expression of FGFR2 and 4, coupled with the low 
expression of catabolic FGFR1 and the finding that FGFR3 is upregulated in 
response to FGF-2 may explain why FGF-2 has been reported to have anabolic 
effects on murine cartilage (Li et al. 2012). 
Due to its catabolic nature, FGFR1 has gained interest as a potential drug target 
in OA. FGFR1 antagonists and genetic deletion of fgfr1 have been investigated 
in murine chondrocytes and experimental models of OA. Inhibiting FGFR1 
genetically and pharmacologically was found to attenuate the degradation of 
articular cartilage in multiple models of experimental arthritis, and this was 
largely attributed to the diminished production of MMP-13 and increased 
expression of the anabolic receptor FGFR3 (Weng et al. 2012; Xu et al. 2016). 
Despite promising results in experimental murine models, no clinical trials for 
FGFR1 antagonists with indications for OA had been conducted at the time of 
this thesis. 
Another member of the FGF growth factor family, FGF-18, is currently under 
intense investigation. The recombinant human FGF-18 drug sprifermin is used in 
clinical trials for osteoarthritis and cartilage injury of the knee. Sprifermin is 
administered as intra-articular injections, and has undergone a randomized, 
double-blind, placebo-controlled proof of concept study, which showed 
statistically significant, dose-dependent reductions in loss of total and lateral 
femorotibial cartilage thickness in patients with OA, with no safety concerns 
(Lohmander et al. 2014; Roemer et al. 2016). Research with sprifermin in vitro 
and ex vivo has shown that sprifermin exposure leads to expansion of hyaline-
cartilage producing chondrocytes and modulation of ECM turnover (Gigout et al. 
2017; Reker et al. 2017). The drug is currently in a Phase 2 clinical trial to 
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investigate the safety and effectiveness of different doses in patients with knee 
OA. 
2.2 Transient receptor potential ion channels 
Transient receptor potential (TRP) ion channels represent a large family of ion 
channels comprising more than 56 subtypes. In mammals, TRPs contain 28 
membrane-associated proteins, which mainly function as non-selective cation 
permeable channels (Nassini et al. 2014). Mammalian TRP channels are divided 
into seven subfamilies based on differences in amino acid sequence homology 
between the different gene products: TRPC (Canonical), TRPV (Vanilloid), 
TRPM (Melastatin), TRPP (Polycystin), TRPML (Mucolipin), TRPN (no 
mechanoreceptor potential, NOMP-C) and TRPA (Ankyrin) with TRPA1 being 
the only known mammalian TRPA channel (Pan et al. 2011). 
TRP subunits generally consist of six putative membrane-spanning segments 
(S1-S6), a pore-forming loop between S5 and S6, and intracellularly located NH2- 
and COOH-termini. Channel subunits are assembled into homo- or 
heterotetramers, which result in the formation of cation-selective ion channels 
(Nilius et al. 2007). Most characterized TRP channels are permeable, though 
poorly selective, to Ca2+. TRPs are gated by diverse stimuli, which include 
binding of extracellular and intracellular messengers, osmotic stress, and changes 
in temperature. There are also some TRP channels that seem to be consitutively 
open (Clapham 2003). 
2.3 TRPA1 
The trpa1 gene was originally cloned from lung fibroblasts in 1999 by Jaquemar 
et al., and it was reported to be located on human chromosome 8 in band 8q13. 
The N-terminal domain was reported to consist of 18 repeats that are related to 
the cytoskeletal protein ankyrin, and the C-terminal domain was said to contain 
six putative transmembrane segments resembling many ion channels (Jaquemar 
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et al. 1999). Due to its multiple ankyrin repeats in the amino-(N-)-terminal part, 
TRPA1 was initially named ANKTM1: Ankyrin-like with transmembrane 
domains 1 (Story et al. 2003). The channel was later renamed TRPA1. 
2.3.1 TRPA1 structure and biophysical properties 
TRPA1 structure 
The trpa1 gene is composed of 27 exons and spans 55 701 base pairs (bp) of the 
human chromosome 8q13. TRPA1 homologues have been found in a number of 
vertebrates and invertebrates. Mammals seem to contain only one trpa1 gene, 
whereas other classes of the Animalia Kingdom contain multiple TRPA1 
homologues (Nilius et al. 2012). The ability of TRPA1 to sense harmful 
electrophilic compounds has been conserved for around 500 million years, but it 
seems that the thermosensitive properties have diverged later (Kang, K. et al. 
2010; Panzano et al. 2010). 
The trpa1 gene encodes a protein, which is roughly 1 100 amino acids and 
120-130 kDa in size, varying slightly between species. The TRPA1 protein 
consist of six putative transmembrane segments (S1-S6), intracellular N- and C-
termini and a pore loop between S5 and S6. The N-terminus contains 14-18 
ankyrin repeat domains (ARDs) composed of 33 amino acids and a large number 
of cysteines (Nilius et al. 2012; Nilius et al. 2011; Story et al. 2003) (Figure 4). 
The TRPA1 pore diameter is estimated to be 1.10 nm under basal conditions, and 
to dilate at least 0.2 nm upon stimulation with the TRPA1 agonist mustard oil 
(MO) (Karashima et al. 2010).  
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Figure 4.  Putative structure of a single TRPA1 protein. The TRPA1 ion channel is a homotetramer, 
with each subunit containing six transmembrane domains (S1-S6) and intracellular N- and C-
terminal domains. The ion-permeable pore is located between S5 and S6, and the site for N855S 
missense mutation causing familial episodic pain syndrome is situated in the intracellular S4-S5 
linker region. The long N-terminal domain of TRPA1 contains multiple ankyrin repeat domains 
(ARD), reactive cysteine (C) and lysine (K) residues involved in electrophilic activation, along with 
the EF hand motive (EF) believed to be involved in Ca2+-dependent activation. 
 
The role of the N-terminal ankyrin repeat domains remains uncertain, but some 
functions have been suggested. The ankyrin repeats are likely to be involved in 
protein-protein interactions (Gaudet 2008), they may also be involved in the 
transition of the channel to the plasma membrane, as this function is impaired 
when the domain is truncated (Nilius et al. 2011). Deletions in the ARD area have 
rendered the channel nonfunctional, probably due to impaired trafficking and 
insertion of the truncated channel to the plasma membrane (Nilius et al. 2011). It 
has also been reported that Ca2+ binding to the ARD causes changes in the 
structure of the N-terminus by increasing its stiffness and altering its end-to-end 
distance. Thereby affecting the open state probability of the channel (Zayats et al. 
2013). 
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Within the N-terminus is a putative EF hand motive which is thought to be 
involved in intracellular Ca2+-dependent activation of TRPA1 (Doerner et al. 
2007; Zurborg et al. 2007). The role of the EF hand-like domain is controversial, 
however, since point mutations have only been shown to have a modest effect on 
Ca2+-dependent activation (Nilius et al. 2011; Wang, YY. et al. 2008). In the 
intracellular S4-S5 linker region of TRPA1 situates an important amino acid 
residue N855S, in which a gain-of-function mutation causes familial episodic 
pain syndrome, which is characterized by debilitating upper body pain episodes 
triggered by cold, fasting and physical stress. The mutation does not seem to alter 
ligand binding but causes an increase in the inward current through the activated 
channel (Kremeyer et al. 2010; Zayats et al. 2013; Zima et al. 2015). 
Located in the N-terminal end of TRPA1 are multiple cysteine residues, which 
are involved in electrophilic activation. The cysteine residues are predicted to 
locate at the interface of adjacent subunits, where covalent modification of 
cysteines may alter interactions between the subunits and promote conformational 
changes leading to channel activation. In addition to activation, modification of 
cysteine residues in TRPA1 has also been shown to have a role in desensitization 
of the channel (Cvetkov et al. 2011; Ibarra and Blair 2013; Macpherson et al. 
2007; Wang, L. et al. 2012). 
 
Electrophysiology 
TRPA1 is classified as a nonselective cation channel, which is permeable to both 
monovalent and bivalent cations such as Ca2+, Na+ and K+. Despite being 
nonselective, TRPA1 has a rather high Ca2+ permeability (Pca), with PCa/PNa 
ranging from 0.84 to 7.9 and the fractional Ca2+ current being up to 23 %. TRPA1 
can be activated by agonists, or to a lesser extent be open constitutively. Agonist 
activated TRPA1 shows a higher PCa/PNa compared to constitutively open 
TRPA1, with respective PCa/PNa reported to be 7.9 and 5.7 (Karashima et al. 2010; 
Nilius et al. 2011; Story et al. 2003). TRPA1 pore, which is estimated to be 1.10 
nm in size, can undergo dilation upon stimulation, and thereby increase Ca2+ 
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permeability and allow passage of larger molecules through the channel 
(Karashima et al. 2010). TRPA1 has a single-channel conductance of 40 – 180 
pS, which is dependent on the experimental conditions and used stimuli (Zygmunt 
and Högestätt 2014). 
Extracellular and intracellular Ca2+ is a significant regulator of TRPA1 
activity. It has been shown to both potentiate and inactivate TRPA1 (Jordt et al. 
2004; Nagata et al. 2005). The exact mechanisms behind these effects are not yet 
clear. Proposed mechanisms include the entry of calcium through TRPA1 and the 
subsequent elevation of intracellular calcium (Wang, YY. et al. 2008), the release 
of calcium from intracellular stores (Jordt et al. 2004), and binding of permeating 
calcium ions to a site within or close to the TRPA1 pore (Nagata et al. 2005). Ca2+ 
has been shown to have a bimodal effect on TRPA1, activating TRPA1 at low 
concentrations and inhibiting it at high concentrations. The presence of 
extracellular Ca2+ also causes activated TRPA1 currents to decay rapidly, whereas 
in its absence both the current activation and the decay are delayed. (Nilius et al. 
2011; Wang, YY. et al. 2008; Zygmunt and Högestätt 2014). 
2.3.2 TRPA1 expression 
TRPA1 is abundantly expressed by a subpopulation of primary sensory neurons 
of the dorsal root ganglia (DRG), trigeminal ganglia (TG) and vagal ganglia 
(VG). TRPA1 is primarily expressed in neurons with unmyelinated C- and thinly 
myelinated Aδ-fibres, and rarely in large myelinated fibres (Bhattacharya et al. 
2008; Nassini et al. 2014; Story et al. 2003). TRPA1 is expressed in both 
peptidergic and non-peptidergic neurons, and mostly in a subpopulation of 
TRPV1-positive neurons. Although some non-TRPV-expressing neurons are also 
known to express TRPA1. 
More recently, TRPA1 has also been found to be expressed in some 
nonneuronal cells, which are typically located in lining-tissues. Nonneuronal cells 
expressing TRPA1 include lung fibroblasts and alveolar epithelial cells 
(Jaquemar et al. 1999; Mukhopadhyay et al. 2011), skin keratinocytes, fibroblasts 
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and melanocytes (Atoyan et al. 2009; Jain et al. 2011), mast cells (Oh et al. 2013), 
rodent β-cells (Cao et al. 2012), urothelial cells (Streng et al. 2008a), 
enterochromaffin cells (Nozawa et al. 2009), endothelial cells (Earley et al. 2009), 
oligodendrocytes (Hamilton et al. 2016), astrocytes (Shigetomi et al. 2011), 
Schwann cells (De Logu et al. 2017), odontoblasts and periodontal ligament cells 
(El Karim et al. 2015; Tsutsumi et al. 2013), and interestingly with regard to OA 
pathogenesis, fibroblast-like synoviocytes (Hatano et al. 2012; Kochukov et al. 
2006). The roles of TRPA1 in these cells under physiological and pathological 
conditions require further research. Some functions have however been identified, 
and putative roles of TRPA1 in these cells include the production of inflammatory 
mediators, vasodilation, and insulin secretion. The regulation of TRPA1 
expression is reviewed in the discussion. 
 
2.3.3 Activators and blockers of TRPA1 
TRPA1 activators 
TRPA1 is activated by a wide array of electrophilic and non-electrophilic factors 
that cause irritation, pain and inflammation. Many TRPA1 agonists are 
electrophilic compounds, which activate TRPA1 by covalently modifying N-
terminal reactive cysteine and lysine residues (Eberhardt et al. 2012; Hinman et 
al. 2006; Macpherson et al. 2007). Electrophiles occur naturally in pungent or 
spicy plants and are found in many industrial products (Viana 2016). Exogenous 
electrophilic TRPA1 activators include isothiocyanates in wasabi, mustard oil and 
horseradish, cinnamaldehyde in cinnamon, allicin and diallyl disulphide in garlic, 
methyl salicylate in wintergreen oil, and acrolein in tobacco smoke, exhaust 
fumes and tear gas (Bandell et al. 2004; Bautista et al. 2005; Bautista et al. 2006; 
Jordt et al. 2004; Macpherson et al. 2007). In research, a commonly used TRPA1 
agonist is allyl isothiocyanate (AITC), a pungent compound found in mustard oil. 
AITC has long been used in pain studies to induce neurogenic inflammation by 
triggering the release of neuropeptides SP and CGRP, and to promote thermal and 
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mechanical hypersensitivity (Bautista et al. 2013; Louis et al. 1989). The 
mechanism of action of AITC remained unknown for years, and it was later 
discovered to be a robust activator of TRPA1 (Jordt et al. 2004). AITC is also 
used in the current study as a TRPA1 agonist. Some important TRPA1 activators 
are listed in Table 1. 
  
 43 
Table 1.  Significant exogenous, endogenous and indirect activators/sensitizers of TRPA1. 
Modified from Gouin et al. 2017. 
Substance Pathways of activation References 
Exogenous activators 
Allyl isothiocyanate  Jordt et al. 2004 
Cinnamaldehyde Direct activation: Bandell et al. 2004 
Allicin Inward current Macpherson et al. 2005 
Acetaldehyde iCa2+ elevation Bautista et al. 2006 
Δ9-tetrahydrocannabinol Release of neuropeptides Jordt et al. 2004 
Acrolein  Release of inflammatory mediators Bautista et al. 2006 
Formalin  McNamara et al. 2007 
Menthol   Story et al. 2003 
Endogenous activators 
Reactive oxygen species:   
Hydrogen peroxide  Andersson et al. 2008, 
Hydroxyl radical  Bessac et al. 2008, 
Superoxide  Sawada et al. 2008 
Reactive nitrogen species:    
Nitric oxide Direct activation: Takahashi et al. 2008, 
Peroxynitrite Inward current Sawada et al. 2008 
Hydrogen sulfide iCa2+ elevation Streng et al. 2008 
Lipid oxidation-derived Release of neuropeptides   
Prostaglandin A2 Release of inflammatory mediators Taylor-Clark et al. 2008b 
15dPGJ2    
Lipid oxidation products    
4-hydroxynonenal  Trevisani et al. 2007, 
4-oxo-nonenal  Taylor-Clark et al. 2008a, 
Nitro-oleic acid  Taylor-Clark et al. 2009 
Diacylglycerol  Jordt et al. 2004 
Methylglyoxal   Eberhardt et al. 2012 
Indirect activators/sensitizers 
Bradykinin Bradykinin receptor B2 (GPCR) Bandell et al. 2004 
Growth factors (eg. NGF) Receptor tyrosine kinase Malin et al. 2011 
Proteases Protease activated receptors (GPCR) Dai et al. 2007 
Low iCa concentration EF-hand Ca2+-binding domain Akopian et al. 2007 
Cytokines (eg. TSLP) TSLP receptor Wilson et al. 2013 
TRPV1 Physical interaction or  Ca2+ second messenger Honda et al. 2014 
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15dPGJ2 - 15-deoxy-δ12,14-prostaglandin J2, GPCR - G protein-coupled receptor, iCa2 - intracellular 
calcium, NGF - nerve growth factor, TRPV1 - transient receptor potential vanilloid 1, TSLP - thymic 
stromal lymphopoietin. 
TRPA1 is also activated by endogenous electrophiles, many of which are 
produced in inflammatory and hypoxic conditions. Important endogenous 
activators of TRPA1 are reactive oxygen and nitrogen species (ROS and RNS). 
ROS, such as hydrogen peroxide (H2O2), hydroxyl radical, and superoxide 
activate TRPA1 by cysteine oxidation and/or disulfide formation (Andersson et 
al. 2008; Bessac and Jordt 2008; Sawada et al. 2008). RNS, which include nitric 
oxide (NO) and peroxynitrite (ONOO¯), have been suggested to regulate TRPA1 
through S-nitrosylation (Sawada et al. 2008; Shimizu et al. 2014; Streng et al. 
2008b; Takahashi et al. 2008; Takahashi and Mori 2011). At moderate 
concentrations, ROS and RNS are important regulatory mediators in various 
signaling processes, such as signal transduction from membrane receptors, and 
oxidative stress responses. However, tissue damage and inflammation can lead to 
detrimental accumulation of ROS and RNS in pathological conditions including 
osteoarthritis, in which oxidative stress and the upregulation of reactive species 
have been linked to chondrocyte apoptosis and cartilage degradation (Droge 
2002; Lepetsos and Papavassiliou 2016; Ziskoven et al. 2010). In addition to 
directly activating TRPA1, reactive species can cause the peroxidation and 
nitration of membrane phospholipids resulting in the formation of highly reactive 
substances 4-hydroxynonenal, 4-oxononenal, 4-hydroxyhexenal and nitrooleic 
acid, which are also potent TRPA1 activators (Andersson et al. 2008; Taylor-
Clark et al. 2008a; Taylor-Clark et al. 2009; Trevisani et al. 2007). Interestingly, 
some prostaglandins have also been found to activate TRPA1. 15-deoxy-δ12,14-
prostaglandin J2 and prostaglandin A2, which are electrophilic carbon-containing 
metabolites of prostaglandins D2 and E2, have been shown to directly activate the 
TRPA1 channel (Cruz-Orengo et al. 2008; Taylor-Clark et al. 2008b). 
In addition to electrophilic compounds, TRPA1 is also activated by some non-
electrophiles. These include nicotine (Talavera et al. 2009), some general and 
local anesthetics including propofol (Lee, SP. et al. 2008; Matta et al. 2008) and 
lidocaine (Leffler et al. 2008), non-electrophilic NSAIDs such as ketoprofen and 
diclofenac (Hu et al. 2010), and menthol, which has a bimodal effect on TRPA1, 
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activating at low concentrations and blocking at high concentrations (Karashima 
et al. 2007). It is currently not known how these non-electrophilic compounds 
activate TRPA1. However, it is not thought to be through covalent modifications, 
but instead by direct interaction with the TRPA1 protein, or some other hitherto 
unknown mechanism (Nilius et al. 2012; Zygmunt and Högestätt 2014). 
Sensitization of TRPA1 by endogenous signaling pathways 
Endogenous signaling pathways can also activate and sensitize TRPA1 indirectly. 
Downstream signaling of G protein-coupled receptors (GPCRs), such as the 
bradykinin receptor B2 (B2R) and protease-activated receptor 2 (PAR2), and 
receptor tyrosine kinases (RTKs), have been shown to modulate TRPA1 function 
(Dai et al. 2007; Gouin et al. 2017; Wang, S. et al. 2008). Secondary mediators 
shown to be involved in GPCR-mediated TRPA1 modulation include 
phospholipase C (PLC) and protein kinase A (PKA), which have been suggested 
to mediate phosphorylation of TRPA1. These endogenous mediators sensitize 
TRPA1 towards other ligands such as AITC and possibly endogenous agonists, 
as well as induce the trafficking of TRPA1 to the cell membrane (Dai et al. 2007; 
Meents et al. 2017; Schmidt et al. 2009; Wang, S. et al. 2008). 
TRPA1 blockers 
TRPA1 has become an attractive drug target due to its role in neuropathic pain 
and inflammation. A promising attribute of TRPA1 as a drug target is its 
peripheral expression pattern allowing for selective targeting of drugs by 
inhalation or topical application, thus reducing possible side effects of systemic 
administration. In addition, genetic deletion or pharmacological blockade of 
TRPA1 have generally not been found to significantly alter protective basal tactile 
and pain detection. The increasing knowledge of endogenous modulators of 
TRPA1 may also be utilized to selectively target TRPA1. Difficulties in targeting 
TRPA1 and developing novel TRPA1 antagonists are variations in the effects of 
TRPA1 antagonists between different species, as well as the widespread 
expression of TRPA1 in many cells and tissues, which may cause unwanted side 
effects (Bautista et al. 2013; Nassini et al. 2014; Viana 2016). Despite the 
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complexities involved, several promising TRPA1 antagonists have been 
developed. Most are currently used as research tools, but some have already been 
investigated in clinical trials. 
Among the first commercial TRPA1 antagonists are HC-030031 (Eid et al. 
2008; McNamara et al. 2007) and its derivative TCS 5861528 (also called 
Chembridge-5861528) (Wei et al. 2009; Wei et al. 2010). HC-030031 was 
developed by Hydra Biosciences in 2007, and it remains one of the most utilized 
TRPA1 antagonists to this day. Both HC-030031 and TCS 5861528 are routinely 
used as pharmacological research tools in both in vitro and in vivo models, and 
they were used in in vitro experiments in this thesis. HC-030031, as well as most 
other existing TRPA1 antagonists, is a small molecule TRPA1 antagonist that 
functions as a reversible negative allosteric modulator, binding to a site distinct 
from the endogenous TRPA1 agonist binding sites (Koivisto et al. 2014). The 
exact site of action of HC-030031 is however still unclear. According to a recent 
study by Gupta et al. (2016), a single amino acid residue N855 in the linker region 
of S4 and S5 of the TRPA1 protein is important for the antagonistic function of 
HC-030031 in humans. The amino acid potentially binds to HC-030031 through 
hydrogen bonding and interacts with the C-terminal region of TRPA1 to increase 
inhibition (Gupta et al. 2016). Interestingly, the amino acid N855 is also the 
location of the gain-of-function mutation causing familial episodic pain syndrome 
(Kremeyer et al. 2010).  Other commonly used TRPA1 antagonists in in vitro and 
in vivo studies include the oxime derivative AP-18 from Novartis (Petrus et al. 
2007) and the later developed, structurally related compound A-967079 from 
Abbott (Chen, J. et al. 2011). Unlike HC-030031, which has not been shown to 
bind inside the TRPA1 pore, A-967079 inhibits TRPA1 by interacting with amino 
acids inside the TRPA1 pore vestibule (Klement et al. 2013; Paulsen et al. 2015). 
The search and development of novel TRPA1 antagonists is ongoing and has 
yielded some novel compounds in recent years (Chen, H. et al. 2018; Lehto et al. 
2016; Nyman et al. 2013; Mäki-Opas et al. 2019; Rooney et al. 2014). 
One of the most promising advances in the development of TRPA1 antagonists 
for clinical use occurred in 2011, when Glenmark Pharmaceuticals Ltd. 
announced that their TRPA1 antagonist GRC 17536 was entering clinical trials 
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for pain and respiratory conditions (Glenmark's novel molecule 'GRC 17536' for 
pain and respiratory entering human trials, 2011). Shortly after, in 2012 and 
2013, phase 2a double-blind placebo-controlled proof of concept studies in 
patients with painful diabetic peripheral neuropathy and refractory chronic cough 
commenced. Glenmark reported to have received positive results from their proof 
of concept study in patients with painful diabetic neuropathy (Glenmark's TRPA1 
Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study, 2014), 
and according to their research pipeline (updated January 2019), Glenmark aims 
to initiate a Phase 2b dose-range finding study in 2019-2020 in patients with 
neuropathic pain (http://www.glenmarkpharma.com/novel-molecular-
entities/research-pipeline). 
2.3.4 Functions of TRPA1 
Many of the physiological and pathological functions of TRPA1 have been 
studied in sensory neurons and the peripheral nervous system. Currently, the 
functional roles of non-neuronal TRPA1 are also under increasing investigation. 
The physiological function of TRPA1 is considered to be mainly chemo- and 
mechanosensation, through which TRPA1 can act as a sensor for noxious 
compounds, tissue damage, cellular stress, and inflammation. Chemosensation is 
the most widely studied function of TRPA1. As discussed earlier, TRPA1 is 
primarily located in the peripheral ends of small myelinated Aδ- and 
unmyelinated C-fibers, where it is activated by numerous noxious compounds 
such as AITC in mustard oil and acrolein in tear gas (Nassini et al. 2014). Upon 
activation, TRPA1 transmits a painful sensation to the central nervous system in 
order to avoid contact with the potentially harmful substance (Nilius et al. 2012). 
The role of TRPA1 in mechanosensation is less clear. Soon after the discovery 
of TRPA1 it was suggested to act as a mechanosensor due to its long ankyrin 
repeat structure being able to form a spring-like structure that can potentially 
sense mechanical forces (Howard and Bechstedt 2004; Sotomayor et al. 2005). 
Since then, multiple in vitro and in vivo models have supported the role of TRPA1 
as a mechanosensor in physiological and pathophysiological 
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mechanotransduction pathways (Brierley et al. 2009; Brierley et al. 2011; 
Kerstein et al. 2009; Kwan et al. 2009; Vilceanu and Stucky 2010; Zhang, XF. et 
al. 2008). However, heterologous TRPA1 gene expression has rarely been able to 
confer mechanosensitivity to the recipient cells, and more research is needed to 
confer whether TRPA1 is intrinsically mechanosensitive (Nilius et al. 2012; 
Zygmunt and Högestätt 2014). 
TRPA1 may also be activated by cold temperatures, although data on the 
subject is controversial (Caspani and Heppenstall 2009; Nilius et al. 2012; Viana 
2016). Species-dependent differences in the cold activation of TRPA1 have been 
observed, and it is possible that TRPA1 is involved in cold transduction in rodents 
but not humans (Chen, J. et al. 2013). It is also possible that instead of being 
involved in physiological cold sensation, TRPA1 has a role in cold hyperalgesia 
and might be sensitized by cold temperature towards other ligands (del Camino 
et al. 2010; Fernandes et al. 2016; Obata et al. 2005). 
Additionally, TRPA1 has been reported to have a role in vasodilation, insulin 
secretion, bladder function, and gastrointestinal tract function (Aubdool et al. 
2016; Earley 2012; Nilius et al. 2012; Yu et al. 2016). The wide expression of 
TRPA1 in many barrier tissues such as skin, lungs, gastrointestinal tract and 
vascular endothelium suggests that TRPA1 may have a broader role in tissue 
homeostasis than is currently known. 
TRPA1 has a well-established role in the mediation of pain. TRPA1 has been 
reported to mediate spontaneous pain, hyperalgesia, and allodynia via direct and 
indirect activation. In hyperalgesia, there is an increased pain response to stimuli 
that normally cause pain, whereas in allodynia pain is elicited by an innocuous 
stimulus (Jensen and Finnerup 2014). TRPA1 has been shown to mediate acute 
nociception as well as chronic pain such as inflammatory and neuropathic pain 
experienced in diseases like arthritis, diabetes and fibromyalgia. This has been 
extensively shown in experimental models, where activation of TRPA1 results in 
painful states, which are attenuated or prevented in TRPA1 KO animals or by 
TRPA1 blockers (Galindo et al. 2018; Laing and Dhaka 2016). TRPA1 activator-
evoked pain responses are also seen in humans; healthy human volunteers have 
experienced spontaneous pain and hyperalgesia after being subjected to 
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cinnamaldehyde (Namer et al. 2005; Olsen et al. 2014). Interestingly, TRPA1 also 
contributes to guarding pain (representing ongoing postoperative pain) in a rat 
model of postoperative pain (Wei et al. 2012). In addition to neurons, nonneuronal 
cells can contribute to TRPA1-related pain by producing inflammatory pain 
mediators, such as prostaglandins, bradykinin, ROS/RNS and nerve growth factor 
(NGF), which can stimulate the expression and/or activation of TRPA1 in 
neurons (Diogenes et al. 2007; Dray 1995; Ronchetti et al. 2017; Taylor-Clark et 
al. 2008b; Wang, S. et al. 2008). TRPA1 is also implicated with itch, a sensation 
closely related to pain. Itch sensation can lead to the avoidance of noxious 
endogenous stimuli, such as allergens, parasites or plant particles. Itch may also 
be chronic resulting from conditions including atopic dermatitis and neuronal 
lesions. TRPA1 has been shown to mediate multiple forms of acute and chronic 
itch, such as serotonin-induced itch, thymic stromal lymphopoietin (TSLP)-
induced itch, and itch associated with chronic atopic dermatitis (Kittaka and 
Tominaga 2017; Oh et al. 2013; Wilson et al. 2013; Xie and Hu 2018). 
In addition to pain, TRPA1 has a significant role in neurogenic inflammation. 
In neurogenic inflammation, noxious stimuli activate TRPA1 channels in 
peripheral sensory nerve terminals, triggering signal transmission as well as the 
release of inflammatory neuropeptides from the activated nerve. Commonly 
released neuropeptides CGRP and SP contribute to rubor, calor and tumor by 
eliciting vasodilation and increasing capillary permeability (Chiu et al. 2012; 
Koivisto et al. 2014). In addition to CGRP and SP, nociceptors release many other 
neuropeptides and molecular mediators, including neurokinins, nitric oxide and 
cytokines (Chiu et al. 2012). Release of neuropeptides to the site of inflammation 
potentiates the inflammatory reaction and causes pain hypersensitivity, 
sometimes referred to as neurogenic pain. Furthermore, recent evidence indicates 
a role for TRPA1 also in inflammatory responses of some nonneuronal cells, 
where TRPA1 activation can trigger the production of inflammatory mediators 
(Bautista et al. 2013; Gouin et al. 2017). 
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2.4 TRPA1 in osteoarthritis 
The pathogenesis of osteoarthritis can be investigated in experimental models 
including spontaneous and post-traumatic models of OA as well as chemically 
and mechanically induced OA (Kuyinu et al. 2016). Chemically induced OA 
models are commonly used to study the effects of drugs on the inflammation or 
pain associated with OA and are performed by injecting a toxic or inflammatory 
compound into the joint of the experimental animal (Kuyinu et al. 2016). 
So far, there are very few reports on the role of TRPA1 in the pathogenesis of 
OA. In most of them, the role of TRPA1 has been investigated by inducing OA 
with the chemical monosodium iodoacetate (MIA). In MIA-induced 
osteoarthritis, an injection of MIA into the articular cavity of an experimental 
animal causes OA-like histopathological changes in the cartilage, subchondral 
bone and synovium, along with increased hyperalgesia and allodynia (Bove et al. 
2003; Fernihough et al. 2004; van der Kraan et al. 1989). The degradative effects 
of MIA on cartilage include inhibition of proteoglycan synthesis and induction of 
chondrocyte death by inhibiting glyceraldehyde-3-phosphate dehydrogenase and 
increasing caspase-3 activation (Dumond et al. 2004; Dunham et al. 1992; 
Grossin et al. 2006; Jiang, L. et al. 2013). MIA also induces inflammation and 
oxidative stress, as shown by increased production of ROS and multiple 
inflammatory factors including IL-1β, IL-6, MMP-13 and inducible nitric oxide 
synthase (iNOS) (Dumond et al. 2004; Jiang, L. et al. 2013; Lee, J. et al. 2013). 
At the time of this thesis, four studies had investigated the role of TRPA1 in 
MIA-induced experimental OA in the mouse or rat. These studies concentrated 
either on the aspect of pain (McGaraughty et al. 2010; Okun et al. 2012) or on 
both pain and inflammation (Horvath et al. 2016; Moilanen, Hämäläinen, 
Nummenmaa et al. 2015b). McGaraughty et al. (2010) showed that systemic 
administration of a TRPA1 blocker attenuated the responses of wide dynamic 
range neurons, i.e. sensory neurons which sense a wide array of stimuli, to 
mechanical stimulation, when measured 21 days after MIA injection 
(McGaraughty et al. 2010). In a study conducted by Okun et al. (2012), it was 
reported that both systemic and intra-articular TRPA1 blocker failed to block 
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MIA-induced decrease in weight bearing or ongoing pain, as investigated 14 days 
post MIA-injection (Okun et al. 2012). 
Unlike in the previous studies, Moilanen et al. (2015b) investigated the role of 
TRPA1 in MIA-induced inflammation and cartilage degradation in addition to 
joint pain (Moilanen, Hämäläinen, Nummenmaa et al. 2015b). The effect of intra-
articular injection of MIA on nociceptive behavior and cartilage damage was 
assessed by spontaneous weight bearing tests up to 28 days and histological 
analysis at day 28 after MIA injection. The results showed that MIA-induced 
histopathological changes in the cartilage, as well as MIA-induced joint pain, 
were attenuated in TRPA1 KO mice as compared to WT mice. MIA was also 
injected into the mouse paw, where it caused an acute inflammatory edema, which 
was attenuated with a TRPA1 antagonist and significantly reduced in TRPA1 KO 
mice compared to WT mice (Moilanen, Hämäläinen, Nummenmaa et al. 2015b). 
In a study by Hórváth et al. (2016) the effects of intra-articular MIA injection on 
knee swelling, histopathological changes and pain behavior were investigated 
during a 21-day experiment. The study found that hypersensitivity and decreased 
weight bearing on the osteoarthritic limb was significantly attenuated in TRPA1 
KO mice, while MIA-evoked knee swelling and histopathological destruction 
were not altered compared to WT mice (Horvath et al. 2016). 
A small number of studies have also indicated a role for TRPA1 in other forms 
of inflammatory arthritides using experimental models such as complete Freund’s 
adjuvant (CFA)-induced inflammatory arthritis (Fernandes et al. 2011; Fernandes 
et al. 2016) and monosodium urate (MSU) crystal-induced gout (Moilanen et al. 
2015a; Trevisan et al. 2014). In the CFA model, TRPA1 was found to mediate 
mechanical hyperalgesia and ongoing nociception (Fernandes et al. 2011; 
Fernandes et al. 2016). TRPA1 was also shown to disrupt the transmission of 
mechanical stimulation of neurons, and mediate chronic mechanical 
hypersensitivity, tibiotarsal joint swelling, histopathological alterations as well as 
myeloperoxidase activity and vascular leakage in CFA-induced arthritis (Horvath 
et al. 2016; McGaraughty et al. 2010). TRPA1 has additionally been linked to the 
pathogenesis of gout, which is one of the most common forms of inflammatory 
arthritis (Richette and Bardin 2010). Experimental gouty arthritis can be induced 
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by intra-articular injections of MSU crystals. Using this model, TRPA1 has been 
shown to mediate pain and hyperalgesia (Moilanen et al. 2015a; Trevisan et al. 
2014) as well as increase inflammatory cell infiltration and production of 
inflammatory mediators (Moilanen et al. 2015a). 
Taken together, it is seen that the role of TRPA1 in osteoarthritis has not yet 
been extensively studied, but some encouraging results on the role of TRPA1 in 
OA-associated pain, inflammation and histopathology have been reported 
(Galindo et al. 2018). In addition to the in vivo data discussed above, some in 
vitro findings also support the concept of TRPA1 as a mediator in OA. Especially 
the discoveries that TRPA1 is activated by inflammatory and hypoxic mediators 
(Zygmunt and Högestätt 2014), such as those found in OA joints, and that TRPA1 
activation regulates the production of inflammatory agents in human 
synoviocytes (Hatano et al. 2012; Yin et al. 2018), encourage further studies 
investigating the expression of TRPA1 in chondrocytes and the potential role of 
TRPA1 in OA pathogenesis. 
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3 AIMS OF THE STUDY 
Cartilage degradation, which is the hallmark of the pathogenesis of OA, is driven 
by an imbalance between the production of catabolic, anabolic and inflammatory 
mediators within the joint. There is currently no disease-modifying drug treatment 
available, and novel drug targets are urgently needed. 
The aim of the present study was to examine the expression of TRPA1 in 
human OA chondrocytes and to investigate its potential role in regulating the 
expression of OA-related catabolic and inflammatory factors, in order to assess 
the potential role of TRPA1 as a novel mediator and drug target in OA. 
The detailed hypotheses of this study were: 
1. TRPA1 is expressed in human OA chondrocytes (I) 
2. TRPA1 expression is enhanced by OA-related inflammatory factors (I) 
3. The expression of TRPA1 in chondrocytes is inhibited by anti-
inflammatory drugs (II) 
4. TRPA1 has an effect on OA-associated catabolic and/or inflammatory 
responses in chondrocytes and cartilage (I, III) 
5. FGF-2, which was found to be enhanced by TRPA1, has destructive 
effects in human OA chondrocytes/cartilage (IV) 
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4 MATERIALS AND METHODS 
4.1 Patients (I-IV) 
Cartilage samples were collected from patients undergoing knee-joint 
replacement surgery in Coxa Hospital for Joint Replacement, Tampere, Finland. 
All patients in this study fulfilled the American College of Rheumatology 
classification criteria for OA (Altman et al. 1986), and written informed consent 
was obtained from the patients. The studies were approved by the Ethics 
Committee of Tampere University Hospital, Tampere, Finland, and carried out in 
accordance with the Declaration of Helsinki. Cartilage samples were used for 
tissue explant and chondrocyte cultures as described below. In the fourth study 
(IV) cartilage tissue samples were collected from 97 patients with OA (60 females 
and 37 males, BMI 30.9 ± 0.6 kg/m2, age 69.8 ± 1.0 years; mean ± SEM).  
4.2 Mice (I,III) 
Wild type and TRPA1 knock-out mice (B6;129P-Trpa1tm1Kykw/J mice, Charles 
River Laboratories, Sulzfeld, Germany) aged 19-22 days were used in mouse 
cartilage culture experiments (studies I, III), and aged 6-12 days in chondrocyte 
culture experiments (study III) as described below. The mice were housed under 
standard conditions (12-12 h light-dark cycle, temperature 22±1 °C) with food 
and water provided ad libitum. Animal experiments were carried out in 
accordance with the legislation for the protection of animals used for scientific 
purposes (Directive 2010/63/EU) and the experiments were approved by The 
National Animal Experiment Board. Animals were sacrificed by carbon 
monoxide followed by cranial dislocation. 
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4.3 Cell and cartilage culture 
4.3.1 Human osteoarthritic cartilage (IV) 
Leftover pieces of OA cartilage from knee-joint replacement surgery were used. 
Full-thickness pieces of articular cartilage from femoral condyles, tibial plateaus 
and patellar surfaces showing macroscopic features of early OA were removed 
aseptically from subchondral bone with a scalpel, cut into small pieces and 
cultured in DMEM with GIBCO GlutaMAX-I supplemented with penicillin (100 
U/ml), streptomycin (100 μg/ml) and amphotericin B (250 ng/ml) (all from 
Invitrogen/Life Technologies, Carlsbad, CA, USA) at 37°C in a humidified 5% 
carbon dioxide atmosphere. Cartilage samples were incubated for 42 hours 
without stimulation. After incubation the culture media were collected and kept 
at -20°C until analyzed, the cartilage explants were weighed, and the results were 
expressed per 100 milligrams of cartilage. 
4.3.2 Human osteoarthritic chondrocytes (I-IV) 
Cartilage pieces obtained from OA patients undergoing knee-joint replacement 
surgery were processed as described in section 4.3.1. The cartilage pieces were 
then washed with PBS, and chondrocytes were isolated by enzymatic digestion 
for 16 hours at 37°C in a shaker by using a collagenase enzyme blend (0.25 mg/ml 
LiberaseTM Research Grade medium; Roche, Mannheim, Germany). Isolated 
chondrocytes were washed and plated on 6, 24, or 96-well plates in culture 
medium [DMEM High Glucose (Sigma-Aldrich, St. Louis, MO, USA) 
supplemented with penicillin (100 U/ml), streptomycin (100 μg/ml) and 
amphotericin B (250 ng/ml), all from Gibco/Life Technologies, Carlsbad, CA, 
USA) containing fetal bovine serum (10 %) (Lonza, Verviers, Belgium)]. 
During experiments in studies I-III, the cells were treated with IL-1β (R&D 
Systems Europe Ltd, Abingdon, UK, studies I-III), IL-17 (R&D Systems Europe 
Ltd, study I), resistin (BioVision Inc., Milpitas, CA, USA, study I), LPS (Sigma-
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Aldrich, study I), dexamethasone (Sigma-Aldrich, study II), aurothiomalate 
(Sigma-Aldrich, study II), the NF-κB inhibitor ammonium 
pyrrolidinedithiocarbamate (PDTC, Sigma-Aldrich, study II), the TRPA1 
antagonist HC-030031 (Sigma-Aldrich, studies I, III), the TRPA1 antagonist TCS 
5861528 (Tocris, Bio-Techne Ltd, Abingdon, UK, study III), or with 
combinations of these compounds as indicated. 
In study IV, the cells were subjected to serum starvation for 24 h before 
experiments. During the experiments, the cells were treated with FGF-2 
(recombinant human FGF-basic; Peprotech, NJ, USA) or with IL-1β (R&D 
Systems Europe Ltd), which was used as a control compound. In FGF receptor 
antagonist experiments, the cells were treated with the selective FGF receptor 
antagonists AZD4547 and NVP-BGJ398 (both from Selleckchem, Munich, 
Germany) with and without FGF-2 stimulation. The cells were pre-treated with 
AZD4547 and NVP-BGJ398 1 h prior to the addition of FGF-2. 
4.3.3 Human T/C28a2 chondrocytes (I,II) 
Immortalized human T/C28a2 chondrocytes (Goldring et al. 1994) were cultured 
in DMEM (Sigma-Aldrich) and Ham’s F-12 medium (Lonza) (1:1, v/v) 
containing heat-inactivated fetal bovine serum (10 %) (Lonza), penicillin (100 
U/ml), streptomycin (100 μg/ml), and amphotericin B (250 ng/ml) (all from 
Gibco/Life Technologies). Cells were grown on 24-well plates for mRNA 
measurements, on 6-well plates for Western Blot measurements, and on 96-well 
plates for Ca2+ assays. During experiments the cells were treated with IL-1β 
(R&D Systems Europe Ltd, studies I,II), IL-17 (R&D Systems Europe Ltd, study 
I), LPS (Sigma-Aldrich, study I), dexamethasone (Sigma-Aldrich, study II), 
aurothiomalate (Sigma-Aldrich, study II), methotrexate (Orion Pharma, Espoo, 
Finland, study II), sulfasalazine (Sigma-Aldrich, study II), hydroxychloroquine 
(Orion Pharma, study II), ibuprofen (Alexis Biochemicals, San Diego, CA, USA, 
study II), ammonium pyrrolidinedithiocarbamate (PDTC, Sigma-Aldrich, study 
II), the TRPA1 antagonist HC-030031 (Sigma-Aldrich, study I) or with 
combinations of these compounds as indicated. 
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4.3.4 HEK 293 cells (I) 
HEK 293 human embryonic kidney cells (American Type Culture Collection, 
Manassas, VA, USA) were cultured in Eagle’s Minimum Essential Medium 
(EMEM) supplemented with  heat-inactivated fetal bovine serum (10 %), sodium 
bicarbonate (1.5%), sodium pyruvate (1 mM), non-essential amino acids (1 mM 
each) (all from Lonza), penicillin (100 U/ml), streptomycin (100 mg/ml) and 
amphotericin B (250 ng/ml) (all from Gibco/Life Technologies) at 37 °C in 5 % 
CO2. The cells were transfected using 0.42 mg/cm2 of human TRPA1 plasmid 
DNA (pCMV6-XL4 from Origene Rockville, MD, USA) with lipofectamine 
2000 (Invitrogen/Life Technologies) according to the manufacturer’s directions. 
Cells were grown on 6-well plates for Western Blot analysis and on 96-well plates 
for Ca2+ assays. 
4.3.5 Mouse cartilage culture (I,III) 
After mice were euthanized, full-thickness articular cartilage from the femoral 
heads was removed and incubated at 37°C in 5% CO2 in DMEM supplemented 
with penicillin (100 U/ml), streptomycin (100 μg/ml), and amphotericin B 
(250 ng/ml) (all from Gibco/Life Technologies) containing fetal bovine serum 
(10 %) (Lonza). The cartilage pieces were exposed to IL-1β (R&D Systems 
Europe Ltd.) for 42 h and thereafter culture media were collected and MMP-3, 
IL-6 and PGE2 concentrations were measured by immunoassay. 
4.3.6 Primary murine chondrocytes (III) 
After mice were euthanized, full-thickness articular cartilage from the femoral 
heads was removed, and chondrocytes were isolated by enzymatic digestion o/n 
without agitation at 37°C in 5% CO2 with Collagenase D enzyme (3 mg/ml, 
Sigma-Aldrich), according to the protocol by Jonason et al. (Jonason et al. 2015). 
Isolated chondrocytes were plated on 24-well plates (2.0 x 105 cells/ml) in culture 
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medium [DMEM High Glucose (Sigma-Aldrich) supplemented with penicillin 
(100 U/ml), streptomycin (100 μg/ml) and amphotericin B (250 ng/ml) (all from 
Gibco/Life Technologies) containing fetal bovine serum (10 %) (Lonza)] and 
cultured for seven days before conducting the experiments. During experiments, 
the cells were treated for 24 h with IL-1β (R&D Systems Europe Ltd), the TRPA1 
antagonists HC-030031 (Sigma-Aldrich) or TCS 5861528 (Tocris, Bio-Techne 
Ltd) or with combinations of these compounds as indicated. 
4.4 RNA extraction and quantitative RT-PCR (I-IV) 
At the indicated time points, culture medium was collected, and total RNA 
extraction was carried out with GenElute Mammalian Total RNA Miniprep kit 
(Sigma-Aldrich) or RNeasy Mini Kit (Qiagen Inc., Hilden, Germany). The 
amount of RNA was measured with a spectrophotometer, and total RNA was 
reverse-transcribed to complementary DNA (cDNA) using Maxima First Strand 
cDNA synthesis kit (Fermentas UAB, Vilnius, Lithuania) or TaqMan Reverse 
Transcription reagents and random hexamers (Applied Biosystems, Foster City, 
CA, USA). After the transcription reaction, the obtained cDNA was diluted 1:5 
(for Maxima First Strand cDNA synthesis kit) or 1:20 (for TaqMan Reverse 
Transcription reagents and random hexamers) with RNase-free water. 
Quantitative PCR was performed using TaqMan Universal PCR Master Mix and 
ABI Prism 7000 or 7500 sequence detection systems (Applied Biosystems). 
The primer and probe sequences and concentrations were optimized according 
to the manufacturer’s guidelines in TaqMan® Universal PCR Master Mix 
Protocol part number 4304449 revision C (Applied Biosystems) (Table 2). 
TaqMan Gene Expression assays (Table 3) were purchased from Life 
Technologies (Life Technologies Europe BV, Bleiswijk, the Netherlands). PCR 
cycling parameters were: incubation at 50 °C for 2 min, incubation at 95 °C for 
10 min, and thereafter 40 cycles of denaturation at 95 °C for 15 s and annealing 
and extension at 60 °C for 1 min. The relative mRNA levels were quantified using 
a standard curve method as described in the Applied Biosystems User Bulletin. 
The ΔΔCt method was used for the TaqMan Gene Expression assays. When 
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calculating results, mRNA expression levels were first normalized against 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA levels. 
 
Table 2.  Primer and probe sequences for quantitative RT-PCR 
Gene Oligonucleotide Sequence 
Human GAPDH 
Forward primer 5'-AAGGTCGGAGTCAACGGATTT-3' 
Reverse primer 5'-GCAACAATATCCACTTTACCAGAGTTAA-3' 
Probe 5'-CGCCTGGTCACCAGGGCTGC-3' 
Human AGC1 
Forward primer 5'-GCCTGCGCTCCAATGACT-3' 
Reverse primer 5'-TAATGGAACACGATGCCTTTCA-3' 
Probe 5'-CCATGCATCACCTCGCAGCGGTA-3' 
Human COL2A1 
Forward primer 5'-GGCAATAGCAGGTTCACGTACA-3' 
Reverse primer 5'-CGATAACAGTCTTGCCCCACTT-3' 
Probe 5'-CTGAAGGATGGCTGCACGAAACATACC-3' 
Human IL-6 
Forward primer 5'-TACCCCCAGGAGAAGATTCCA-3' 
Reverse primer 5'-CCGTCGAGGATGTACCGAATT-3' 
Probe 5'-CGCCCCACACAGACAGCCACTC-3' 
Human MMP1 
Forward primer 5'-TTGAAGCTGCTTACGAATTTGC-3' 
Reverse primer 5'-GAAGCCAAAGGAGCTGTAGATGTC-3' 
Probe 5'-CAGAGATGAAGTCCGGTTTTTCAAAGGGA-3' 
Human MMP13 
Forward primer 5'-TGATCTCTTTTGGAATTAAGGAGCAT-3' 
Reverse primer 5'-GGAACTACTTGTCCAGGTTTCATCAT-3' 
Probe 5'-CCCTCTGGCCTGCTGGCTCATG-3' 
Mouse GAPDH 
Forward primer 5'-GCATGGCCTTCCGTGTTC-3' 
Reverse primer 5'-GATGTCATCATACTTGGCAGGTTT-3' 
Probe 5'-TCGTGGATCTGACGTGCCGCC-3' 
Mouse IL-6 
Forward primer 5'-TCGGAGGCTTAATTACACATGTTC-3' 
Reverse primer 5'-CAAGTGCATCATCGTTGTTCATAC-3' 
Probe 5'-CAGAATTGCCATTGCACAACTCTTTTCTCA-3' 
AGC - aggrecan, COL - collagen, GAPDH - glyceraldehyde-3-phosphate dehydrogenase,  
IL - interleukin, RT-PCR - reverse transcription polymerase chain reaction, MMP - matrix 
metalloproteinase 
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Table 3.  TaqMan Gene Expression Assays for quantitative RT-PCR  
Gene TaqMan Gene Expression Assay 
Human FGF-2 Hs00266645_m1 
Human FGFR1 Hs00915142_m1 
Human FGFR2 Hs01552926_m1 
Human FGFR3 Hs00179829_m1 
Human FGFR4 Hs01106908_m1 
Human IL-11 Hs01055414_m1 
Human LIF Hs01055668_m1 
Human TRPA1 Hs00175798_m1 
Mouse FGF-2 Mm00433287_m1 
Mouse IL-11 Mm00434162_m1 
Mouse LIF Mm00434762_g1 
FGF - fibroblast growth factor, FGFR - fibroblast growth factor receptor, IL - interleukin, LIF - leukemia 
inhibitory factor, TRPA1 - transien receptor potential ankyrin 
 
4.5 Protein extraction and western blotting (I,II) 
After the cell culture experiments, cells were rapidly washed with ice-cold PBS 
and solubilized in cold lysis buffer containing Tris-HCl (50 mM, pH 8), NaCl 
(150 mM), EDTA (5 mM), Nonidet P-40 (1%), Na deoxylate (0.5%), SDS 
(0.1%), phenylmethylsulfonyl fluoride (0.5 mM), sodiumorthovanadate (1 mM), 
leupeptin (20 μg/ml), aprotinin (50 μg/ml), NaF (5 mM) and 
sodiumpyrophosphate (2 mM). The cells were incubated in the lysis buffer at 4 °C 
for 30 min, vortexing every 5 min. Thereafter the samples were centrifuged 
(12 000 g, 4 °C, 15 min) and supernatants were collected and stored at -70 °C. An 
aliquot of the supernatant was used to determine protein concentration by the 
Coomassie blue method (Bradford 1976). 
Prior to Western Blot, TRPA1 proteins were immunoprecipitated with TRPA1 
antibody NB110-40763 (2 μg, NovusBiologicals, LCC, Littleton, CO, USA) or 
SAB2105082 (2 μg, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) 
using protein A/G PLUS-Agarose (sc-2003, Santa Cruz Biotechnology, Inc.), 
according to the manufacturer’s instructions. The immunoprecipitated TRPA1 
protein samples were loaded onto an 8 % SDS-polyacrylamide electrophoresis 
 61 
gel and electrophoresed for 5 h at 100 V in a buffer containing Tris–HCl (95 mM), 
glycine (960 mM), and SDS (0.5%). After electrophoresis, the proteins were 
transferred to a nitrocellulose membrane (Novex, Life Technologies). After 
transfer, the membrane was blocked in TBS/T (20 mM Tris–base pH 7.6, 150 
mM NaCl, 0.1% Tween-20) containing 5% nonfat milk for 1 h at room 
temperature and incubated in the blocking solution at 4 °C overnight with the 
primary antibody for TRPA1 (NB110-40763, 1:1000, NovusBiologicals). On the 
next day, the membrane was incubated in the blocking solution for 1 h at room 
temperature with the respective secondary antibody for TRPA1 (goat anti-rabbit 
HRP-conjugate sc-2004, 1:10 000, Santa Cruz Biotechnology, Inc.). Bound 
antibody was detected using Super Signal® West Dura chemiluminescent 
substrate (Pierce, Rockford, IL, USA) and Image Quant LAS 4000 mini imaging 
system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
4.6 Enzyme-linked immunosorbent assay (ELISA) (I,III,IV) 
Culture medium samples were stored at -20 °C until assayed. Concentrations of 
IL-6, MMP-1, MMP-3, MMP-13, PGE2 and FGF-2 in medium samples were 
determined by ELISA with commercial reagents (PGE2: Cayman Chemical Co., 
Ann Arbor, MI, USA; human IL-6: eBioscience Inc. San Diego, CA, USA; MMP-
1, MMP-3, MMP-13, FGF-2 and mouse IL-6: R&D Systems Europe Ltd). 
4.7 Fluo-3-AM measurements (I,II) 
TRPA1 mediated Ca2+ influx was measured in HEK 293 cells transfected with 
human TRPA1 plasmid, in human T/C28a2 chondrocytes and in primary human 
OA chondrocytes. The cells were loaded with 4 μM fluo-3-acetoxymethyl ester 
(Fluo-3-AM, Sigma-Aldrich) and 0.08 % Pluronic F-127® (Sigma-Aldrich) in 
Hanks’ balanced salt solution (HBSS, Lonza) containing 1 mg/ml of bovine 
serum albumin, 2.5 mM probenecid and 25 mM HEPES pH 7.2 (all from Sigma-
Aldrich) for 30 min at room temperature. The intracellular free Ca2+ levels were 
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assessed by Victor3 1420 multilabel counter (Perkin Elmer, Waltham, MA, USA) 
at excitation/emission wavelengths of 485/535 nm. In the experiments, the cells 
were first pre-incubated with the TRPA1 antagonist HC-030031 (100 μM, Sigma-
Aldrich) or the vehicle for 30 min at +37 °C. Thereafter, the TRPA1 agonist allyl 
isothiocyanate (AITC, 50 μM, Sigma-Aldrich) was added and the measurements 
were continued for 30 s after which a robust Ca2+ influx was induced by 
application of the control ionophore compound ionomycin (1 μM, Sigma-
Aldrich). 
4.8 Next-Generation RNA-sequencing (NGS) (III) 
Samples for next-generation RNA sequencing were prepared by pooling 
chondrocytes from 11 TRPA1 KO mice and 12 corresponding WT mice. Five 
samples obtained from the pool of TRPA1 KO mice and four samples from the 
pool of WT mice were sequenced. Sequencing of the samples was performed at 
the Finnish Institute of Molecular Medicine (FIMM) sequencing core, Helsinki, 
Finland, using the Illumina HiSeq 2500 sequencing platform. Sequencing depth 
was 20 million paired-end reads 100 bp in length. Initial analysis of the data was 
performed in the FIMM sequencing core (up to the preparation of the count 
matrices). Read quality was first assessed using FastQC (Andrews 2010), and the 
reads were trimmed using Trimmomatic (Bolger and Giorgi 2014). Trimmed 
reads were aligned to reference mouse genome with STAR (Dobin et al. 2013). 
Count matrices were prepared with the featureCounts program (Liao et al. 2014). 
Gene expression levels were calculated as Reads per Kilobase per Million 
(RPKM) (Mortazavi et al. 2008). Differential gene expression was assessed with 
DESeq2 (Love et al. 2014) using the Chipster software (Chipster software, CSC 
- IT Center for Science, Espoo, Finland). For the purposes of further analysis, 
genes with a minimum of 2.0 fold change (FC) and False Discovery Rate (FDR)-
corrected p-value < 0.05 were deemed biologically and statistically significant. 
Functional analysis was performed using the DAVID database (Huang da et al. 
2009). 
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4.9 Statistics (I-IV) 
Data were analyzed using SPSS version 20.0 for Windows software (SPSS Inc, 
Chicago, IL, USA) and Graph-Pad InStat version 3.00 software (GraphPad 
Software, San Diego, CA, USA). The results are presented as mean + SEM unless 
otherwise indicated. 
Unpaired t-test, paired t-test, ordinary or repeated measures one-way analysis 
of variance (ANOVA) followed by Dunnett or Bonferroni correction for multiple 
comparisons were used in the statistical analysis as indicated. Differences were 
considered significant at * = p < 0.05, ** = p < 0.01 and *** = p < 0.001. 
In study IV, the data used for correlation studies were natural logarithm (LN) 
transformed in order to obtain a normal distribution. Pearson’s correlation 
analysis was carried out, with r values over +0.3 and under -0.3 considered to 
indicate a correlation. 
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5 SUMMARY OF THE RESULTS 
5.1 TRPA1 is functionally expressed in human osteoarthritic 
chondrocytes (I) 
5.1.1 TRPA1 mRNA is expressed in human chondrocytes 
The first step of this study was to examine if TRPA1 mRNA is expressed in 
human chondrocytes. By stimulating primary human osteoarthritic chondrocytes 
and immortalized human T/C28a2 chondrocytes with the inflammatory cytokine 
IL-1β, we were able to show that TRPA1 mRNA is indeed expressed in both of 
these cell types. The TRPA1 mRNA expression was found to peak at 48h in 
primary human OA chondrocytes, and at 6h in human T/C28a2 chondrocytes 
after adding IL-1β, and to decline thereafter (Figure 5). 
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Figure 5.  Primary human OA chondrocytes (A) and human T/C28a2 chondrocyte cell line (B) 
express TRPA1 mRNA and its expression is enhanced by IL-1 in a time-dependent manner. 
Cultures of primary human OA chondrocytes (A) and human T/C28a2 chondrocytes (B) were 
stimulated with IL-1β (100 pg/ml) for 0–96 h and 0–24 h, respectively, and thereafter total RNA 
was extracted. TRPA1 mRNA levels were measured by RT-qPCR, and the results were normalized 
against GAPDH mRNA. The mRNA levels are expressed as arbitrary units with the levels 
measured at 24 h (A; primary OA chondrocytes) or 6 h (B; T/C28a2 chondrocytes) set as 100 %; 
and the values at the other time points are related to those values. Primary chondrocyte samples 
were obtained from three to five different donors and the experiments were carried out in duplicate. 
Human T/C28a2 chondrocyte experiments were carried out in quadruplicate. Results are 
expressed as mean + SEM. One-way ANOVA followed by Dunnett’s post-test was used in the 
statistical analysis; **indicates p < 0.01 compared to the control (0 h) sample. (Modified from 
Nummenmaa et al. Arthritis Res Ther. 2016, 18:185) 
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5.1.2 TRPA1 mRNA expression is increased by OA-related inflammatory factors 
We next investigated whether known OA-related inflammatory mediators IL-1β, 
IL-17, LPS and resistin increased the expression of TRPA1 mRNA in human 
chondrocytes. Primary human OA chondrocytes were stimulated with increasing 
doses of IL-1β, IL-17 and resistin, and a single dose of LPS. Human T/C28a2 
chondrocytes were treated with increasing doses of IL-1β, and single doses of IL-
17 and LPS. All of these factors upregulated the expression of TRPA1 mRNA; 
IL-1β, IL-17 and resistin in a concentration dependent manner in primary 
chondrocytes and IL-1β in T/C28a2 chondrocytes (Figure 6). 
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Figure 6.  TRPA1 mRNA expression is increased following stimulation with inflammatory 
factors IL-1β, IL-17, LPS, and resistin in primary human OA chondrocytes (A-D) and in 
human T/C28a2 chondrocyte cell line (E). Isolated primary human OA chondrocytes were 
stimulated with IL-1β (1–100 pg/ml) (A), IL-17 (10–100 ng/ml) (B), LPS (10 ng/ml) (C) and resistin 
(0.3–3 μg/ml) (D); and human T/C28a2 chondrocytes with IL-1β (1–100 pg/ml), IL-17 (100 ng/ml) 
and LPS (10 ng/ml) (E) for 24 h; and thereafter total RNA was extracted. TRPA1 mRNA levels 
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were measured by RT-qPCR, and the results were normalized against GAPDH mRNA levels. The 
results are expressed as a percentage in comparison to untreated control samples, which were set 
as 100 %. Primary chondrocyte samples were obtained from four different donors and the 
experiments were performed in duplicate. Human T/C28a2 chondrocyte experiments were carried 
out in quadruplicate. Results are expressed as mean + SEM. Repeated measures ANOVA (A, B, 
D) and one-way ANOVA (E) followed by Dunnett’s post-test or paired t test (C) was used in the 
statistical analysis; *p < 0.05 and **p < 0.01, compared to the untreated control samples. (Modified 
from Nummenmaa et al. Arthritis Res Ther. 2016, 18:185) 
5.1.3 Human chondrocytes express a functional TRPA1 channel 
After determining the expression of TRPA1 mRNA in human chondrocytes, we 
set out to show that the mRNA is translated into protein. We stimulated primary 
human OA chondrocytes and immortalized human T/C28a2 chondrocytes with 
IL-1β, extracted total protein, and performed Western Blot analysis. Remarkably, 
we were able to show the production of TRPA1 protein in primary human OA 
chondrocytes as well as immortalized T/C28a2 chondrocytes (Figure 7). HEK 
293 cells transiently transfected with hTRPA1 plasmid were used as positive 
control cells in the Western Blot analysis. 
In order to show that TRPA1 proteins produced by primary human OA 
chondrocytes and immortalized T/C28a2 chondrocytes form a functional TRPA1 
channel, Ca2+ measurements were performed. The activation of the TRPA1 
channel causes a substantial influx of Ca2+ into the activated cell (Nilius 2007). 
Therefore, to establish the presence of a functional TRPA1 channel, we 
stimulated the chondrocytes with the selective TRPA1 agonist AITC and 
measured the change in intracellular calcium with the Fluo-3-AM assay. We 
found that AITC stimulation elicited an increase in intracellular calcium. 
Furthermore, it was seen that treatment with the selective TRPA1 antagonist HC-
030031 prevented this reaction. HEK 293 cells transiently transfected with 
hTRPA1 plasmid were used as positive control cells (Figure 8). 
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Figure 7.  TRPA1 protein is expressed in primary human OA chondrocytes and human T/C28a2 
chondrocyte cell line. Chondrocyte cultures were stimulated with IL-1β (100 pg/ml) for 24 h. 
Extracted proteins were immunoprecipitated and TRPA1 was detected with Western blot analysis. 
HEK 293 cells transiently transfected with human TRPA1 plasmid were used as a positive control. 
Representative blot of three independent experiments with similar results. (Reprinted with 
permission from Nummenmaa et al. Arthritis Res Ther. 2016, 18:185) 
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Figure 8.  The TRPA1 ion channel is functional in primary human OA chondrocytes (A, B) and 
human T/C28a2 chondrocyte cell line (C) as shown by TRPA1-mediated Ca2+ influx. Primary 
human chondrocytes (A, B) and human T/C28a2 chondrocytes (C) were cultured with or without 
IL-1β (100 pg/ml) for 24 h. HEK 293 cells transfected with a plasmid encoding human TRPA1 were 
used as positive control cells (D). The cells were loaded with Fluo-3-AM and the TRPA1-mediated 
Ca2+ influx was measured by Victor3 multilabel counter at excitation/emission wavelengths of 
485/535 nm at 1/s frequency. The cells were first preincubated with the TRPA1 antagonist HC-
030031 (100 μM) or the vehicle for 30 min at +37 °C. In the measurements, basal fluorescence 
was first recorded for 15 s and thereafter the selective TRPA1 agonist allyl isothiocyanate (AITC; 
50 μM) was added and the measurement was continued for 30 s after which the control ionophore 
compound ionomycin (1 μM) was introduced to the cells. IL-1β stimulation resulted in an elevation 
in AITC-induced Ca2+ influx compared to unstimulated control cells, and it was attenuated by the 
selective TRPA1 antagonist HC-030031. The results were normalized against the background and 
expressed as mean of eight simultaneous measurements. Curves in A, C and D express results 
from one representative experiment of four independent experiments with similar results. In (B) 
area under the curve (AUC) from 15 to 45 s was calculated from measurements of primary 
chondrocytes from four donors (each with eight repeats). Results are expressed as mean + SEM. 
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Repeated measures ANOVA followed by Dunnett’s post-test was used in the statistical analysis; 
**p < 0.01 compared to the IL-1β-treated samples. (Modified from Nummenmaa et al. Arthritis Res 
Ther. 2016, 18:185) 
 
5.2 TRPA1 expression is downregulated by dexamethasone and 
aurothiomalate in human chondrocytes (II) 
Since TRPA1 is an inducible channel, we wanted to investigate whether clinically 
used drugs affect the expression of TRPA1. We tested the effects of disease 
modifying antirheumatic drugs (DMARDs) methotrexate, sulfasalazine, 
hydroxychloroquine and aurothiomalate, the glucocorticoid dexamethasone and 
the non-steroidal anti-inflammatory drug ibuprofen on the expression of TRPA1 
in human T/C28a2 chondrocytes. Dexamethasone and aurothiomalate were found 
to inhibit TRPA1 mRNA expression in a dose-dependent manner (Figure 9A), 
whereas methotrexate, sulfasalazine, hydroxychloroquine and ibuprofen had no 
effect when tested at a 10 μM concentration. Importantly, dexamethasone and 
aurothiomalate were also found to inhibit TRPA1 protein expression in these cells 
(Figure 9C). 
We next confirmed that dexamethasone and aurothiomalate inhibited TRPA1-
dependent Ca2+ influx, indicating that the formation of a functional TRPA1 
channel was also inhibited. Human chondrocytes that were cultured in the 
presence of IL-1β showed an increase in TRPA1-dependent Ca2+ influx. This 
effect was prevented in cells, which were treated with dexamethasone or 
aurothiomalate, confirming the downregulation of a functional TRPA1 channel 
by these two drugs (Figure 10). 
To verify the effects of dexamethasone and aurothiomalate in primary 
chondrocytes, we stimulated primary human OA chondrocytes with IL-1β in the 
presence and absence of dexamethasone and aurothiomalate. We discovered that 
dexamethasone and aurothiomalate also inhibited IL-1β-induced TRPA1 
expression in these cells (Figure 9B). 
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Glucocorticoids and aurothiomalate have previously been shown to inhibit 
activation of the transcription factor NF-κB (Hartmann et al. 2016; Vuolteenaho 
et al. 2005). Furthermore, the NF-κB signaling pathway has been proposed to be 
involved in TRPA1 induction (Hatano et al. 2012). Due to this, we investigated 
the effect of NF-κB inhibitor PDTC on the expression of TRPA1. Interestingly, 
also PDTC downregulated TRPA1 expression in primary human OA and 
immortalized T/C28a2 chondrocytes (Figure 9A-B). 
 
Figure 9.  Dexamethasone and aurothiomalate inhibit TRPA1 expression in human 
chondrocytes. Human chondrocytes (primary human chondrocytes or T/C28a2 chondrocyte cell 
line) were cultured with IL-1β alone or in combination with the anti-inflammatory compounds 
dexamethasone or aurothiomalate, or with the selective NF-κB inhibitor PDTC at concentrations 
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given in the figure. (A, B) For TRPA1 mRNA expression analysis, human T/C28a2 chondrocytes 
(A) were incubated for 6 hours and the experiments were carried out in quadruplicate; primary 
chondrocytes (B) were incubated for 24 hours and the experiments were carried out in duplicate 
and repeated with cells from six different donors. TRPA1 mRNA levels were measured by RT-
qPCR, and the results were normalised against GAPDH mRNA levels. (C) For TRPA1 protein 
analysis human T/C28a2 chondrocytes were incubated for 24 hours after which proteins were 
extracted and immunoprecipitated. TRPA1 protein was detected with Western blot. The figure 
shows one representative blot of six independent experiments with similar results. Results are 
expressed as a percentage compared to IL-1β-treated samples which are set as 100%, and shown 
as mean + SEM. Ordinary (A,C) or repeated measures one-way ANOVA (B) followed by Bonferroni 
post-test was used in the statistical analysis, ***p < 0.001 compared to the IL-1β-treated samples. 
(Modified from Nummenmaa et al. RMD Open 2017, 3(2):e000556) 
 
Figure 10.  Dexamethasone and aurothiomalate inhibit the functional TRPA1 ion channel. Human 
T/C28a2 chondrocytes were incubated with IL-1β alone or in combination with dexamethasone or 
aurothiomalate for 24 hours. Thereafter, the cells were loaded with Fluo-3-AM and TRPA1-
mediated Ca2+ influx was measured by Victor3 multilabel counter at excitation/emission 
wavelengths of 485/535 nm at 1/s frequency. In the measurements, basal fluorescence was first 
recorded for 15 s and thereafter the selective TRPA1 agonist allyl isothiocyanate (AITC; 50 μM) 
was added and the measurements were continued for 30 s. The results were normalized against 
the background and expressed as a mean of eight measurements. Results in (A) are expressed 
as relative fluorescence units, and in (B) AUC from 15 to 45 s was calculated. Results in (B) are 
expressed as mean + SEM. One-way ANOVA followed by Bonferroni post-test was used in the 
statistical analysis, ***p < 0.001 compared to the IL-1β-treated samples. (Modified from 
Nummenmaa et al. RMD Open 2017, 3(2):e000556) 
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5.3 Effects of TRPA1 in chondrocytes and cartilage (I,III) 
Not only was the expression of TRPA1 in chondrocytes and cartilage shown for 
the first time in this study, but it was also the first time for the functions of TRPA1 
in this tissue to be examined. The effects of TRPA1 on the expression of OA-
related inflammatory and catabolic factors in chondrocytes and cartilage were 
investigated by using pharmacological inhibitors, as well as genetic deletion of 
TRPA1. 
5.3.1 TRPA1 mediates IL-6 expression in human OA chondrocytes, and murine 
cartilage and chondrocytes 
We examined the effect of TRPA1 on the OA-related cytokine IL-6 by using 
cartilage and chondrocytes from TRPA1 KO and corresponding WT mice, as well 
as primary human OA chondrocytes. In next-generation RNA sequencing (RNA-
Seq) analysis, IL-6 was found to be highly expressed in IL-1β-treated 
chondrocytes from WT mice, with the expression level being significantly lower 
in chondrocytes from TRPA1 KO mice (Table 4). Due to this finding, we 
examined the RNA-seq data for other members of the IL-6 cytokine family and 
found that LIF and IL-11 were also significantly downregulated in chondrocytes 
from TRPA1 KO mice (Table 4).   
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Table 4.  Members of IL-6 cytokine family with attenuated expression in chondrocytes from 
TRPA1 KO mice compared to cells from corresponding WT mice. Next-generation RNA 
sequencing was performed on IL-1β-treated chondrocytes obtained from TRPA1 deficient 
(knockout, KO) and corresponding wild-type (WT) mice. Mean expression is given as reads per 
kilobase per million (RPKM). Ratios of gene expression levels are given as fold change (FC) values 
determined with DESeq2, with negative values denoting downregulated genes in chondrocytes 
from TRPA1 KO mice. RNA-seq results were verified by qRT-PCR, where p-values are given as 
Bonferroni-adjusted. 
Gene 
RNA-Seq qRT-PCR 
RPKM 
(WT) 
RPKM 
(TRPA1 KO) FC Adj. p-value FC Adj. p-value 
IL-6 Interleukin 6 202.37 48.26 -3.86 < 0.0001 -8.93 < 0.001 
Lif Leukemia inhibitory factor 12.03 5.19 -2.16 < 0.0001 -3.95 < 0.001 
IL-11 Interleukin 11 1.11 0.21 -4.14 < 0.0001 -4.56 < 0.001 
 
Next, we verified the results from the RNA-Seq data with qRT-PCR (Table 4) 
and examined the findings further with a larger population of chondrocytes from 
TRPA1 KO and corresponding WT mice. Chondrocytes from both genotypes 
were treated with IL-1β alone, and chondrocytes from WT mice were additionally 
treated with IL-1β together with two selective TRPA1 antagonists: HC-030031 
and TCS 5861528. IL-1β upregulated the expression of IL-6 in both genotypes, 
however this response was significantly attenuated in chondrocytes from TRPA1 
KO mice. Further, the TRPA1 antagonists HC-030031 and TCS 5861528 
significantly inhibited the IL-1β-enhanced expression of IL-6 in WT 
chondrocytes (Figure 11A). The expression of IL-11 was also upregulated by IL-
1β and attenuated by the TRPA1 antagonists HC-030031 and TCS 5861528, in 
chondrocytes from WT mice. IL-1β had no effect on IL-11 expression in 
chondrocytes from TRPA1 KO mice (Figure 11B). 
The effect of TRPA1 on the production of IL-6 was also examined by using 
articular cartilage explants from TRPA1 KO and corresponding WT mice. IL-1β 
treatment upregulated IL-6 production in cartilage from WT mice. This response 
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was attenuated in cartilage from TRPA1 KO mice, where IL-1β did not cause a 
significant increase in the production of IL-6 (Figure 12). 
 
 
Figure 11.  IL-1β-induced IL-6 (A) and IL-11 (B) expression is attenuated by genetic deletion and 
pharmacological inhibition of TRPA1 in murine chondrocytes. Chondrocytes were obtained 
from TRPA1 deficient (knockout, KO) mice and corresponding wild-type (WT) mice. The 
chondrocytes were cultured with IL-1β (100 pg/ml) alone, or together with the selective TRPA1 
antagonists HC-030031 (100 μM) or TCS 5861528 (100 μM) for 24 h and thereafter total RNA was 
extracted. IL-6 and IL-11 mRNA levels were measured with qRT-PCR and normalized against 
GAPDH mRNA levels. The results are expressed as fold change in comparison to the control 
samples of each genotype. WT n = 13 (TCS treatment n = 10), KO n = 15. Results are expressed 
as mean + SEM. One-way ANOVA followed by Bonferroni post-test was used in the statistical 
analysis; *** p < 0.001 compared to the IL-1β-treated WT samples. 
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Figure 12.  IL-1β-induced production of IL-6 in cartilage is attenuated by genetic deletion of 
TRPA1. Cartilage samples were obtained from TRPA1 deficient (knockout, KO) mice and 
corresponding wild-type (WT) mice. The cartilage pieces were cultured in the presence of IL-1β 
(100 pg/ml) or without stimulation for 42 h, after which the culture medium was collected and IL-6 
was measured by immunoassay. The results are expressed as mean + SEM, n = 6. One-way 
ANOVA followed by Bonferroni post-test was used in the statistical analysis; ** p < 0.01, *** p < 
0.001. 
Finally, we wanted to verify that the results seen in mouse cartilage and 
chondrocytes are also found in human chondrocytes. Primary human OA 
chondrocytes were treated with IL-1β and the selective TRPA1 antagonist HC-
030031. The results showed that the TRPA1 antagonist attenuated the expression 
of IL-6, LIF and IL-11 in these cells, suggesting that TRPA1 is involved in the 
expression of these factors also in human OA cartilage (Figure 13). 
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Figure 13.  IL-1β-enhanced expression of IL-6 (A,B), LIF (C) and IL-11 (D) in primary human OA 
chondrocytes is attenuated by pharmacological inhibition of TRPA1. Cultures of primary 
human OA chondrocytes were stimulated with IL-1β (100 pg/ml) in the presence and absence of 
selective TRPA1 antagonist HC-030031 (100 μM) for 24 h, after which the medium was collected, 
and total mRNA was extracted. IL-6 was measured from the cell culture medium with immunoassay 
(B), and IL-6, Lif and IL-11 mRNA was measured by qRT-PCR and normalized against GAPDH 
mRNA levels (A, C-D). Results are expressed as a percentage compared to IL-1β-treated samples, 
which are set as 100 % (A, C-D) and shown as mean + SEM. Samples were obtained from seven 
different donors and the experiments were carried out in duplicate. Paired t-test was used in the 
statistical analysis; *p < 0.05 and ** p < 0.01 compared to IL-1β-treated samples 
5.3.2 FGF-2 expression is attenuated by pharmacological inhibition and genetic 
deletion of TRPA1 in human OA and murine chondrocytes 
FGF-2 is an intriguing inflammatory and catabolic factor that is found at elevated 
concentrations in the synovial fluid of OA patients (Ellman et al. 2013). We set 
out to investigate whether TRPA1 is involved in the regulation of FGF-2 
expression. By utilizing next-generation RNA sequencing analysis, we found that 
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the expression of FGF-2 was attenuated in IL-1β-treated chondrocytes from 
TRPA1 KO mice compared to corresponding WT mice (RPKM 9.74 and 31.48, 
respectively). These results were verified with qRT-PCR using a larger set of 
analogous samples. Treatment with IL-1β resulted in the upregulation of FGF-2 
expression in chondrocytes from WT mice, but not in chondrocytes from TRPA1 
KO mice (Figure 14). 
The results were then further investigated with primary human OA 
chondrocytes by stimulating the cells with IL-1β alone and together with the 
selective TRPA1 antagonist HC-030031. In these cells, IL-1β treatment increased 
the expression of FGF-2, and this effect was significantly attenuated by the 
TRPA1 antagonist HC-030031 (Figure 15). Together these results suggest that 
TRPA1 is involved in the regulation of FGF-2 expression in chondrocytes. 
 
 
Figure 14.  IL-1β-enhanced expression of FGF-2 is attenuated by genetic deletion of TRPA1 in 
mouse chondrocytes. Chondrocytes were obtained from TRPA1 deficient (knockout, KO) mice 
and corresponding wild-type (WT) mice. The chondrocytes were cultured without stimulation or 
with IL-1β (100 pg/ml) for 24 h and thereafter total RNA was extracted. FGF-2 mRNA levels were 
measured with qRT-PCR and normalized against GAPDH mRNA levels. The results are expressed 
as fold change in comparison to the control samples of each genotype. WT n = 13-14, KO n = 16. 
Results are expressed as a percentage compared to IL-1β-treated samples which are set as 
100 %, and shown as mean + SEM. One-way ANOVA followed by Bonferroni post-test was used 
in the statistical analysis; *** p < 0.001 compared to the IL-1β-treated WT samples. 
 
 80 
 
Figure 15.  IL-1β-enhanced expression of FGF-2 is attenuated by pharmacological inhibition of 
TRPA1 in primary human OA chondrocytes. Cultures of primary human OA chondrocytes were 
stimulated with IL-1β (100 pg/ml) in the presence and absence of the selective TRPA1 antagonist 
HC-030031 (100 μM) for 24 h, after which total mRNA was extracted. FGF-2 mRNA was measured 
by qRT-PCR and normalized against GAPDH mRNA levels. Results are expressed as a 
percentage compared to IL-1β-treated samples, which are set as 100 % and shown as mean + 
SEM. Samples were obtained from nine different donors and the experiments were carried out in 
duplicate or quadruplicate. Paired t-test was used in the statistical analysis; *p < 0.05 compared to 
IL-1β-treated samples. 
 
5.3.3 MMP-enzyme and PGE2 production is attenuated by genetic deletion and 
pharmacological inhibition of TRPA1 
MMP-enzymes are considered key mediators of cartilage ECM degradation in 
OA (Glyn-Jones et al. 2015; Troeberg and Nagase 2012). In addition, the 
prostaglandin E2 is an important mediator of pain in arthritic conditions (Lee, AS. 
et al. 2013). Due to the important roles these factors play in OA, we aimed to 
investigate whether TRPA1 affects their production. This was examined by 
utilizing cartilage explants from TRPA1 KO and corresponding WT mice as well 
as pharmacological inhibition of TRPA1 in primary human OA chondrocytes. 
We treated cartilage explants from TRPA1 KO and corresponding WT mice 
with IL-1β, which expectedly upregulated the production of MMP-3 and PGE2. 
Remarkably, this effect was significantly attenuated in the cartilage explants from 
TRPA1 KO mice as compared to the corresponding WT mice (Figure 16). We 
 81 
then further investigated these findings in primary human OA chondrocytes by 
stimulating the cells with IL-1β alone and together with the selective TRPA1 
antagonist HC-030031. We found that IL-1β-enhanced production of MMP-1, 
MMP-3, MMP-13 and PGE2 was attenuated with HC-030031 in these cells 
(Figure 17). The results suggest that TRPA1 has a role in the upregulation of these 
catabolic factors in OA cartilage. 
 
Figure 16.  IL-1β-induced production of MMP-3 (A) and PGE2 (B) in the cartilage is attenuated by 
genetic deletion of TRPA1. Cartilage samples were obtained from TRPA1-deficient (knockout, 
KO) and corresponding wild-type (WT) mice. The samples were cultured with and without IL-1β 
(100 pg/ml) for 42 h and thereafter the culture medium was collected and analyzed for 
concentrations of MMP-3 and PGE2 by ELISA. The results are expressed as a percentage 
compared to untreated control samples, which are set as 100 % and shown as mean + SEM, n = 6–
9. Unpaired t-test was used in the statistical analysis; *p < 0.05, **p < 0.01, and ***p < 0.001 
compared to the WT mice. (Modified from Nummenmaa et al. Arthritis Res Ther. 2016, 18:185) 
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Figure 17.  IL-1β-enhanced expression of MMP-1 (A), MMP-3 (B), MMP-13 (C) and PGE2 (D) in 
primary human OA chondrocytes is attenuated by pharmacological inhibition of TRPA1. 
Cultures of primary human OA chondrocytes were stimulated with IL-1β (100 pg/ml) in the 
presence and absence of the selective TRPA1 antagonist HC-030031 (100 μM) for 24 h. MMP-1, 
MMP-3, MMP-13, and PGE2 concentrations in the culture media were measured by ELISA and the 
results are expressed as mean + SEM. Samples were obtained from eight patients and the 
experiments were carried out in duplicate. Paired t-test was used in the statistical analysis; *p < 
0.05, **p < 0.01, and ***p < 0.001 compared to the IL-1β-treated samples. (Modified from 
Nummenmaa et al. Arthritis Res Ther. 2016, 18:185) 
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5.4 Effects of FGF-2 and FGF receptor antagonists in human OA 
cartilage and chondrocytes (IV) 
During this thesis, we observed that TRPA1 is involved in regulating the 
expression of FGF-2 in chondrocytes. Due to this result and the intriguing roles 
fibroblast growth factors have been proposed to play in chondrocyte metabolism 
(Ellman et al. 2013), we wanted to investigate the effects of FGF-2 and 
commercial FGF receptor antagonists in OA cartilage and chondrocytes. 
5.4.1 FGF-2 correlates with MMP-enzymes in human OA cartilage explants 
The correlations between FGF-2 and catabolic MMP-enzymes were investigated 
using cartilage samples obtained from 97 OA patients undergoing knee 
replacement surgery. The concentrations of FGF-2, MMP-1 and MMP-13 
released from the cartilage explants into the culture media during a 42 h 
incubation period were measured. OA cartilage was found to release all of the 
measured factors: FGF-2 28.4 ± 1.5 pg/100 mg cartilage, MMP-1 12.7 ± 1.4 
ng/100 mg cartilage, and MMP-13 1.0 ± 0.1 ng/100 mg cartilage. Notably, the 
levels of FGF-2 correlated positively with the levels of both MMP-1 (r = 0.414, 
p < 0.001) and MMP-13 (r = 0.362, p < 0.001) (Figure 18). 
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Figure 18.  Levels of FGF-2 released by human OA cartilage correlate positively with the levels 
of (A) MMP-1 and (B) MMP-13. Cartilage explants from OA patients (n = 97) undergoing joint 
replacement surgery were incubated for 42 h and the levels of FGF-2, MMP-1, and MMP-13 
released into the culture medium were measured by immunoassay. Results were natural log (LN) 
transformed to obtain a normal distribution and analyzed using Pearson correlation. (Reprinted 
with permission from Nummenmaa et al. Scand J Rheumatol. 2015, 44(4):321) 
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5.4.2 FGF-2 stimulation exerts catabolic and anti-anabolic responses in human 
OA chondrocytes 
FGF-2 has been shown to signal through four tyrosine kinase FGF receptors: 
FGFR1-4 (Ornitz and Itoh 2015). We wanted to confirm that the human OA 
chondrocytes express these receptors and found that the chondrocytes expressed 
all four receptors, with the expression of the catabolism-associated receptor 
FGFR1 being the highest and FGFR4 being extremely low (Figure 19). 
 
Figure 19.  FGF receptor expression profiles of primary human OA chondrocytes. Chondrocytes 
were cultured for 24 h and the mRNA expression of FGFR1–4 was detected by qRT-PCR. The 
results from three patients were combined. Results are expressed as a percentage compared to 
FGFR1, which is set as 100 % and are shown as mean + SEM. (Modified from Nummenmaa et al. 
Scand J Rheumatol. 2015, 44(4):321) 
 
Primary human OA chondrocytes were then cultured in the presence and 
absence of FGF-2 for 24h and the expression of catabolic MMP-enzymes as well 
as cartilage matrix components aggrecan and collagen II were determined. FGF-
2 increased the production of the cartilage matrix degrading enzymes MMP-1 and 
MMP-13. Conversely, the expression of aggrecan and collagen II were decreased 
by FGF-2 stimulation compared to untreated control cells (Figure 20). 
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Figure 20.  FGF-2 enhances the production of MMP-1 (A, B) and MMP-13 (C, D) and down-
regulates the expression of aggrecan (E) and collagen II (F) in primary human OA 
chondrocytes. Chondrocyte cultures were stimulated with FGF-2 (200 ng/ml) for 24 h. MMP, 
aggrecan and collagen II mRNA expression was detected by qRT-PCR, and MMP production was 
measured by immunoassay. The mRNA expression levels were normalized against GAPDH mRNA 
levels. The results from nine patients were combined for protein production analysis (B, D) and 
from 10 patients for mRNA expression analysis (A, C, E, F). Results are expressed as a percentage 
compared to untreated control samples, which are set as 100 % and shown as mean + SEM. 
Paired t-test was used in the statistical analysis, *p < 0.05, **p < 0.01, and ***p < 0.001 compared 
to untreated control samples. (Modified from Nummenmaa et al. Scand J Rheumatol. 2015, 
44(4):321) 
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5.4.3 FGF-2 receptor antagonists induce anabolic and anti-catabolic responses 
in human OA chondrocytes 
Primary human OA chondrocytes were treated with increasing concentrations of 
the FGF-2 receptor antagonists AZD4547 and NVP-BGJ398 in the presence and 
absence of FGF-2. Both antagonists inhibited the mRNA and protein production 
of MMP-1 and MMP-13 in a dose-dependent manner. This effect was seen with 
the exogenous FGF-2 stimulation, and surprisingly, also without FGF-2 
stimulation (Figures 21-22). Due to the results seen without exogenous FGF-2 
treatment, we investigated whether the primary human OA chondrocytes 
produced FGF-2. We found that the cells did indeed produce FGF-2 at a level of 
1.8 ± 1.0 ng/106 cells (n = 5). 
 
Figure 21.  FGF-2 antagonists AZD4547 and NVP-BGJ398 downregulate the expression of MMP-
1 (A, B) and MMP-13 (C, D) in the presence and absence of exogenous FGF-2. Isolated primary 
human OA chondrocytes were treated with increasing concentrations of AZD4547 and BGJ398  
(1–300 nM) in the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. MMP-1 and 
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MMP-13 mRNA levels were measured by qRT-PCR, and the results were normalized against 
GAPDH mRNA levels. The results from two or three patients were combined. The results are 
expressed as a percentage in comparison to untreated control samples, which are set as 100 % 
and shown as mean + SEM. Repeated-measures ANOVA with Bonferroni’s post-test was used in 
the statistical analysis, *p < 0.05, **p < 0.01, and ***p < 0.001 compared to untreated control or 
FGF-2 treated samples. (Modified from Nummenmaa et al. Scand J Rheumatol. 2015, 44(4):321) 
 
Figure 22.  FGF-2 antagonists AZD4547 and NVP-BGJ398 down-regulated the production of 
MMP-1 (A, B) and MMP-13 (C, D) in the presence and absence of exogenous FGF-2. Isolated 
primary human OA chondrocytes were treated with increasing concentrations of AZD4547 and 
BGJ398 (1–300 nM) in the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. MMP-
1 and MMP-13 protein levels in the culture media were measured by immunoassay. The results 
from two or three patients were combined. The results are expressed as a percentage in 
comparison to untreated control samples, which are set as 100% and shown as mean + SEM. 
Repeated-measures ANOVA with Bonferroni’s post-test was used in the statistical analysis, 
*p <0.05, **p <0.01, and ***p < 0.001 compared to untreated control or FGF-2 treated samples. 
(Modified from Nummenmaa et al. Scand J Rheumatol. 2015, 44(4):321) 
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We also examined the effects of the FGF-2 receptor antagonists AZD4547 and 
NVP-BGJ398 on the major cartilage matrix components aggrecan and collagen 
II. Both compounds dose-dependently increased the expression of aggrecan and 
collagen II in the presence and absence of FGF-2 stimulation (Figure 23). Taken 
together, these FGF receptor antagonists showed a beneficial effect on the balance 
between catabolic and anabolic factors in cartilage by shifting the balance towards 
anabolism. 
 
Figure 23.  FGF-2 antagonists AZD4547 and NVP-BGJ398 up-regulated the expression of 
aggrecan (A, B) and collagen II (C, D) in the presence and absence of exogenous FGF-2. 
Isolated primary human OA chondrocytes were treated with increasing concentrations of AZD4547 
and BGJ398 (1–300 nM) in the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. 
Aggrecan and collagen II mRNA levels were measured by qRT-PCR, and the results were 
normalized against GAPDH mRNA levels. The results from three patients were combined. The 
results are expressed as a percentage in comparison to untreated control samples, which are set 
as 100 % and shown as mean + SEM. Repeated-measures ANOVA with Bonferroni’s post-test 
was used in the statistical analysis, *p < 0.05, **p < 0.01, and ***p < 0.001 compared to untreated 
control or FGF-2 treated samples. (Modified from Nummenmaa et al. Scand J Rheumatol. 2015, 
44(4):321) 
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6 DISCUSSION 
6.1 Methodology 
At commencement of this study, the expression and function of the TRPA1 cation 
channel had been widely studied in neurons, but its expression and functions in 
nonneuronal cells were less understood. The aim of the present study was to 
examine the possible expression of TRPA1 in primary human OA chondrocytes 
and to investigate its functions in OA cartilage. In the experiments, cartilage 
explants and primary chondrocytes isolated from leftover pieces of OA cartilage 
from knee-joint replacement surgery were used, along with an immortalized 
human chondrocyte cell line. In addition, cartilage tissue and primary 
chondrocytes obtained from TRPA1 deficient (knock-out, KO) and 
corresponding wild type (WT) mice were used. 
All the primary human chondrocytes and cartilage explants used in this study 
were obtained from OA patients. This is advantageous, as the metabolism and 
gene expression profiles of OA chondrocytes are altered compared to healthy 
cells. Therefore, studying them gives a more accurate depiction of the responses 
seen in cartilage during osteoarthritis. It would be valuable to compare non-
osteoarthritic primary chondrocytes and cartilage with osteoarthritic ones; 
however, the availability of such human tissue is extremely limited. 
Many of the experiments in this study were performed with cultures of primary 
chondrocytes. The use of primary cells is beneficial as they better resemble the in 
vivo situation compared to immortalized cells. Cultured primary cells may 
undergo transcriptional alterations and phenotypic changes during culture. Due to 
this, primary chondrocytes in this study were cultured for short periods and never 
passaged during experiments, as a long culture period and passaging of 
chondrocytes have been shown to increase dedifferentiation (Cope et al. 2019; 
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Darling and Athanasiou 2005; Salvat et al. 2005). Other disadvantages include 
the relatively small number of cells obtained from each donor, limiting the size 
of individual experiments, and the heterogeneity of samples due to different 
disease stages and phenotypes, and patient-related variables. To overcome the 
limitations of primary cultures, an immortalized human chondrocyte cell line 
T/C28a2 (Goldring et al. 1994) was used. Immortalized cell lines have several 
advantages, such as the abundant availability of cells for each experiment, the 
uniformity of the cells, and the stability of the cell line for multiple passages. A 
notable disadvantage is that immortalization often leads to some phenotypic 
changes and loss of typical chondrocyte characteristics. In addition to the cell 
culture methods used in this study, the induced pluripotent stem cell (iPSC) 
technology offers a potential new tool for OA research. With iPSC technology, 
adult somatic cells can be reprogrammed into self-renewing induced pluripotent 
stem cells, which can then be differentiated into chondrocyte-like cells. This is an 
interesting possibility, as it provides an abundant source of cells and can be 
utilized to investigate hereditary risk genes when using patient-derived iPCSs. 
However, the current techniques to differentiate iPSCs to chondrocyte-like cells 
are still suboptimal, and research to improve them is ongoing. In addition, the 
iPSC-derived chondrocytes do not resemble osteoarthritic chondrocytes in all 
aspects (Murphy et al. 2017; Suchorska et al. 2017). 
In addition to chondrocytes, cartilage tissue explants were also used. This 
method has the advantage of chondrocytes remaining in their natural micro-
environment; in contact with their extracellular matrix in a three-dimensional 
setting, with the cells remaining non-dividing. This experimental setup better 
resembles the natural in vivo environment and maintains the typical chondrocyte 
phenotype. However, it is harder to control the differences between each sample, 
as the number of cells varies between tissue pieces. Also, cell death occurs at the 
cut tissue edges, and physical attributes of cartilage may change during culture. 
Additional complexities with using cartilage explants include limited penetration 
of stimulants and drugs into the cartilage, difficulty of RNA extraction and small 
number of cells per sample (Cope et al. 2019). As discussed in the review of 
literature, chondrocytes residing in different layers and locations in cartilage have 
slightly different attributes. In order to obtain representative samples with all 
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types of chondrocytes present, multiple full thickness cartilage pieces (i.e. from 
the cartilage surface to the bone edge) from numerous parts of the joint were used. 
In the present study, multiple models (cartilage explants, primary cells and 
immortalized cell lines) were used in parallel, and they produced consistent and 
mutually confirmative results. 
Cartilage and chondrocytes from TRPA1 KO and corresponding WT mice 
were used in this thesis in addition to human samples. Commercially available 
B6;129P-Trpa1tm1Kykw/J mice and their corresponding WT mice were obtained 
from Charles River laboratories. These KO mice have been developed by deleting 
the pore-forming region of TRPA1. Essentially, the exons encoding for S5 and 
S6 transmembrane domains as well as the pore loop of mouse TRPA1 were 
disrupted. This may still result in the production of a truncated form of TRPA1, 
and to avoid any unwanted effects, an endoplasmic reticulum retention signal and 
stop codon were inserted in frame with the altered exons (Kwan et al. 2006). 
The mRNA and protein levels of the genes of interest were investigated with 
standard methods of molecular and cell biology. Quantitative reverse 
transcription PCR (qRT-PCR) was used for the detection of mRNA, and Western 
blot and ELISA were used for protein measurements. In addition, next-generation 
RNA sequencing (RNA-seq) was used for genome-wide expression analysis 
comparing chondrocytes from TRPA1 KO and corresponding WT mice. RNA-
seq is a widely used method to study the transcriptome, i.e. the set of mRNA 
transcripts expressed by a cell at a given time. RNA-seq is considered very 
reliable, and in this study, the expression of the genes of interest were also verified 
with qRT-PCR. A limitation of RNA-seq is its high cost, due to which only a 
small amount of samples can be analyzed for a given experiment. In this study, 
the findings from the RNA-seq data have been verified with a larger set of 
analogous samples with qRT-PCR and by examining the observed effects in 
further cartilage and chondrocyte culture experiments. 
The functionality of the TRPA1 channel in chondrocytes was assessed by 
performing the Fluo-3-AM assay, which is a widely used method to assess 
changes in intracellular calcium concentration. HEK 293 cells transiently 
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transfected with a hTRPA1 plasmid were used as positive controls and 
nontransfected HEK 293 cells as negative controls in the experiments. During the 
experiments, the cells were exposed to the potent TRPA1 agonist AITC to 
selectively activate TRPA1 channels. AITC treatment induced a potent Ca2+ 
influx in the TRPA1 expressing cells but not in the nontransfected negative 
controls, thus indicating that the AITC-mediated Ca2+ influx was specific for 
TRPA1. This was further validated by the result that pre-treatment with HC-
030031, a widely used selective TRPA1 antagonist (Eid et al. 2008), prevented 
AITC-induced Ca2+ influx. 
The present study focused on the presence of TRPA1 in cartilage/chondrocytes 
and their potential roles in the pathogenesis of osteoarthritis. Tissue and 
chondrocytes from OA patients were used, and in addition to this, an OA-like 
environment was mimicked by treating cultures with the pro-inflammatory 
cytokine IL-1β. IL-1β is found in OA joints and is considered to be a key cytokine 
in the pathogenesis of OA. The presence of IL-1β in culture creates an 
environment closer to the inflammatory state of OA joints and is a widely used in 
vitro model to investigate the pathogenesis of OA. The concentration used in 
experiments (100 pg/ml) is similar to the levels that have been measured in the 
synovial fluid of OA patients (Tsuchida et al. 2014; Westacott et al. 1990). 
6.2 TRPA1 expression in human chondrocytes 
A major finding of this study was that the TRPA1 cation channel is functionally 
expressed in human chondrocytes. This was shown in primary human 
osteoarthritic chondrocytes as well as in immortalized human chondrocyte cell 
line T/C28a2. The expression of TRPA1 was shown at the mRNA level with qRT-
PCR and at the protein level by Western blot. We also showed the functionality 
of the channel by measuring TRPA1-mediated Ca2+ influx with the Fluo-3-AM 
assay. The expression and activation of TRPA1 in human chondrocytes was 
therefore comprehensively shown, to satisfy the criteria set by Fernandes et al. 
(Fernandes et al. 2012). 
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TRPA1 was first cloned from lung fibroblasts in 1999 by Jaquemar et al. 
(Jaquemar et al. 1999). Since then it has primarily been studied in cells of the 
nervous system, where it is widely expressed by a subpopulation of sensory 
neurons of the dorsal root ganglia (DRG), trigeminal ganglia (TG) and vagal 
ganglia (VG) (Nassini et al. 2014). The function of TRPA1 in these cells has also 
been extensively studied and includes nociception, itch, and neurogenic 
inflammation (Nassini et al. 2014; Nilius et al. 2012). More recently, the 
expression of TRPA1 in nonneuronal cells has also started to gain interest. Before 
the beginning of this thesis, the expression of TRPA1 had been conclusively 
shown in a very small number of nonneuronal cells, and further studies are needed 
to elaborate the functional significance of TRPA1 expression in these cells. 
Nonneuronal cells shown to express the TRPA1 channel include lung epithelial 
cells, keratinocytes, lung and skin fibroblasts as well as synoviocytes (Atoyan et 
al. 2009; Hatano et al. 2012; Jaquemar et al. 1999; Kochukov et al. 2006). The 
present study added primary human OA chondrocytes to the list of nonneuronal 
cells identified to express the TRPA1 channel. 
The expression and functionality of TRPA1 in primary human OA 
chondrocytes is a major finding that may explain some of the responses seen in 
osteoarthritic chondrocytes and cartilage. Within the OA joint, there is a hypoxic 
and inflammatory state, which is characterized by excessive production of 
reactive species such as ROS and RNS as well as a number of inflammatory 
factors including IL-1, TNF, IL-6, IL-11, IL-17 and LIF (Franz et al. 2018; 
Rahmati et al. 2016; Robinson et al. 2016). The expression and activation of 
TRPA1 has previously been shown to be increased by factors associated with 
hypoxia and inflammation (Andersson et al. 2008; Hatano et al. 2012; Yoshida et 
al. 2006), which led us to hypothesize that the environment within the OA joint 
is conducive to stimulate TRPA1 expression. Therefore, we investigated the 
effects of multiple OA-related factors on the expression of TRPA1 in chondrocyte 
cultures and found that IL-1β, IL-17, LPS and the adipocytokine resistin 
upregulated TRPA1 expression compared to untreated controls. The OA- or 
hypoxia-related factors IL-6, NGF, YKL-40 (chitinase-3-like protein 1) and 
CoCl2 (hypoxia-mimetic agent cobalt chloride) showed no or a very small effect 
on TRPA1 expression (data not shown). The upregulation of TRPA1 by multiple 
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OA-related and inflammatory factors suggests that the expression of the TRPA1 
channel may be upregulated within the joint during OA. 
As IL-1β had the strongest effect on TRPA1 mRNA expression, we also 
investigated its effect on TRPA1 protein production and TRPA1-mediated Ca2+ 
influx. As a positive control, we used HEK 293 cells, which were transiently 
transfected with hTRPA1 plasmid to attain a stable and high expression of the 
channel. We used nontransfected HEK 293 cells as negative controls. The human 
TRPA1 protein is 128 kDa in size. Using specific TRPA1 antibodies and the 
Western blot method, we saw a protein band of this size in the primary human 
OA chondrocytes and immortalized human T/C28a2 chondrocytes, as well as in 
the TRPA1-transfected HEK 293 cells, but not in the nontransfected HEK 293 
cells. Similarly, we observed TRPA1-dependent Ca2+ influx in both types of 
human chondrocytes, as well as the TRPA1-transfected HEK 293 cells, but not 
in the nontransfected control cells. 
Chondrocytes have also been shown to express other members of the TRP ion 
channel family. By using PCR analysis, articular chondrocytes from OA patients 
were shown to express TRPC1, TRPC3, TRPC6, TRPM5, TRPM7, TRPV1 and 
TRPV2 (Gavenis et al. 2009). In addition, Western blot and 
immunohistochemical analysis demonstrated that equine articular chondrocytes 
express TRPV4, TRPV5 and TRPV6 (Hdud et al. 2012). 
During the course of this project, additional TRPA1-expressing nonneuronal 
cells have been identified. In an interesting study by Pereira et al., peripheral 
blood leukocytes from RA patients were found to express TRPA1. Furthermore, 
the expression of TRPA1 correlated positively with pain severity and disability 
(Pereira et al. 2017). In addition, mouse CD4+ T cells were recently identified to 
express TRPA1 (Bertin et al. 2017). These results demonstrate the ongoing 
interest in investigating the involvement of nonneuronal TRPA1 in rheumatic 
diseases as well as inflammation. 
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6.3 Effects of dexamethasone and aurothiomalate on TRPA1 
expression 
We showed in the current study that synthetic glucocorticoid dexamethasone and 
DMARD aurothiomalate inhibit the production of a functional TRPA1 channel 
in human chondrocytes. This thesis has therefore produced novel data on the 
pharmacological regulation of TRPA1 expression, an area that is still largely 
unknown, especially in nonneuronal cells. Concurrently, this study produced new 
data on the pharmacological effects of two clinically used anti-inflammatory 
drugs, dexamethasone and aurothiomalate. These drugs are effective in the 
treatment of arthritis by retarding cartilage degradation and attenuating the 
inflammatory reaction. 
This is the first study showing that clinically used anti-inflammatory and 
antirheumatic drugs inhibit the expression of TRPA1 in human chondrocytes, or 
to my knowledge in any other cell type. There are, however, some previous 
reports on the effects of anti-inflammatory and antirheumatic drugs on the 
activation of the TRPA1 channel. A metabolite of the NSAID ibuprofen, namely 
ibuprofen-acyl glucuronide, was reported to selectively antagonize the human and 
rodent TRPA1 channel in nociceptors, which may contribute to the anti-
inflammatory and analgesic properties of ibuprofen (De Logu et al. 2019). 
Additionally, the NSAID etodolac, which is a semi-selective COX-2 inhibitor, 
was reported to selectively activate, and subsequently desensitize TRPA1 
channels in TRPA1-expressing HEK 293 cells and murine DRG neurons. 
Notably, stimulating the TRPA1-expressing HEK 293 cells with etodolac at 
concentrations found in plasma during clinical use showed poor activation but 
significant desensitization of the TRPA1 channel (Inoue et al. 2012; Wang, S. et 
al. 2013). Furthermore, Hatano et al. have shown the antirheumatic drug 
auranofin to be a potent stimulator of TRPA1 channels in a human neuroblastoma 
cell line and TRPA1-transfected HEK 293 cells (Hatano et al. 2013). 
Glucocorticoids are commonly used for their potent anti-inflammatory effects 
and, in the treatment of knee OA, glucocorticoids are used as intra-articular 
injections (Hochberg et al. 2012; McAlindon et al. 2014). Glucocorticoids have a 
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wide effect on cellular functions through regulation of innumerable inflammatory 
and metabolic genes. Generally, glucocorticoids function by entering the cell and 
binding to cytoplasmic glucocorticoid receptors (GRs). The ligand-bound GRs 
then dimerize, translocate to the nucleus, and interact with specific DNA 
sequences called glucocorticoid response elements (GREs) to initiate the 
expression of target genes. The suppression of gene transcription is largely 
attributed to the direct or indirect inhibition of transcription factor activation. By 
these mechanisms, glucocorticoids enhance the expression of many anti-
inflammatory genes and suppress the activity of a wide range of pro-inflammatory 
genes and those encoding cartilage matrix degrading enzymes, and the present 
results add TRPA1 to the inflammatory genes down-regulated by glucocorticoids 
(Hartmann et al. 2016; Rang et al. 2019). 
Important anti-inflammatory actions of dexamethasone include inhibition of 
pro-inflammatory transcription factors, particularly NF-κB and AP-1, leading to 
a reduction in the transcription of pro-inflammatory genes, including multiple 
cytokines COX-2 and iNOS (Hartmann et al. 2016; Hayashi et al. 2004; Rang et 
al. 2019). Some of the actions of glucocorticoids may also be mediated in the 
cytosol through interactions between liganded GRs and regulatory factors such as 
kinases and phosphatases (Hartmann et al. 2016). Dexamethasone also functions 
by increasing the expression of certain anti-inflammatory factors such as annexin-
1 and mitogen-activated protein kinase phosphatase 1 (MKP-1) (Janka-Junttila et 
al. 2012; Kassel et al. 2001; Tuure et al. 2017). Some anti-inflammatory effects 
are also thought to be caused by post-transcriptional regulation, as dexamethasone 
has been reported to destabilize iNOS and COX-2 mRNA, thereby reducing NO 
and PGE2 synthesis (Korhonen et al. 2002; Lasa et al. 2001; Newton et al. 1998). 
The DMARD aurothiomalate is a gold compound that is administered as 
intramuscular injections (Kean and Kean 2008; Rang et al. 2019). Aurothiomalate 
reduces pain and retards the progression of rheumatoid arthritis by reducing 
cartilage degradation and bone erosion, and relieving inflammation. Despite 
having been used for many decades, its molecular mechanisms of action remain 
poorly understood. Currently known effects of aurothiomalate include reducing 
serum levels of IL-6 in rheumatoid arthritis patients (Lacki et al. 1995) and 
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inhibiting the production of nitric oxide as well as prostaglandins such as PGE2 
(Nieminen et al. 2010; Tuure et al. 2015; Vuolteenaho et al. 2005). 
Aurothiomalate has also been shown to inhibit the expression of other 
inflammatory and catabolic factors COX-2, IL-6, IL-1β, TNF-α and MMP-3 
(Nieminen et al. 2008; Nieminen et al. 2010; Yanni et al. 1994). Suggested 
mechanisms for the inhibition of inflammatory factors include suppressing NF-
κB activation, increasing the expression of anti-inflammatory phosphatase MKP-
1, and reducing COX-2 mRNA stability (Nieminen et al. 2008; Nieminen et al. 
2010; Vuolteenaho et al. 2005). 
Exactly how these drugs regulate the expression of TRPA1 in chondrocytes 
remains unknown. We showed in this study that inhibition of the transcription 
factor NF-κB downregulated TRPA1 mRNA expression in chondrocytes. 
Accordingly, it has been reported by Hatano et al. that the TRPA1 promoter 
region contains at least six putative binding sites for NF-κB, and that NF-κB is 
involved in TRPA1 induction in human synoviocytes (Hatano et al. 2012). 
Additionally, the NF-κB signaling pathway was shown to be essential for TRPA1 
mRNA expression in an experimental model of allergic contact dermatitis, where 
inhibiting NF-κB activation also inhibited TRPA1 expression (Kang, J. et al. 
2017). These results, together with the previous findings that dexamethasone and 
aurothiomalate inhibit NF-κB activation (Hartmann et al. 2016; Vuolteenaho et 
al. 2005), suggest that their effects on TRPA1 expression in chondrocytes may 
be, at least partly, via NF-κB inhibition. It is also possible that dexamethasone 
and/or aurothiomalate regulate TRPA1 by post-transcriptional mechanisms, as 
both drugs have previously been shown to destabilize mRNA of pro-
inflammatory factors (Korhonen et al. 2002; Lasa et al. 2001; Nieminen et al. 
2010). Overall, the regulation of TRPA1 expression has not been extensively 
elucidated, and current knowledge of the field is reviewed in Paragraph 6.3.1. 
Treatment with glucocorticoids and aurothiomalate can cause various 
unwanted effects. Single intra-articular injections or short-term treatment with 
low doses of glucocorticoids do not usually cause adverse effects. Although, 
despite the common conception that intra-articular glucocorticoid injections in 
the treatment of OA do not cause adverse events, concerns have been raised about 
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potential long-term effects (Baschant et al. 2013; Juni et al. 2015). There are some 
indications of deleterious effects of glucocorticoids in chondrocytes and cartilage. 
In a clinical trial with OA patients, intra-articular glucocorticoid treatment was 
shown to cause greater cartilage volume loss measured by MRI compared to 
placebo treatment (McAlindon et al. 2017). Furthermore, the synthesis of 
cartilage ECM components aggrecan and type II collagen were shown to be 
downregulated in cultured chondrocytes following glucocorticoid stimulation 
(Song et al. 2012). Glucocorticoids have also been suggested to reduce 
chondrocyte viability by increasing oxidative stress and apopotosis (Song et al. 
2012; Suntiparpluacha et al. 2016). 
In the treatment of conditions requiring prolonged systemic administration or 
high doses, glucocorticoids are associated with multiple serious unwanted effects, 
including osteoporosis, suppression of the body’s response to infection and 
injury, weakened production of endogenous glucocorticoids as well as metabolic 
disorders such as hyperglycemia, muscle wasting and Cushing’s syndrome (Rang 
et al. 2019; van der Goes et al. 2014). Aurothiomalate on the other hand slowly 
accumulates in the synovial cells of joints, along with other cells and tissues 
including kidney tubules, the adrenal cortex, liver cells and macrophages, and can 
cause potentially severe skin rashes, stomatitis, flu-like symptoms, proteinuria, 
thrombocytopenia and other blood dyscrasias (Rang et al. 2019). Therefore, a 
better understanding of the specific molecular mechanisms of both of these drugs 
is needed for the development of more specific drugs with potentially fewer side 
effects. Accordingly, this study has presented a novel mechanism of action for 
these drugs in the downregulation of an inducible cation channel that mediates 
inflammatory and analgesic responses. 
6.3.1 Current knowledge on the regulation of TRPA1 expression 
Considering that TRPA1 has predominantly been studied in sensory neuronal 
cells, it is not surprising that the regulation of its expression is best known in DRG 
neurons. Especially the upregulation of TRPA1 expression has been reported in 
multiple studies. In DRG neurons, the expression of TRPA1 has been reported to 
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be increased by IL-6 cytokine family signal transducer glycoprotein 130 (gp130), 
the cytokine IL-13, neuronal survival factor artemin, the TRPA1 agonist mustard 
oil (MO), and nerve growth factor (NGF), which also increases TRPA1 
expression in TG neurons (Diogenes et al. 2007; Elitt et al. 2006; Ikeda-
Miyagawa et al. 2015; Malsch et al. 2014; Obata et al. 2005; Oh et al. 2013; 
Schmidt et al. 2009). Of these stimulants, we also investigated the effect of NGF 
on TRPA1 expression in chondrocytes, due to the growing interest in NGF as an 
important mediator in OA and OA pain. According to our preliminary results, 
NGF alone did not affect TRPA1 expression (data not shown). However, the 
effects of NGF inhibition are not known. Notably, the anti-NGF antibodies 
tanezumab and fasinumab are currently being investigated in Phase 3 clinical 
trials in OA patients, where they were shown to increase the risk of rapidly 
progressing OA (RPOA) (Dakin et al. 2019; Karsdal et al. 2018). It is interesting 
to speculate whether blocking TRPA1 in these patients could affect the incidence 
of RPOA during tanezumab treatment. 
Most of the aforementioned studies do not offer a molecular mechanism for 
the upregulation of TRPA1 expression. However, Obata et al. suggested NGF to 
upregulate TRPA1 via p38 MAPK activation, and Malsch et al. proposed the 
upregulation of TRPA1 expression by gp130 to be mediated by the JAK-STAT 
pathway (Malsch et al. 2014; Obata et al. 2005). Conversely, the AMP activated 
kinase (AMPK), which is an intracellular sensor and modulator of energy 
expenditure, was shown to decrease plasma membrane expression of TRPA1 in 
cultured DRG neurons (Wang, S. et al. 2018). 
There are also fragmentary data on the regulation of TRPA1 expression in 
nonneuronal cells. In human fibroblast-like synoviocytes TRPA1, expression was 
reported to be increased by inflammatory factors IL-1α and TNF-α through NF-
κB signaling and the activation of the transcription factor hypoxia-inducible 
factor-1α (HIF1α) (Hatano et al. 2012). The expression of TRPA1 is also potently 
increased by IL-13 and to a lesser extent by interferon γ (IFN-γ) and reactive 
oxygen species H2O2, in murine bone marrow-derived mast cells (Oh et al. 2013). 
Additionally, in cultured human bronchial epithelial cells, cigarette smoke 
extract, which has many compounds that agonize the TRPA1 channel, increased 
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TRPA1 mRNA expression (Lin et al. 2015). In the same study, it was seen that 
exposing mice to cigarette smoke increased lung epithelial TRPA1 expression, 
when compared to air-exposure control mice. The mechanisms behind the 
increase of TRPA1 expression in these studies are however not clear. 
Overall, the regulation of TRPA1 expression in nonneuronal cells is poorly 
understood and warrants further investigation. The current study contributed to 
this data by identifying factors that induce or inhibit TRPA1 expression in human 
chondrocytes. TRPA1 expression was shown to be upregulated by IL-1β, IL-17, 
LPS and resistin. Notably, the IL-1β-induced upregulation of TRPA1 was 
reduced by the NF-κB inhibitor PDTC. Further, two novel factors, 
dexamethasone and aurothiomalate, were found to downregulate TRPA1 
expression, potentially through inhibition of the NF-κB pathway. 
According to literature, IL-1β, IL-17, LPS and resistin (i.e. the factors shown 
to upregulate TRPA1 expression in chondrocytes in this study) all activate the 
NF-κB signaling pathway. IL-1β and IL-17 can do so through IL-1 and IL-17 
receptors, respectively, while LPS and resistin have been shown to signal through 
the receptor TLR4. LPS is an exogenous TLR4 activator, whereas resistin has 
been reported to function as an endogenous activator of TLR4. Signaling through 
TLR4 leads to the activation of the NF-κB pathway, ultimately resulting in the 
expression of NF-κB-dependent genes (Liu, T. et al. 2017; Tarkowski et al. 2010). 
In addition to NF-κB, various other putative transcription factor binding sites 
have been identified in the promoter region of TRPA1 (Table 5), but the 
functional significance of most of these sites remains largely unknown. 
Table 5.  Transcription factors of the human TRPA1 gene. Transcription factors identified to have 
a binding site in the human TRPA1 promoter region. (GeneCards human gene database, 
www.genecards.com, Hatano et al, 2012) 
ER-α,  FOXI1,  HFH-3,  HIF1α,  ITF-2, NF-AT,  NF-AT1,  NF-AT2,  NF-AT3, NF-AT4,  NF-κB, Tal-1β 
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6.4 TRPA1 and production of proinflammatory and catabolic factors 
The TRPA1 channel has long been known to mediate neurogenic inflammation 
and has more recently also been linked to inflammatory responses in some 
nonneuronal cells. In inflammatory reactions, neuronal TRPA1 channels are 
involved in the excitation of neurons, release of inflammatory neuropeptides, and 
consequent inflammation-associated pain. Also, in some nonneuronal cells, 
inflammatory agents activate TRPA1, which feeds forward the inflammatory 
reaction by increasing the production of inflammatory factors, which can then 
further activate nearby cells and cause cell and tissue damage (Bautista et al. 
2013; Viana 2016). Therefore, after we had discovered that a functional TRPA1 
channel is expressed in human OA chondrocytes, and that its expression is 
upregulated by the key OA-related factor IL-1β, we aimed to investigate whether 
TRPA1 regulates the expression of inflammatory and/or catabolic factors in 
chondrocytes and cartilage. Remarkably, we found TRPA1 to be involved in the 
regulation of the IL-6 family cytokines IL-6, LIF and IL-11 as well as the growth 
factor FGF-2, catabolic factors MMP-1, MMP-3, MMP-13, and inflammatory 
and analgesic factor PGE2, which are significant factors in the pathogenesis and 
pathology of OA. 
A limitation of this study is that the mechanisms by which TRPA1 affects the 
production of inflammatory and catabolic factors in chondrocytes have not been 
determined and warrant further studies. This is not uncommon, as some other 
studies have reported a link between TRPA1 and the up- or downregulated 
expression of inflammatory agents but have not reported the exact mechanisms 
behind these effects (Gouin et al. 2017; Viana 2016). However, in an interesting 
study by Lin et al., an elaborate mechanism for TRPA1-mediated production of 
IL-8 was suggested. In the study, cultured lung epithelial cells were stimulated 
with cigarette smoke extract. This increased the level of extracellular ROS 
leading to the activation of the TRPA1 channel. This resulted in substantial Ca2+ 
influx into the activated cells, promoting the activation of NADPH oxidase, which 
in turn led to an increase in intracellular ROS levels, subsequently activating 
MAP kinases and the NF-κB signaling cascade, ultimately leading to the 
upregulation of IL-8 (Lin et al. 2015). 
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In general, the effects of TRPA1 are largely attributed to the substantial Ca2+ 
influx and subsequent elevation of intracellular Ca2+ following TRPA1 activation 
(Zygmunt and Högestätt 2014). In addition to Ca2+ influx from the extracellular 
environment, Ca2+ can also be liberated from intracellular stores such as the 
endoplasmic reticulum, mitochondria and lysosomes (Gees et al. 2010; Raffaello 
et al. 2016). TRPA1 is hypothesized to be involved in this mechanism, as it is also 
intracellularly active and expressed in secretory vesicles and granules. There is 
also data to support a role for TRPA1 in Ca2+ release from these secretory vesicles 
(Dong et al. 2010; Gees et al. 2010). Regulation of inflammatory gene expression 
is one of the effects of intracellular calcium increase (Berridge et al. 2000; 
Korhonen et al. 2001). This regulation of gene expression can occur for example 
through the regulation of cyclic AMP (cAMP), activation of PLC and the MAPK 
signaling pathway as well as activation of transcription factors such as NF-κB and 
NF-AT (Berridge et al. 2000; Racioppi and Means 2008; Vuong et al. 2015). 
TRPA1 has the highest permeability towards Ca2+ but is also permeable to other 
monovalent and bivalent ions such as Zn2+, Mg2+, Na+ and K+ (Zygmunt and 
Högestätt 2014). Other ions besides Ca2+ therefore likely also account for some 
of the actions of TRPA1. However, their significance in TRPA1-induced changes 
in cellular functions have been far less researched. 
The following paragraphs discuss in more detail our current results on the 
effects of TRPA1 on the production of proinflammatory and catabolic factors, 
placing them in the context of current knowledge of TRPA1-mediated 
inflammatory gene expression, and discussing their relevance with regards to OA 
pathogenesis. 
6.4.1 IL-6 
According to the present results, TRPA1 regulates IL-6 expression in articular 
chondrocytes. TRPA1 was also found to be involved in the regulation of other IL-
6 cytokine family members, LIF and IL-11. These are significant findings, as IL-
6 is currently considered to be one of the key inflammatory mediators driving the 
pathogenesis of OA (Kapoor et al. 2011; Rahmati et al. 2016). Elevated levels of 
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IL-6 are found in the serum and synovial fluid of OA patients, with the levels 
correlating positively with cartilage loss as well as the incidence, or severity, of 
radiographic knee OA (Kaneko et al. 2000; Laavola et al. 2018; Larsson et al. 
2015; Livshits et al. 2009; Stannus et al. 2010). In addition, LIF and IL-11 are 
reported to be involved in the inflammatory reaction of the OA joint (Rahmati et 
al. 2016). 
The current results showing TRPA1-dependent upregulation of IL-6 
expression are supported by other in vivo and in vitro studies. In experimental 
models of allergic contact dermatitis and MSU crystal-induced inflammation, 
genetic deletion and pharmacological inhibition of TRPA1 reduced the 
production of IL-6 (Kang, J. et al. 2017; Liu, B. et al. 2013; Moilanen et al. 
2015a). Additionally, TRPA1 was recently shown to mediate peritoneal IL-6 
synthesis in response to peritoneal dialysis fluid administration in the rat (Nilsson 
et al. 2017). In cultured primary human periodontal ligament cells, activation of 
TRPA1 increased the expression of IL-6. This was repressed by a Ca2+ chelator, 
indicating that the increase in IL-6 expression was due to the TRPA1-mediated 
increase in intracellular Ca2+ (Son et al. 2015). Unlike in the aforementioned 
studies, in cultured human synoviocytes the activation of TRPA1 was shown to 
downregulate IL-1α-induced IL-6 production (Hatano et al. 2012), suggesting 
that the effect of TRPA1 on IL-6 production may be cell-type specific. However, 
in a more recent study, LPS-stimulated primary human OA synoviocytes showed 
decreased production of IL-6 following pharmacological inhibition or gene 
silencing of TRPA1 (Yin et al. 2018). These findings in synoviocytes suggest that 
the regulation of IL-6 production was influenced by the different stimulants, or 
that the phenotype and gene expression patterns of OA synoviocytes differed 
from that of non-OA synoviocytes. 
IL-6 has recently raised increasing interest as one of the key inflammatory 
mediators in OA pathogenesis. It is crucially involved in the cartilage degradation 
as well as subchondral bone remodeling in OA (Haseeb and Haqqi 2013; Kapoor 
et al. 2011; Kwan Tat et al. 2004). Considering the effects of IL-6 in joint tissues, 
it is not surprising that it is being investigated as a drug target in OA. The IL-6 
receptor antagonist tocilizumab is currently in a phase 3 clinical trial with 
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indications for pain and function in patients with refractory hand OA 
(NCT02477059). In addition to antagonizing the IL-6 receptor, another approach 
could be to target the expression of IL-6. Based on the findings of this thesis, and 
previous reports on the effects of TRPA1 on IL-6 production, it can be 
hypothesized that selectively inhibiting the expression and/or activation of 
TRPA1 in OA cartilage could downregulate the expression of IL-6. Notably, the 
inhibition of TRPA1 in cartilage could simultaneously downregulate the 
production of other deleterious agents, such as LIF and IL-11. 
6.4.2 FGF-2 
We investigated the effect of TRPA1 on the growth factor FGF-2 and found that 
in chondrocytes, TRPA1 was involved in regulating its expression. This is a novel 
finding, linking TRPA1 to the expression of FGF-2 for the first time. As FGF-2 
is an interesting factor in the pathogenesis of cartilage degradation in OA, we 
decided to investigate the effects of FGF-2 in human OA cartilage and 
chondrocytes further. 
We first examined the possible correlations between the levels of FGF-2 and 
cartilage matrix degrading enzymes MMP-1 and MMP-13 in cartilage explant 
cultures from 97 OA patients undergoing knee-joint replacement surgery. The 
levels of FGF-2 correlated positively with both enzymes MMP-1 and MMP-13, 
which encouraged us to continue the study using primary human OA chondrocyte 
cultures. 
FGF-2 exerts its effects by signaling through four receptors: FGFR1-4 (Ornitz 
and Itoh 2015; Zhang, X. et al. 2006). Before investigating the effects of FGF-2 
further, we examined the receptor expression profiles of the primary human OA 
chondrocytes and found that they expressed all four receptors, with the expression 
of FGFR1 being highest. In support of this finding, human chondrocytes have 
previously been reported to express all four receptors with the expression of 
FGFR1 and FGFR3 being the most prominent (Yan et al. 2011). Further, it has 
been reported that in OA cartilage the expression of FGFR1 is increased while 
the expression of FGFR3 is decreased (Weng et al. 2012; Yan et al. 2011). This 
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is significant as the catabolic effects of FGF-2 are mediated through FGFR1, 
whereas signaling through FGFR3 is thought to elicit anabolic effects (Ellman et 
al. 2013; Muddasani et al. 2007; Yan et al. 2011; Yan et al. 2012). Notably, 
another member of the FGF growth factor family, FGF-18, has been shown to 
signal through receptor FGFR3 and induce anabolic responses in chondrocytes, 
and is being investigated as a novel drug in OA (Davidson et al. 2005; Gigout et 
al. 2017; Reker et al. 2017). The recombinant human FGF-18 drug sprifermin is 
currently undergoing clinical trials for osteoarthritis and cartilage injury of the 
knee (Lohmander et al. 2014; Roemer et al. 2016). 
The effects of FGF-2 and FGF receptor antagonists AZD4547 (Gavine et al. 
2012) and NVP-BGJ398 (Guagnano et al. 2011) were then investigated in 
cultured primary human OA chondrocytes. FGF-2 treatment increased the 
production of catabolic enzymes MMP-1 and MMP-13, whereas the expression 
of major cartilage matrix components aggrecan and type II collagen was 
decreased. This catabolic and anti-anabolic function of FGF-2 in human 
chondrocytes is supported by previous findings, showing that FGF-2 stimulation 
increased MMP-13 and ADAMTS-5 expression, and inhibited aggrecan 
expression in adult human articular chondrocytes (Im et al. 2007; Wang, X. et al. 
2004; Yan et al. 2012), and that in alginate-cultured human articular chondrocytes 
and cartilage explants FGF-2 inhibited proteoglycan synthesis (Loeser et al. 2005; 
Posever et al. 1995). As discussed in the review of literature, FGF-2 has been 
found to have anabolic effects in murine cartilage. This is hypothesized to result 
from differing receptor expression profiles between different species. Unlike in 
human cartilage, the expression of receptors FGFR2 and FGFR4 are predominant 
in murine articular cartilage, and the expression of the catabolism-associated 
receptor FGFR1 is low. Futher, in murine articular cartilage the expression of 
anabolism-associated receptor FGFR3 is upregulated in response to FGF-2 (Li et 
al. 2012). 
Treating cultured human OA chondrocytes with FGF-2 together with the 
FGFR antagonists AZD4547 and NVP-BGJ398 counteracted the catabolic and 
anti-anabolic effects of FGF-2: the expression of MMP-1 and MMP-13 was 
decreased, while the expression of aggrecan and collagen II was increased. 
 107 
Surprisingly, this beneficial effect was also seen without exogenous FGF-2 
stimulation, which lead us to hypothesize that the cells produced endogenous 
FGF-2. We had already shown in this study that FGF-2 was released from 
cartilage explants of OA patients, and we wanted to investigate whether FGF-2 is 
produced by chondrocytes or perhaps had diffused into the cartilage through the 
synovial fluid. We found that the chondrocytes did indeed produce FGF-2, which 
is a significant finding considering the potential in vivo activity of FGFR 
antagonists in the treatment of OA. We also measured the concentrations of FGF-
2 in the synovial fluid and plasma of OA patients and found FGF-2 to be present 
at concentrations of 25.0 ± 25.7 pg/ml (n = 33) and 33.3 ± 22.0 pg/ml (n = 93), 
respectively (data not shown). 
AZD4547 and NVP-BGJ398 are selective FGFR antagonists, which target the 
catabolism-associated receptor FGFR1 with the highest selectivity. The current 
results are supported by a study published the following year, where a novel 
FGFR1 antagonist G141 inhibited FGF-2-induced upregulation of MMP-13 and 
ADAMTS-5 expression as well as downregulation of aggrecan and collagen II 
expression in human articular chondrocytes, and reduced proteoglycan 
degradation in FGF-2-stimulated human cartilage explants (Xu et al. 2016). The 
use of FGFR1 antagonists as DMOADs is also supported by studies in mouse 
models, showing that fgfr1 deletion or pharmacological inhibition reduced 
articular cartilage degradation (Weng et al. 2012; Xu et al. 2016). 
Our results, together with those of others, have shown FGF-2 to be a catabolic 
and anti-anabolic mediator in human cartilage and chondrocytes. Inhibition of 
FGF-2 with specific receptor antagonists has shown promising effects on the 
balance of catabolic and anabolic factors in in vitro and ex vivo studies as well as 
experimental mouse models, but none have reached clinical trials yet. Another 
approach to preventing the effects of FGF-2 could be to decrease the expression 
of FGF-2 in chondrocytes. The results of this thesis indicate that TRPA1 is 
involved in the upregulation of FGF-2 expression in chondrocytes. Therefore, the 
inhibition of TRPA1 and the subsequent downregulation of FGF-2 could have 
beneficial effects on the balance of catabolic and anabolic mediators within OA 
cartilage. 
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6.4.3 MMP-enzymes and PGE2 
Finally, we wanted to investigate the potential effects of TRPA1 on major 
catabolic factors associated with cartilage ECM breakdown in osteoarthritis. As 
discussed in the review of literature, the matrix metalloproteinases MMP-1, 
MMP-3 and MMP-13 are among the key cartilage matrix degrading enzymes in 
OA (Troeberg and Nagase 2012). Additionally, we wanted to investigate the 
effect of TRPA1 on the eicosanoid PGE2, which is an important mediator of pain 
and inflammation in OA (Lee, AS. et al. 2013; Sokolove and Lepus 2013). 
Furthermore, PGE2 has been reported to increase the production and activation of 
MMP-enzymes and inhibit proteoglycan synthesis in osteoarthritic cartilage 
(Attur et al. 2008). In this study, genetically or pharmacologically inhibiting 
TRPA1 reduced the production of MMP-1, MMP-3, MMP-13 and PGE2 in 
cultured primary human OA chondrocytes and mouse cartilage explants, 
suggesting a role for TRPA1 in the regulation of their production. 
The effect of TRPA1 on MMP-enzyme production in chondrocytes and 
cartilage is a novel finding. Similar results have however been obtained from 
cultured primary human fibroblast-like synoviocytes and synovial fibroblasts. A 
study by Yin et al. showed that in LPS-stimulated human OA fibroblast-like 
synoviocytes pharmacological inhibition with a specific TRPA1 antagonist, and 
gene silencing by small interfering RNA (siRNA), downregulated the production 
of MMP-1 and MMP-3, along with the inflammatory cytokines IL-1β, TNF-α and 
IL-6 (Yin et al. 2018). In cultured human RA synovial fibroblasts, TNF-induced 
production of MMP-3, as well as IL-6 and IL-8, were downregulated following 
treatment with the cannabinoid receptor antagonist anandamide in a TRPA1-
dependent manner (Lowin et al. 2015). 
The inhibition of MMP expression and activity would be an important aspect 
in the treatment of OA as well as other pathologies such as cancer and periodontal 
disease. Accordingly, research into MMP inhibitor design has been active for 
decades. Most commonly, the development of MMP inhibitors has focused on 
active site inhibition, but unfortunately, these inhibitors have lacked specificity 
and caused unwanted off-target effects. Recently, utilizing secondary binding 
sites in addition to the active site has been investigated to improve specificity of 
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the inhibitors (Fields 2015). Some factors regulating the expression of MMPs 
have been identified, and one approach to MMP inhibition could be to target their 
expression instead of just their activity. In cartilage, TRPA1 inhibition could 
potentially downregulate the expression of key OA-related MMP-enzymes. 
The effect of TRPA1 on the production of PGE2 in cartilage and chondrocytes 
is also a novel finding and is supported by previous in vivo and in vitro data. In 
experimental models of hyperalgesia and cough, TRPA1 was identified as a key 
mediator of PGE2-induced nociceptive and tussive effects (Dall'Acqua et al. 2014; 
Grace et al. 2012). Additionally, there is in vitro data showing that the activation 
of TRPA1 in cultured human dermal keratinocytes and fibroblasts increases the 
secretion of PGE2 (Jain et al. 2011). TRPA1 activation has also been reported to 
increase expression of the inducible prostaglandin synthase COX-2 (Moilanen et 
al. 2012; Moilanen, Hämäläinen, Nummenmaa et al. 2015b). PGE2 is a significant 
mediator of pain in OA (Lee, AS. et al. 2013). Upregulated production of PGE2 
due to TRPA1 activation is significant in both neuronal and nonneuronal cells: in 
nonneuronal cells of the joint, such as chondrocytes or fibroblasts, the increased 
production of PGE2 can stimulate nearby neurons leading to increased OA-related 
pain. 
6.5 Clinical aspects 
At present, there is no effective treatment to prevent or retard the structural 
changes occurring in the joint during osteoarthritis. Therefore, there is an urgent 
need for novel drug targets for the development of disease-modifying OA drugs. 
In addition to the prevention of structural changes in the joint tissues, effective 
analgesic treatment is required. 
Osteoarthritis is a disease that affects the entire joint structure. Cartilage is the 
most severely affected tissue, but pathognomonic features are also found in the 
subchondral bone, synovial membrane, ligaments and periarticular muscles 
(Glyn-Jones et al. 2015). What initiates the inflammatory and catabolic process 
in the OA joint is unkown, and drug development is complicated by the lack of 
early diagnosis as well as the fact that OA is a heterogeneous disease (Karsdal et 
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al. 2016; Van Spil et al. 2019). OA is commonly divided into multiple 
phenotypes, which can be classified as metabolic, subchondral bone, synovitis-
driven, cartilage-driven, ageing-driven and trauma-driven phenotypes 
(Mobasheri et al. 2017; van der Kraan et al. 2016). Ultimately, in all forms of OA 
an inflammatory and hypoxic state develops within the OA joint, characterized 
by the presence of pro-inflammatory mediators, reactive species, and cartilage 
degrading enzymes (Robinson et al. 2016; Wang, X. et al. 2018). These mediators 
exert many deleterious effects in the joint tissues, one of the most important being 
the acceleration of cartilage degradation. Inhibiting their production and/or 
activity is therefore a promising prospect in the development of novel drugs. 
In the present study, we investigated the cation channel TRPA1 as a possible 
mediator and novel drug target in OA. We discovered TRPA1 to be expressed in 
human chondrocytes, where its expression is enhanced by IL-1β, a key cytokine 
in OA pathogenesis. In addition to IL-1β, also IL-17, LPS and resistin were found 
to increase TRPA1 expression. According to literature, some other OA-associated 
cytokines, as well as reactive oxygen and nitrogen species, also increase TRPA1 
expression and activation in other cell types (Bautista et al. 2013; Viana 2016). 
We also showed that the anti-inflammatory drugs dexamethasone and 
aurothiomalate inhibited the formation of a functional TRPA1 channel in 
chondrocytes, suggesting that some of the effects of these drugs may be elicited 
through TRPA1 inhibition. Finally, we showed TRPA1 to be involved in 
regulating the production of multiple OA-related inflammatory and catabolic 
factors in chondrocytes, namely IL-6, IL-11, LIF, FGF-2, MMP-1, MMP-3, 
MMP-13 and PGE2. The major findings of this thesis on the expression and 
functions of TRPA1 in chondrocytes/cartilage are summarized in Figure 24. 
Due to the multiple inflammatory and catabolic factors regulated by TRPA1 
in chondrocytes, as well as other cell types, it presents as an intriguing novel drug 
target. TRPA1 antagonists have previously been investigated in experimental 
disease models, including atopic dermatitis, allergic asthma, acute allergic 
inflammation, colitis, acute inflammation, gouty inflammation and arthritis 
(Caceres et al. 2009; Engel et al. 2011; Liu, B. et al. 2013; Moilanen et al. 2012; 
Moilanen et al. 2015a; Moilanen, Hämäläinen, Nummenmaa et al. 2015b; 
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Moilanen et al. 2019). In addition, Glenmarcks TRPA1 antagonist GRC 17536 
has been investigated in clinical trials for painful diabetic neuropathy. Results 
from these in vivo models and clinical trials seem promising, and importantly, the 
TRPA1 antagonists do not seem to cause significant systemic side-effects. The 
notion of TRPA1 as a drug target in OA has been proposed due to its functions in 
sensory neurons and the potential to diminish neuropathic and inflammatory pain 
(Galindo et al. 2018; Koivisto et al. 2018). The present study extends this concept 
also to nonneuronal cells involved in OA. Since TRPA1 is expressed in 
chondrocytes and involved in the upregulation of inflammatory and catabolic 
mediators, it serves as potential drug target in OA. Intriguingly, according to the 
present results, showing the inhibition of TRPA1 by the drugs dexamethasone 
and aurothiomalate, TRPA1 may already be a previously unidentified target of 
anti-inflammatory drug treatment. 
Locally inhibiting TRPA1 in cartilage and in the knee joint could 
simultaneously exert analgesic and disease modifying effects. Analgesic effects 
could be obtained with TRPA1 antagonists by blocking the activity of TRPA1 in 
innervating neurons, and additionally, by downregulating the production of 
inflammatory pain mediators in nonneuronal TRPA1-expressing cells of the joint. 
Based on the results of this thesis, the inhibition of TRPA1 in osteoarthritic 
cartilage and chondrocytes could potentially decrease the production of multiple 
inflammatory and catabolic mediators, thus reducing the deleterious 
inflammation and cartilage degradation of OA. Although as mentioned earlier, 
the research on TRPA1 antagonists is mostly reliant on experimental disease 
models, and additional clinical trials are needed to evaluate the potential of 
TRPA1 antagonists as drug treatment. 
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Figure 24.  Schematic summary of the main results on the expression and function of TRPA1 in 
chondrocytes in the present study. TRPA1 was discovered to be functionally expressed in 
human OA chondrocytes and immortalized human T/C28a2 chondrocytes. The expression of 
TRPA1 is enhanced by IL-1β, IL-17, LPS and resistin, and the activation of TRPA1 results in an 
elevation of intracellular Ca2+. TRPA1 is involved in regulating the expression of multiple mediators 
of inflammation, catabolism and inflammatory pain: IL-6-family cytokines (IL-6, LIF, IL-11), FGF-2, 
MMP-1, MMP-3, MMP-13 and PGE2 in chondrocytes. The expression of TRPA1 is downregulated 
by anti-inflammatory drugs dexamethasone and aurothiomalate, as well as the NF-κB inhibitor 
PDTC. [Ca2+]i - intracellular calcium, FGF - fibroblast growth factor, IL - interleukin, LIF - leukemia 
inhibitory factor, LPS - lipopolysaccharide, MMP - matrix metalloproteinase, NF-κB - nuclear factor 
κB, PDTC - ammonium pyrrolidinedithiocarbamate, PGE2 - prostaglandin E2, TRPA - transient 
receptor potential ankyrin. 
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7 SUMMARY AND CONCLUSIONS 
The aim of the present study was to investigate the expression and effects of the 
TRPA1 cation channel in human OA chondrocytes and cartilage. Primary human 
OA chondrocytes and cartilage, immortalized human T/C28a2 chondrocytes as 
well as chondrocytes and cartilage from TRPA1 KO and corresponding WT mice 
were used in the studies. 
The major findings and conclusions are: 
1. TRPA1 channel was shown to be functionally expressed in primary 
human OA chondrocytes and immortalized T/C28a2 chondrocytes. This 
is a novel finding, adding chondrocytes to the few nonneuronal cells 
demonstrated to express TRPA1. 
2. TRPA1 expression is upregulated by OA-related inflammatory factors IL-
1β, IL-17 and resistin, and by the TLR4 activating bacterial product 
lipopolysaccharide (LPS). Most notably the cytokine IL-1β is considered 
one of the important inflammatory mediators driving cartilage 
degradation in OA. Inflammatory factors IL-6, NGF, YKL-40 and the 
hypoxia-mimetic agent CoCl2 showed no or a very small effect on TRPA1 
expression in human chondrocytes. 
3. TRPA1 expression is downregulated by the anti-inflammatory drugs 
dexamethasone and aurothiomalate in human chondrocytes, potentially 
through inhibition of the transcription factor NF-κB, while methotrexate, 
sulfasalazine, hydroxychloroquine and ibuprofen had no effect. 
 114 
4. TRPA1 is involved in the upregulation of cytokines IL-6, IL-11 and LIF, 
growth factor FGF-2, catabolic enzymes MMP-1, MMP-3, MMP-13, and 
inflammatory and analgesic factor PGE2 in chondrocytes/cartilage. 
 
5. The expression of FGF-2 is enhanced by TRPA1 in human OA and 
murine chondrocytes. FGF-2 exerts catabolic and anti-anabolic effects in 
human OA chondrocytes. The effects of FGF-2 are counteracted by FGF 
receptor antagonists, which cause the downregulation of catabolic 
enzymes MMP-1 and MMP-13 and upregulate the expression of major 
cartilage matrix components aggrecan and type II collagen. 
In summary, this study has shown that the TRPA1 ion channel is functionally 
expressed in primary human osteoarthritic chondrocytes, where its expression is 
upregulated by OA-related inflammatory factors and downregulated by clinically 
used anti-inflammatory drugs dexamethasone and aurothiomalate. The inhibition 
of TRPA1 by these drugs suggests that TRPA1 may already be a previously 
unidentified target of anti-inflammatory drug treatment. TRPA1 was also shown 
to be involved in mediating the expression of pro-inflammatory and catabolic 
factors significant in the pathogenesis of OA. These results present TRPA1 as a 
novel factor and a potential drug target in osteoarthritis. Additionally, this thesis 
has produced valuable information on the nonneuronal expression of TRPA1, 
expanding our knowledge of this multifunctional ion channel.  
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Edvinille. Kiitos Arttu avusta, tuesta ja joustavuudesta, joita ilman tämän työn 
viimesteleminen vauvavuoden aikana ei olisi ollut mahdollista. 
 
Tampereella 6.1.2020 
Elina Nummenmaa 
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Abstract
Background: Transient receptor potential ankyrin 1 (TRPA1) is a membrane-associated cation channel, widely
expressed in neuronal cells and involved in nociception and neurogenic inflammation. We showed recently that
TRPA1 mediates cartilage degradation and joint pain in the MIA-model of osteoarthritis (OA) suggesting a hitherto
unknown role for TRPA1 in OA. Therefore, we aimed to investigate whether TRPA1 is expressed and functional in
human OA chondrocytes.
Methods: Expression of TRPA1 in primary human OA chondrocytes was assessed by qRT-PCR and Western blot.
The functionality of the TRPA1 channel was assessed by Ca2+-influx measurements. Production of MMP-1, MMP-3,
MMP-13, IL-6, and PGE2 subsequent to TRPA1 activation was measured by immunoassay.
Results: We show here for the first time that TRPA1 is expressed in primary human OA chondrocytes and its
expression is increased following stimulation with inflammatory factors IL-1β, IL-17, LPS, and resistin. Further, the
TRPA1 channel was found to be functional, as stimulation with the TRPA1 agonist AITC caused an increase in Ca2+
influx, which was attenuated by the TRPA1 antagonist HC-030031. Genetic depletion and pharmacological
inhibition of TRPA1 downregulated the production of MMP-1, MMP-3, MMP-13, IL-6, and PGE2 in osteoarthritic
chondrocytes and murine cartilage, respectively.
Conclusions: The TRPA1 cation channel was found to be functionally expressed in primary human OA
chondrocytes, which is an original finding. The presence and inflammatory and catabolic effects of TRPA1 in human
OA chondrocytes propose a highly intriguing role for TRPA1 as a pathogenic factor and drug target in OA.
Keywords: Osteoarthritis, Chondrocyte, TRPA1, Inflammation, Matrix metalloproteinase
Background
Transient receptor potential ankyrin 1 (TRPA1) is a
membrane-associated cation channel which mediates
pain and hyperalgesia [1, 2] and functions as a chemo-
sensor of noxious compounds [3–5]. TRPA1 was first
discovered in 1999 [6] and has since then been found to
be widely expressed in afferent sensory neurons, espe-
cially in Aδ and C fibers of nociceptors [7, 8]. In
addition to pain, TRPA1 also has a role in mediating
neurogenic inflammation [9, 10]. More recently, TRPA1
has been found to be expressed also in some nonneuro-
nal cells such as keratinocytes [11] and synoviocytes [12]
but the functional roles of nonneuronal expression re-
main to be studied.
TRPA1 is activated by numerous exogenous pungent
compounds such as allyl isothiocyanate (AITC) from
mustard oil [5], acrolein from exhaust fumes and to-
bacco smoke [9], and allicin from garlic [3]. Interest-
ingly, TRPA1 is also activated and sensitized by agents
formed endogenously in inflammatory reactions, such as
nitric oxide [13], hydrogen peroxide [14] and nitro-oleic
acid [15]. The activation of TRPA1 causes an influx of
cation ions, particularly Ca2+, into the activated cells
[16] and this elevation of intracellular Ca2+ has been
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shown to trigger an action potential in neuronal cells
[16, 17]. Interestingly, among the many regulatory effects
of the alterations of intracellular Ca2+ concentration, its
increase has also been shown to affect the gene expres-
sion of inflammatory mediators [18–20].
Recent evidence suggests TRPA1 to have a role in in-
flammation through exogenous activation by TRPA1 ag-
onists and also through endogenous mechanisms.
TRPA1 has been shown to mediate carrageenan-induced
inflammatory edema [21], tumor necrosis factor (TNF)-
triggered hyperalgesia [22], airway hyperreactivity and
inflammation [23, 24], and to relate to acute gouty arth-
ritis [25, 26]. Very recently we found that TRPA1 has a
role in mediating acute inflammation, cartilage destruc-
tion, and joint pain in monosodium iodoacetate (MIA)-
induced inflammation and osteoarthritis in the mouse
[27].
Osteoarthritis (OA) is the most common cause of
musculoskeletal disability and pain worldwide and its
prevalence is constantly increasing as the population
ages. OA is a degenerative disease of the joints, which is
characterized by inflammation and hypoxia within the
joint, leading to cartilage degradation, joint deformity,
disability, and pain [28, 29]. OA-related cartilage degrad-
ation is caused by a growing imbalance between the pro-
duction of catabolic, anabolic, and inflammatory
mediators within the joint driven by the increased ex-
pression of matrix-degrading metalloproteinases and
proinflammatory mediators such as interleukin (IL)-6
and prostaglandin E2 (PGE2) [28].
TRPA1 has not previously been investigated in chon-
drocytes. However, factors involved in hypoxia and in-
flammation, such as hydrogen peroxide (H2O2), nitric
oxide (NO), and IL-6 have been shown to upregulate the
expression or activation of TRPA1 in some other cells
[12–14]. Furthermore, the activation of TRPA1 has been
reported to enhance the production of inflammatory fac-
tors [12, 21, 26, 30]. Since there is a hypoxic and inflam-
matory state in OA joints [28, 31], and TRPA1 has been
shown to be involved in the mediation of acute inflam-
mation and cartilage degradation in MIA-induced osteo-
arthritis [27], we hypothesized that TRPA1 is expressed
in the chondrocytes in osteoarthritic joints, where its ac-
tivation could play a vital part in the inflammation and
pathogenesis of OA. In the present study, we tested that
hypothesis by measuring the expression and function of
TRPA1 in primary human OA chondrocytes.
Methods
Cell culture
Primary chondrocyte cultures were carried out as previ-
ously described [32]. Leftover pieces of OA cartilage
from knee joint replacement surgery were used under
full patient consent. The patients in this study fulfilled
the American College of Rheumatology classification cri-
teria for OA [33] and the study was approved by the
Ethics Committee of Tampere University Hospital, Tam-
pere, Finland (reference number R09116), and carried
out in accordance with the Declaration of Helsinki. The
procedures to isolate and culture the primary chondro-
cytes are described in the supplementary data (Add-
itional file 1). During experiments the cells were treated
with IL-1β (R&D Systems Europe Ltd, Abingdon, UK),
IL-17 (R&D Systems Europe Ltd.), lipopolysaccharide
(LPS) (Millipore Sigma, St. Louis, MO, USA), resistin
(BioVision Inc., Milpitas, CA, USA), the TRPA1 antag-
onist HC-030031 (Millipore Sigma) or with combina-
tions of these compounds as indicated.
Immortalized human T/C28a2 chondrocytes [34] were
cultured as described in the supplementary data (Add-
itional file 1). During the experiments T/C28a2 chondro-
cytes were treated with IL-1β (R&D Systems Europe
Ltd), IL-17 (R&D Systems Europe Ltd.), LPS (Millipore
Sigma), HC-030031 (Millipore Sigma) or with combina-
tions of these compounds as indicated.
HEK 293 human embryonic kidney cells (American
Type Culture Collection, Manassas, VA, USA) were cul-
tured as described in the supplementary data (Additional
file 1). The cells were transfected using 0.42 mg/cm2 of
human TRPA1 plasmid DNA (pCMV6-XL4 by Origene,
Rockville, MD, USA) with lipofectamine 2000 (Invitro-
gen, Life Technologies, Carlsbad, CA, USA) according to
the manufacturer’s instructions.
Animals
Wild-type (WT) and TRPA1 knockout (KO) male
B6;129P-Trpa1(tm1Kykw)/J mice (Charles River Labora-
tories, Sulzfeld, Germany) aged 19–22 days were used in
mouse cartilage culture experiments. Mice were housed
under standard conditions (12–12 h light–dark cycle, 22
± 1 °C) with food and water provided ad libitum. Animal
experiments were carried out in accordance with the le-
gislation for the protection of animals used for scientific
purposes (Directive 2010/63/EU) and the experiments
were approved by The National Animal Experiment
Board (reference number UTA 845/712-86). Animals
were sacrificed by carbon monoxide followed by cranial
dislocation.
Mouse cartilage culture
After mice were euthanized, full-thickness articular car-
tilage from femoral heads were removed and cultured as
described in the supplementary data (Additional file 1).
The cartilage pieces were exposed to IL-1β (R&D Sys-
tems Europe Ltd.) or its vehicle for 42 h and thereafter
culture media were collected and matrix metalloprotein-
ase (MMP)-3, IL-6, and PGE2 concentrations were mea-
sured by immunoassay.
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Western blot measurements
After the cell culture experiments, total protein was ex-
tracted, and TRPA1 was immunoprecipitated and ana-
lyzed with Western blot as described in the
supplementary data (Additional file 1). TRPA1 antibody
NB110-40763 (Novus Biologicals, LCC, Littleton, CO,
USA) was used as the primary antibody and goat anti-
rabbit HRP-conjugate (sc-2004, Santa Cruz Biotechnol-
ogy, Inc., Dallas, TX, USA) as the secondary antibody in
the Western blot analysis.
Immunoassay
Concentrations of IL-6, MMP-1, MMP-3, MMP-13 and
PGE2 in medium samples were determined by enzyme-
linked immunosorbent assay (ELISA) with commercial
reagents (PGE2: Cayman Chemical Co., Ann Arbor, MI,
USA; human IL-6: eBioscience Inc. San Diego, CA, USA;
MMP-1, MMP-3, MMP-13 and mouse IL-6: R&D Sys-
tems Europe Ltd).
RNA extraction and quantitative RT-PCR
At the indicated time points, total RNA was extracted
and analyzed by quantitative reverse transcription poly-
merase chain reaction (qRT-PCR) for the expression of
TRPA1 mRNA as described in the supplementary data
(Additional file 1).
Ca2+-influx measurements
TRPA1-mediated Ca2+ influx was measured in HEK293
cells [35] transfected with human TRPA1 plasmid, in
human T/C28a2 chondrocytes, and in primary human
OA chondrocytes as described previously [36]. Briefly,
the cells were loaded with 4 μM fluo-3-acetoxymethyl
ester (Fluo-3-AM, Millipore Sigma) and 0.08 % Pluronic
F-127® (Millipore Sigma in Hanks’ balanced salt solution
(HBSS, Lonza, Verviers, Belgium) containing 1 mg/ml of
bovine serum albumin, 2.5 mM probenecid and 25 mM
HEPES pH 7.2 (all from Millipore Sigma) for 30 min at
room temperature. The intracellular-free Ca2+ levels
were assessed by Victor3 1420 multilabel counter (Per-
kin Elmer, Waltham, MA, USA) at excitation/emission
wavelengths of 485/535 nm. In the experiments, the cells
were first preincubated with the TRPA1 antagonist HC-
030031 (100 μM, Millipore Sigma) or the vehicle for
30 min at +37 °C. Thereafter, the TRPA1 agonist allyl
isothiocyanate (AITC, 50 μM, Millipore Sigma) was
added and the measurements were continued for 30 s
after which a robust Ca2+ influx was induced by applica-
tion of the control ionophore compound ionomycin
(1 μM, Millipore Sigma).
Statistical analysis
Data were analyzed using Graph-Pad InStat version 3.00
software (GraphPad Software, San Diego, CA, USA).
The results are presented as mean + standard error of
the mean (SEM) unless otherwise indicated. Unpaired t
test, paired t test, one-way analysis of variance (ANOVA)
or repeated-measures ANOVA, followed by Dunnett’s
test were used in the statistical analysis. Differences were
considered significant at p < 0.05, p < 0.01, and p < 0.001.
Results
TRPA1 is expressed in primary human OA chondrocytes
and in immortalized human T/C28a2 chondrocyte cell line
Primary human OA chondrocytes and immortalized hu-
man T/C28a2 chondrocyte cell line expressed TRPA1.
The expression was measured by quantitative RT-PCR
on isolated total mRNA using a specific TaqMan assay.
The proinflammatory cytokine IL-1β was found to in-
crease TRPA1 expression in a time-dependent manner:
in primary chondrocytes the expression of TRPA1 in-
creased up to 48 hours and declined thereafter (Fig. 1a),
whereas in the human T/C28a2 chondrocytes the ex-
pression maximum was at 6 hours (Fig. 1b). In addition,
TRPA1 expression was also enhanced by inflammatory
factors IL-17, LPS, and resistin (Fig. 2).
To verify the translation of TRPA1 mRNA into pro-
tein, we extracted total protein from primary human OA
chondrocytes and human T/C28a2 chondrocytes and
performed Western blot analysis. HEK293 cells transi-
ently transfected with TRPA1 plasmid were used as posi-
tive control and the protein was detected with a specific
human TRPA1 antibody. Remarkably, both cell types
were found to express TRPA1 protein as seen in Fig. 3.
Human chondrocytes express a functional TRPA1 channel
To confirm that TRPA1 mRNA and the subsequent pro-
tein expressed by human chondrocytes produces a func-
tional channel, Ca2+-influx measurements were carried
out. Primary human chondrocytes and T/C28a2 chon-
drocytes were cultured with IL-1β, which was found to
stimulate TRPA1 expression, or with its vehicle for 24 h,
and thereafter TRPA1 was activated with the TRPA1
agonist AITC. IL-1β stimulation resulted in an increased
responsiveness to AITC as seen as an enhanced Ca2+ in-
flux, and the selective TRPA1 antagonist HC-030031
was shown to prevent this effect (Fig. 4).
MMP, IL-6 and PGE2 production is downregulated by gen-
etic depletion and pharmacological inhibition of TRPA1
After finding that functional TRPA1 was indeed
expressed in chondrocytes, we aimed to further examine
the possible arthritogenic role of the TRPA1 channel.
We investigated the effect of genetic depletion of TRPA1
on the production of OA-related factors MMP-3, IL-6,
and PGE2 by using articular cartilage samples from
TRPA1-deficient (knockout, KO) and corresponding
wild-type (WT) mice. IL-1β treatment increased MMP-
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3, IL-6, and PGE2 production in cartilage as expected.
Remarkably, this response was significantly attenuated in
the cartilage from the TRPA1 KO mice as compared to
the corresponding WT mice (Fig. 5). Further, we treated
primary human chondrocytes with IL-1β alone and to-
gether with the selective TRPA1 antagonist HC-030031
for 24 h. Interestingly, the selective TRPA1 antagonist
HC-030031 downregulated IL-1β-enhanced MMP-1,
MMP-3, MMP-13, IL-6, and PGE2 production by 25–
45 % (Fig. 6), suggesting that TRPA1 plays a role in the
upregulation of these catabolic and inflammatory factors
in OA cartilage.
Discussion
The findings of the present study suggest a hitherto un-
known role for TRPA1 in the pathogenesis of OA. We
have shown for the first time the expression of the
TRPA1 channel in primary human OA chondrocytes
and in the human T/C28a2 chondrocyte cell line. We
showed the expression of TRPA1 mRNA and protein by
Fig. 1 Primary human OA chondrocytes (a) and human T/C28a2 chondrocyte cell line (b) express TRPA1 mRNA and its expression is enhanced by IL-1 in
a time-dependent manner. Cultures of primary human OA chondrocytes (a) and human T/C28a2 chondrocytes (b) were stimulated with IL-1β (100 pg/ml)
for 0–96 h and 0–24 h, respectively, and thereafter total RNA was extracted. TRPA1 mRNA levels were measured by qRT-PCR, and the results were
normalized against GAPDH mRNA. The mRNA levels are expressed as arbitrary units with the levels measured at 24 h (a; primary OA chondrocytes) or 6 h
(b; T/C28a2 chondrocytes) set as 100 %; and the values at the other time points are related to those values. Primary chondrocyte samples were obtained
from three to five different donors and the experiments were carried out in duplicate. Human T/C28a2 chondrocyte experiments were carried out in
quadruplicate. Results are expressed as mean + SEM. One-way ANOVA followed by Dunnett’s post-test was used in the statistical analysis; **indicates
p< 0.01 compared to the control (0 h) sample. OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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qRT-PCR and Western blot, respectively. We were also
able to show that the expressed TRPA1 was functional,
as evidenced by Ca2+-influx measurements. Further, we
found TRPA1 to have a role in mediating the production
of OA-related factors MMP-1, MMP-3, MMP-13, IL-6,
and PGE2 as evidenced by pharmacological inhibition
and genetic depletion of TRPA1.
TRPA1 was first discovered in 1999 in fetal lung fibro-
blasts [6]. Since then it has been mainly studied in differ-
ent afferent sensory neurons such as Aδ and C fibers of
- - -
--
--
-
-
-
-
-
-
-
-
-
- -
-
Fig. 2 TRPA1 mRNA expression is increased following stimulation with inflammatory factors IL-1β, IL-17, LPS, and resistin in primary human OA
chondrocytes (a-d) and in human T/C28a2 chondrocyte cell line (e). Isolated primary human OA chondrocytes were stimulated with IL-1β (1–100 pg/
ml) (a), IL-17 (10–100 ng/ml) (b), LPS (10 ng/ml) (c). and resistin (0.3–3 μg/ml) (d); and human T/C28a2 chondrocytes with IL-1β (1–100 pg/ml), IL-17
(100 ng/ml) and LPS (10 ng/ml) (e) for 24 h; and thereafter total RNA was extracted. TRPA1 mRNA levels were measured by qRT-PCR, and the results
were normalized against GAPDH mRNA levels. The results are expressed as a percentage in comparison to untreated control samples, which was set
as 100 %. Primary chondrocyte samples were obtained from four different donors and the experiments were performed in duplicate. Human T/C28a2
chondrocyte experiments were carried out in quadruplicate. Results are expressed as mean + SEM. Repeated measures ANOVA (a, b, d) and one-way
ANOVA (e) followed by Dunnett’s post-test or paired t test (c) was used in the statistical analysis; *p < 0.05 and **p < 0.01, compared to the untreated
control samples. IL interleukin, LPS lipopolysaccharide, OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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nociceptors [7, 8]. More recently, however, TRPA1 has
also been found to be expressed in some nonneuronal
cells such as keratinocytes [11, 37, 38], synoviocytes [12,
39] and airway epithelial and smooth muscle cells [30].
It is noteworthy, that not all of these studies have shown
functionality of the TRPA1 ion channel and some have
only reported the expression of TRPA1 at the mRNA
level. In the present study, we have comprehensively
shown the expression and activation of TRPA1 in hu-
man chondrocytes, to support the criteria set by Fer-
nandes et al. [40]. We were able to show for the first
time the expression of both TRPA1 mRNA and protein
and the functionality of the TRPA1 channel in primary
human OA chondrocytes and in human T/C28a2 chon-
drocyte cell line. This finding is particularly interesting
as in OA joints there is a hypoxic [31] and inflammatory
[28, 41] state and related factors, H2O2, NO, and IL-6,
have previously been shown to upregulate the expression
and activation of TRPA1 [12–14]. According to Hatano
et al. [12] the human TRPA1 promoter has at least six
putative nuclear factor kappa B (NF-kB) binding sites
and ten core hypoxia response elements (HREs), which
are binding sites for hypoxia-inducible factor (HIF) tran-
scription factors. HIFs are known to mediate adaptive
responses to hypoxia as well as to be activated by in-
flammation [42, 43] and the binding of HIFs to consen-
sus HREs on their target genes regulates gene
transcription.
After discovering TRPA1 expression in chondrocytes,
we aimed to investigate whether inflammatory factors/
mechanisms related to the pathogenesis of OA [28, 29]
regulate expression of TRPA1, which would indicate a
role for TRPA1 as a mediator in OA. IL-1β is considered
as a major player in OA associated with cartilage de-
struction. IL-1β is elevated in OA joints and it sup-
presses type II collagen and aggrecan expression,
stimulates the release of MMP-1, MMP-3, and MMP-13,
and induces the production of IL-6 and some other cy-
tokines as well as PGE2 [28]. In part IL-17 feeds forward
these mechanisms as it further induces IL-1β, TNF, and
IL-6 production, upregulates NO and MMPs and down-
regulates proteoglycan levels related to the pathogenesis
of OA [28]. Based on our results, IL-1β and IL-17 both
also induce TPRA1 expression and intriguingly, some of
the IL-1β-induced inflammatory and catabolic effects are
partly mediated by TRPA1. In OA the innate immune
system and in particular toll-like receptors (TLRs) acti-
vated by cartilage matrix degradation products, also play
a significant part in disease progression. Chondrocytes
express TLRs, which trigger major inflammatory path-
ways and are activated by bacterial lipopolysaccharide
(LPS) and damage-associated molecular patterns [29],
and also the adipocytokine resistin known to be
expressed in OA joints [44] has been shown to trans-
duce its effects through toll-like receptor 4 [45]. In the
present study, we found that both LPS and resistin in-
creased expression of TRPA1 in human chondrocytes,
suggesting a TLR-mediated mechanism to enhance
TRPA1 expression in OA cartilage. In support of the
present results, Hatano et al. showed that TRPA1 gene
expression was enhanced in synoviocytes by inflamma-
tory factors TNF-α and IL-1 [12], and the present study
together with that of Hatano et al. [12] suggests a previ-
ously unrecognized mechanism that links TRPA1 as an
inducible factor to joint inflammation.
Activation of TRPA1 results in a substantial influx of
Ca2+ into the stimulated cells [46]. Here we verified the
functionality and activation of the TRPA1 channel in hu-
man chondrocytes by measuring Ca2+ influx using the
TRPA1 agonist AITC as well as the TRPA1 antagonist
HC-030031. As shown previously, elevated intracellular
Ca2+ concentration may affect the expression of inflam-
matory genes both in a direct or indirect manner [20].
In the present study, we found that TRPA1 regulated the
production of inflammatory and catabolic factors,
namely MMP enzymes, IL-6, and PGE2 in chondrocytes.
IL-1-induced MMP-3, IL-6, and PGE2 production in the
cartilage from TRPA1-deficient mice was less than half
β β
Fig. 3 TRPA1 protein is expressed in primary human OA chondrocytes and human T/C28a2 chondrocyte cell line. Chondrocyte cultures were
stimulated with IL-1β (100 pg/ml) for 24 h. Extracted proteins were immunoprecipitated and TRPA1 was detected with Western blot analysis. HEK293
cells transiently transfected with human TRPA1 plasmid were used as a positive control. Representative blot of three independent experiments with
similar results. IL interleukin, TRPA1 transient receptor potential ankyrin 1
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of that found in the cartilage from wild-type mice. Ac-
cordingly, the selective TRPA1 antagonist HC-030031
reduced IL-1-induced MMP-1, MMP-3, MMP-13, IL-6,
and PGE2 production by 25–45 % in primary human
OA chondrocytes. In the latter experiment, the cells
were incubated in the presence of IL-1 and HC-030031
for 24 h; therefore the result may be an underestimate of
the effect of total inhibition of TRPA1 in OA chondro-
cytes because HC-030031 is a reversible TRPA1 antag-
onist with a relatively short half-life [47]. These findings
Fig. 4 The TRPA1 ion channel is functional in primary human OA chondrocytes (a, b) and human T/C28a2 chondrocyte cell line (c) as shown by
TRPA1-mediated Ca2+ influx. Primary human chondrocytes (a, b) and human T/C28a2 chondrocytes (c) were cultured with or without (control)
IL-1β (100 pg/ml) for 24 h. HEK293 cells transfected with plasmids encoding human TRPA1 were used as positive control cells (d). The cells were
loaded with Fluo-3-AM and the TRPA1-mediated Ca2+ influx was measured by Victor3 multilabel counter at excitation/emission wavelengths of
485/535 nm at 1/s frequency. The cells were first preincubated with the TRPA1 antagonist HC-030031 (100 μM) or the vehicle for 30 min at +37 °
C. In the measurements, basal fluorescence was first recorded for 15 s and thereafter the selective TRPA1 agonist allyl isothiocyanate (AITC;
50 μM) was added and the measurement was continued for 30 s after which the control ionophore compound ionomycin (1 μM) was introduced
to the cells. IL-1β stimulation resulted in an elevation in AITC-induced Ca2+ influx compared to unstimulated control cells, and it was attenuated
by the selective TRPA1 antagonist HC-030031. The results were normalized against the background and expressed as mean of eight simultaneous
measurements. Curves in A, C and D express results from one representative experiment. In (b) area under the curve (AUC) from 15 to 45 s was
calculated from measurements of primary chondrocyte from four donors (each with eight repeats). Results are expressed as mean + SEM.
Repeated measures ANOVA followed by Dunnett’s post-test was used in the statistical analysis; **p < 0.01 compared to the IL-1β-treated samples.
IL interleukin, OA osteoarthritis, TRPA1 transient receptor potential ankyrin 1
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are supported by previous studies indicating that TRPA1
activation regulates the production of IL-1 in keratinocytes
[38], IL-6 and IL-8 in synoviocytes [12], and PGE2 along
with leukotriene B4 in fibroblasts and keratinocytes [48].
We have recently found that TRPA1 also regulates the ex-
pression of cyclooxygenase-2 (COX-2) [21, 27] and the pro-
duction of monocyte chemotactic protein-1 (MCP-1), IL-6,
IL-1β, myeloperoxidase (MPO), MIP-1α and MIP-2 in in-
flammatory conditions [26]. The detailed molecular mecha-
nisms of this regulation remain, however, to be studied.
TRPA1 is shown to be involved in pain, hyperalgesia, and
neurogenic inflammation [10, 16, 49, 50]. In OA-related
pain, the role of TRPA1 has been investigated in studies by
Moilanen et al. [27] McGaraughty et al. [51] and Okun et
al. [52] using the MIA-model of OA. The two first-
mentioned studies [27, 51] concluded TRPA1 to contribute
to joint pain in experimental OA. In addition, Moilanen et
al. [27] reported that TRPA1-deficient mice developed less
severe cartilage changes following MIA injections. Accord-
ingly, we showed here that TRPA1 is functionally expressed
in chondrocytes. We also examined the possible functions
of the channel by treating primary chondrocyte cultures
with IL-1β and the selective antagonist HC-030031 [2, 53,
54]. Our results suggest an inflammatory and catabolic role
for TRPA1 in human chondrocytes, as we found inhibition
of TRPA1 to suppress the production of OA-related factors
MMP-1, MMP-3, MMP-13, IL-6, and PGE2. These results
were supported by experiments with cartilage from WT
and TRPA1-deficient mice: following stimulation with IL-
1β MMP-3, IL-6, and PGE2 production was lower in the
cartilage from TRPA1-deficient mice than from WT ani-
mals. These results together suggest that TRPA1-activating
Fig. 5 IL-1β-induced production of MMP-3 (a), IL-6 (b), and PGE2 (c) in the cartilage is attenuated by genetic depletion of TRPA1. Cartilage samples
were obtained from TRPA1-deficient (knockout, KO) and corresponding wild-type (WT) mice. The samples were cultured with and without IL-1β
(100 pg/ml) for 42 h and thereafter the culture medium was collected and analyzed for concentrations of MMP-3, IL-6, and PGE2 by immunoassay. The
results are expressed as mean + SEM, n = 6–9. Unpaired t test was used in the statistical analysis; *p < 0.05, **p < 0.01, and ***p < 0.001 compared to the
WT mice. IL interleukin, MMP matrix metalloproteinase, PGE2 prostaglandin E2, TRPA1 transient receptor potential ankyrin 1
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factors are present in OA joints, and that TRPA1 mediates,
at least partly, OA-related pain, inflammation, and cartilage
destruction in neuronal and nonneuronal cells in the joint.
Conclusions
In conclusion, we found the TRPA1 cation channel to be
functionally expressed in primary human OA chondrocytes
and in part to mediate inflammatory and catabolic effects,
which are both original findings. The inflammatory and hyp-
oxic environment in the OA joint is conducive to enhance
the expression and activation of TRPA1. The presence and
effects of TRPA1 in human OA cartilage as found in the
present study, together with the previous findings on TRPA1
in experimentally induced OA [27, 51] propose an intriguing
role for TRPA1 as a mediator and drug target in OA.
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Transient receptor potential ankyrin 1 
(TRPA1) is a ligand-gated membrane-bound 
cation channel. TRPA1 has been largely 
studied in neurons, where it mediates pain 
and neurogenic inflammation and acts 
as a chemosensor for harmful exogenous 
compounds.1 2 More recently, TRPA1 has 
been found to be activated also by endoge-
nous compounds formed in inflammatory 
conditions characteristic to arthritis, such as 
reactive oxygen and nitrogen species.3
We have recently discovered that TRPA1 
is functionally expressed in primary human 
osteoarthritic chondrocytes,4 where it 
upregulated the production of mediators 
related to arthritis: interleukin (IL)-6, pros-
taglandin E2 and matrix metalloproteinases 
1, 3 and 13.4 Furthermore, we showed in 
monosodium iodoacetate-induced experi-
mental arthritis that TRPA1 activation medi-
ates inflammation, cartilage degradation 
and pain.5 TRPA1 thus emerges as a novel 
factor associated with arthritis. Therefore, 
we investigated the effects of disease-mod-
ifying antirheumatic drugs methotrexate, 
sulfasalazine, hydroxychloroquine and 
aurothiomalate, glucocorticoid dexameth-
asone and non-steroidal anti-inflammatory 
drug ibuprofen on the expression of TRPA1 
in human chondrocytes.
Human T/C28a2 chondrocytes6 were 
cultured with the aforementioned drugs, 
along with IL-1β, which was recently found 
to upregulate TRPA1 expression in chon-
drocytes.4 Dexamethasone and aurothioma-
late inhibited TRPA1 mRNA expression in a 
dose-dependent manner (figure 1A), while 
methotrexate (10 μM), sulfasalazine (10 μM), 
hydroxychloroquine (10 μM) and ibuprofen 
(10 μM) had no effect. Dexamethasone 
and aurothiomalate also decreased TRPA1 
protein levels (figure 1C).
Next, we examined if the observed drug 
effects on TRPA1 expression levels are func-
tional, that is, if they are translated to changes 
in TRPA1-mediated calcium influx. In chon-
drocytes, which had been cultured in the 
presence of IL-1β, TRPA1-mediated calcium 
influx was increased; while that effect was 
reversed in cells which had been cultured with 
a combination of IL-1β and dexamethasone 
or aurothiomalate (figure 1D,E), confirming 
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Key messages
What is already known about this subject?
 ? Transient receptor potential ankyrin 1 (TRPA1) is 
a membrane-associated cation channel primarily 
studied in sensory neurons, where it acts as a 
chemosensor of pungent compounds and mediates 
pain.
 ? TRPA1 has recently emerged as a potential factor/
mediator in arthritis; we have shown TRPA1 to 
mediate inflammatory and catabolic responses 
in primary human chondrocytes, as well as 
cartilage degradation, inflammation and pain in an 
experimental model of arthritis.
What does this study add?
 ? This study shows that anti-inflammatory drugs 
dexamethasone and aurothiomalate downregulate 
the expression of functional TRPA1 in human 
chondrocytes.
How might this impact on clinical practice?
 ? These results show a previously unknown 
mechanism of action for dexamethasone and 
aurothiomalate via downregulation of TRPA1, and 
thus provides a novel concept for the development 
of drugs for arthritis with analgesic and disease 
modifying properties.
2 Nummenmaa E, et al. RMD Open 2017;3:e000556. doi:10.1136/rmdopen-2017-000556
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Figure 1 Dexamethasone and aurothiomalate inhibit TRPA1 expression in human chondrocytes. Human chondrocytes 
(primary human chondrocytes or T/C28a2 chondrocyte cell line) were cultured with IL-1β alone or in combination with the anti-
inflammatory compound dexamethasone or aurothiomalate, or with the selective NF-κB inhibitor PDTC at concentrations given 
in the figure. (A, B) For TRPA1 mRNA expression analysis, human T/C28a2 chondrocytes (A) were incubated for 6 hours and 
the experiments were carried out in quadruplicate; primary chondrocytes (B) were incubated for 24 hours and the experiments 
were carried out in duplicate and repeated with cells from six donor patients. Total RNA was extracted and TRPA1 mRNA 
levels were measured by quantitative RT-PCR (TaqMan Gene Expression Assay for human TRPA1, Hs00175798_m1), and the 
results were normalised against GAPDH mRNA levels. (C) For TRPA1 protein analysis human T/C28a2 chondrocytes were 
incubated for 24 hours after which proteins were extracted and immunoprecipitated with TRPA1 antibody (SAB2105082, 
Sigma-Aldrich), and TRPA1 was detected with Western blot (with primary antibody: NB110-40763, NovusBiologicals). The 
figure shows one representative blot of six independent experiments with similar results. (D, E) For Ca2+ influx analysis human 
T/C28a2 chondrocytes were incubated with IL-1β alone or in combination with dexamethasone or aurothiomalate for 24 hours. 
Thereafter, the cells were loaded with Fluo-3-AM and the TRPA1-mediated Ca2+ influx was measured by Victor3 multilabel 
counter at excitation/emission wavelengths of 485/535 nm at 1/s frequency. In the measurements, basal fluorescence was 
first recorded for 15 s and thereafter the selective TRPA1 agonist AITC was added and the measurements were continued 
for 30 s. The results were normalised against the background and expressed as a mean of eight measurements. In (E), AUC 
from 15 to 45 s was calculated. Results are expressed as mean+SEM, results in (A–C) are expressed as a percentage in 
comparison to IL-1β-treated samples which were set as 100%. Statistical significance of the results was calculated with 
one-way or repeated measures ANOVA followed by Bonferroni post-test. Data were analysed using GraphPad InStat V.3.0. 
***p<0.001. AITC, allyl isothiocyanate; ANOVA, analysis of variance; AUC, area under the curve; GAPDH, glyceraldehyde-
3-phosphate dehydrogenase; IL, interleukin; NF-κB, nuclear factor kappa B; OA, osteoarthritic; PDTC, ammonium
pyrrolidinedithiocarbamate; RT-PCR, reverse transcription PCR; TRPA1, transient receptor potential ankyrin 1.
3Nummenmaa E, et al. RMD Open 2017;3:e000556. doi:10.1136/rmdopen-2017-000556
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the functional downregulation of TRPA1 expression by 
these two drugs.
To confirm the effects of dexamethasone and 
aurothiomalate in primary human chondrocytes, cells 
were isolated from cartilage samples obtained from joint 
replacement surgery and cultured as described previ-
ously.4 Dexamethasone and aurothiomalate downreg-
ulated IL-1β-induced TRPA1 expression also in these 
primary chondrocytes (figure 1B).
The current results show for the first time that two 
anti-inflammatory drugs which are effective in the 
treatment of arthritis and retard cartilage degradation, 
namely dexamethasone and aurothiomalate, down-
regulate the expression of TRPA1 in human chondro-
cytes. Notably, inhibition of the transcription factor 
nuclear factor kappa B (NF-κB) also downregulated 
TRPA1 expression (figure 1A,B). Accordingly, Hatano 
et al7 reported recently that the TRPA1 promoter has at 
least six putative NF-κB binding sites; they also showed 
NF-κB to be involved in the induction of TRPA1 in synov-
iocytes. Glucocorticoids8 as well as aurothiomalate9 have 
been shown to inhibit NF-κB activation. Therefore, the 
downregulation of TRPA1 expression by these drugs may 
occur, at least in part, via inhibition of NF-κB.
The present findings, together with previous results,4 5 7 
strongly suggest TRPA1 as a novel factor and drug target 
in arthritis.
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Abstract  
Objectives: FGF-2 belongs to the family of fibroblast growth factors and is found in the synovial 
fluid from patients with osteoarthritis (OA). The purpose of the present study was to investigate the 
effects of FGF-2 on human OA cartilage/chondrocytes by assessing the associations of FGF-2 with 
cartilage degrading enzymes MMP-1 and MMP-13 and the major cartilage matrix components 
aggrecan and collagen II.  
Methods: Cartilage samples were obtained from 97 OA patients undergoing total knee replacement 
surgery. Cartilage tissue cultures were conducted and levels of FGF-2, MMP-1 and MMP-13 released 
into the culture medium were measured by immunoassay. The effects of FGF-2 on the expression of 
MMP-1, MMP-13, aggrecan and collagen II were further investigated in cultures of primary human 
OA chondrocytes.  
Results: FGF-2, MMP-1 and MMP-13 were released into the culture medium from cartilage samples 
obtained from patients with OA. FGF-2 concentrations correlated positively with the concentrations 
of MMP-1 (r=0.414, p<0.001) and MMP-13 (r=0.362, p<0.001). FGF-2 also up-regulated the 
production of MMP-1 and MMP-13, and down-regulated the expression of aggrecan and collagen II, 
in human OA chondrocyte cultures. Further, FGF receptor antagonists AZD4547 and NVP-BGJ398 
down-regulated the expression of MMP-1 and MMP-13 and up-regulated aggrecan and collagen II 
both in the absence and in the presence of exogenous FGF-2.  
Conclusions: The present results suggest that, in contrast to its growth factor like effects in some 
other tissues, FGF-2 induces catabolic effects in human OA cartilage. Moreover, FGF-receptor 
antagonists showed promising beneficial effects on the balance of catabolic and anabolic factors 
within OA cartilage. 
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Introduction 
The fibroblast growth factor (FGF) family represents an interesting group of molecules that are 
involved in the regulation of connective tissue development and metabolism. Recently, two members 
of the FGF family, FGF-2 and FGF-18, have been suggested to have a regulatory role also in cartilage 
(1). According to literature, these effects are mediated primarily through receptors FGFR1 and 
FGFR3 (2). Activation of FGFR3 induces cartilage matrix synthesis (3). FGF-18 is regarded as an 
anabolic growth factor which signals primarily through FGFR3 and has a role in articular cartilage 
repair and chondrogenesis (3-5). The effects of recombinant FGF-18, sprifermin, on the progression 
of osteoarthritis (OA) have been investigated in a Phase II clinical trial and the results were recently 
published (6). Interestingly, sprifermin treatment had a dose dependent reducing effect on the loss of 
total and lateral femorotibial cartilage thickness and volume and joint space narrowing in the lateral 
femorotibial compartment (which were secondary end points in the study). In contrast, FGF-2 has 
been suggested to signal also through FGFR1 and the role of FGF-2 in cartilage metabolism is 
controversial. Some studies have indicated a catabolic or anti-anabolic role (7-11), while others have 
reported chondroprotective effects (12-15).  
OA is the most common joint disease worldwide. It is a slowly progressing inflammatory disease of 
the joints, which involves cartilage degradation, synovial inflammation and subchondral bone 
remodeling (16,17). Cartilage degradation, which is the hallmark of pathogenesis in OA, is caused 
by an imbalance between the production of catabolic and anabolic mediators within the joint. This 
imbalance increases as OA progresses and degradation exceeds regeneration, shifting the balance 
towards catabolism. Currently OA remains an incurable disease with an unmet need for disease 
modifying OA drugs (DMOADs), which could enable the prevention, retardation or repair of cartilage 
destruction. 
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When the OA process has reached the catabolic phase, the production of matrix degrading enzymes 
is increased and the de novo production of extracellular matrix components, such as aggrecan and 
collagen II, is decreased (17). MMP-1 (collagenase 1) and MMP-13 (collagenase 3) are enzymes that 
efficiently degrade collagen II, which is the main collagen component in articular cartilage. These 
MMPs are secreted in response to different stimuli, such as cytokines and growth factors from 
arthritic joints (18). Recently, MMP-13 has gained special attention as a cartilage matrix degrading 
enzyme and is thought to be the main collagen degrading enzyme in OA. Both MMP-1 and MMP-13 
are present in normal and OA cartilage and the expression of MMP-13 has been shown to be 
significantly increased in late stage human OA chondrocytes (19,20). 
In OA patients FGF-2 is found in the synovial fluid (9,21) and the expression of its type 1 receptor is 
up-regulated. FGF-2 may therefore expedite the progression of OA as FGFR1 mediates catabolic 
responses (11). That assumption is supported by studies in fgfr1 KO animals (22). We hypothesized 
that despite having growth factor like functions in some other cell types and animal models (13,15), 
in human OA chondrocytes FGF-2 may function as a catabolic mediator and a potential drug target. 
The objective of the current study was to test the hypothesis by investigating the effects of FGF-2 and 
FGF receptor antagonists on the expression of catabolic enzymes MMP-1 and MMP-13, and the 
cartilage matrix components aggrecan and collagen II in human OA chondrocytes.  
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Materials and Methods  
Patients and clinical studies 
The patients in this study fulfilled the American College of Rheumatology classification criteria for 
OA (23). The clinical studies were performed as previously described by Koskinen et al. (24). In 
brief, cartilage tissue samples were collected from 97 patients (60 females and 37 males, body mass 
index (BMI) 30.9 ± 0.6 kg/m2, age 69.8 ± 1.0 years; mean ± SEM) with OA undergoing total knee 
replacement surgery at Coxa Hospital for Joint Replacement, Tampere, Finland. Cartilage samples 
were processed as described below, and the amounts of FGF-2, MMP-1 and MMP-13 released by the 
cartilage ex vivo during a 42-hour incubation were measured as described below. The study was 
approved by the Ethics Committee of Tampere University Hospital, Tampere, Finland, and carried 
out in accordance with the Declaration of Helsinki. Written informed consent was obtained from the 
patients. 
 
Cartilage cultures 
Cartilage cultures were carried out as previously described by Koskinen et al. (25). Leftover pieces 
of OA cartilage from knee joint replacement surgery were used. Full-thickness pieces of articular 
cartilage from femoral condyles, tibial plateaus and patellar surfaces showing macroscopic features 
of early OA were removed aseptically from subchondral bone with a scalpel, cut into small pieces 
and cultured in DMEM with GIBCO GlutaMAX-I supplemented with penicillin (100 U/ml), 
streptomycin (100 ?g/ml) and amphotericin B (250 ng/ml) (all from Invitrogen/Life Technologies, 
Carlsbad, CA, USA) at 37°C in a humidified 5% carbon dioxide atmosphere. Cartilage samples were 
incubated for 42 hours. Thereafter, the culture media were collected and stored at -20°C until 
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analyzed; the cartilage explants were weighed and the results were expressed per 100 milligrams of 
cartilage. 
 
Primary chondrocyte experiments 
Primary chondrocyte experiments were carried out as previously described (25). The obtained 
cartilage was processed the same way as for cartilage cultures (see above). Pieces of cartilage were 
washed with PBS, and chondrocytes were isolated by enzymatic digestion for 16 hours at 37°C in a 
shaker by using a collagenase enzyme blend (1 mg/ml Liberase TM Research Grade medium; Roche, 
Mannheim, Germany). Isolated chondrocytes were washed and plated on 24-well plates (2.0 × 105 
cells/ml) in culture medium (DMEM U1, Lonza, Basel, Switzerland, supplemented with penicillin 
(100 U/ml), streptomycin (100 ?g/ml) and amphotericin B (250 ng/ml) all from Gibco/Life 
Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum. Before experiments the cells 
were subjected to serum starvation for 24 h. During the experiments the cells were treated with FGF-
2 (200 ng/ml recombinant human FGF-basic; Peprotech, NJ, USA) and IL-1? (100 pg/ml recombinant 
human IL-1?; R&D Systems Europe Ltd, Abingdon, UK) which was used as a control compound, 
for 24 hours. In FGFR antagonist experiments we used selective FGF receptor antagonists AZD4547 
and NVP-BGJ398 (26,27). AZD4547 targets FGFR1/2/3 with IC50 values of 0.2 nM/2.5 nM/1.8 nM 
and shows weaker activity against FGFR4 (IC50 of 165 nM) (26). NVP-BGJ398 inhibits FGFR1/2/3 
with IC50 values of 0.9 nM/1.4 nM/1 nM, respectively, and shows weaker activity against FGFR4 
(IC50 of 60 nM) (27). The cells were treated with increasing concentrations of AZD4547 or NVP-
BGJ398 (1-300 nM; both from Selleckchem, Munich, Germany) with and without exogenous FGF-2 
added into the culture medium (200 ng/ml) for 24 h. The cells were pre-treated with AZD4547 and 
NVP-BGJ398 for 1 h prior to the addition of FGF-2, and then further incubated for 24 h. 
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Concentrations of MMP-1 and MMP-13 in culture media were determined by immunoassay as 
described below. To investigate mRNA expression total RNA was extracted and quantitative reverse 
transcription PCR was carried out as described below. 
 
Immunoassay 
Concentrations of FGF-2, MMP-1 and MMP-13 in medium samples were determined by ELISA with 
commercial reagents (R&D Systems Europe Ltd, Abingdon, UK). 
 
 RNA extraction and quantitative RT-PCR 
RNA extraction and quantitative RT-PCR was performed as previously described (28). At the 
indicated time points, culture medium was collected and total RNA extraction was carried out with 
GenElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich, St. Louis, MO, USA). The amount 
of RNA was measured with a spectrophotometer. Total RNA was then reverse-transcribed to cDNA 
using TaqMan Reverse Transcription reagents and random hexamers (Applied Biosystems, Foster 
City, CA, USA) in 10 ?L reaction volume. After the transcription reaction, the obtained cDNA was 
diluted 1:20 with RNase-free water. Quantitative PCR was performed using TaqMan Universal PCR 
Master Mix and ABI Prism 7000 sequence detection system (Applied Biosystems, Foster City, CA, 
USA). The primer and probe sequences and concentrations were optimized according to the 
manufacturer’s guidelines in TaqMan® Universal PCR Master Mix Protocol part number 4304449 
revision C (Applied Biosystems, Foster City, CA, USA) and are listed in Table 1. The probes 
contained 6-FAM as 5´-reporter dye and TAMRA as 3´-quencher. Primers and probes were obtained 
from Metabion (Martinsried, Germany). TaqMan Gene Expression assays for human FGFR1 
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(Hs00915142_m1), human FGFR2 (Hs01552926_m1), human FGFR3 (Hs00179829_m1) and 
human FGFR4 (Hs01106908_m1) were purchased from Life Technologies (Life Technologies 
Europe BV, Bleiswijk, the Netherlands). PCR cycling parameters were: incubation at 50 ºC for 2 min, 
incubation at 95 ºC for 10 min, and thereafter 40 cycles of denaturation at 95 ºC for 15 s and annealing 
and extension at 60 ºC for 1 min. The relative mRNA levels were quantified using a standard curve 
method as described in the Applied Biosystems User Bulletin. For the TaqMan Gene Expression 
assays the ??Ct method was used. When calculating results, mRNA expression levels were first 
normalized against GAPDH mRNA levels. 
 
Statistical analysis 
Data were analyzed using SPSS version 20.0 for Windows software (SPSS Inc, Chicago, IL, USA) 
and Graph-Pad InStat version 3.00 software (GraphPad Software, San Diego, CA, USA). The results 
are presented as means + SEM unless otherwise indicated. The data were natural log (LN) 
transformed in order to obtain a normal distribution and Pearson’s correlation analysis was carried 
out, with r values over +0.3 and under -0.3 considered to indicate a correlation. Differences between 
groups were tested by one-way analysis of variance (ANOVA) or repeated-measures ANOVA, 
followed by Bonferroni correction for multiple comparisons when appropriate. Differences were 
considered significant at *p < 0.05, **p < 0.01 and ***p < 0.001. 
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Results 
The correlations between FGF-2 and MMP-1 and MMP-13 released from human OA 
cartilage  
Ninety-seven OA patients undergoing total knee replacement surgery were included in the study. 
Cartilage samples from these patients were cultured for 42 h and the concentrations of FGF-2, MMP-
1 and MMP-13 released from the cartilage were determined in the culture medium. OA cartilage 
released all of the measured factors: FGF-2 28.4 ± 1.5 pg/100mg cartilage, MMP-1 12.7 ± 1.4 
ng/100mg cartilage and MMP-13 1.0 ± 0.1 ng/100mg cartilage. Interestingly, the levels of released 
FGF-2 correlated positively with those of MMP-1 (r = 0.414, p < 0.001) and MMP-13 (r = 0.362, p 
< 0.001) (Fig. 1). 
 
The effects of FGF-2 on MMP-1, MMP-13, aggrecan and collagen II expression in human 
OA chondrocytes  
FGF-2 has been shown to signal through receptors FGFR1-4. To confirm that the OA chondrocytes 
expressed these receptors, we determined the mRNA levels of FGFR1-4. The chondrocytes expressed 
all of the receptors, with the expression of FGFR1 being highest and expression of FGFR4 being very 
low (Fig. 2).  
Human OA chondrocytes were cultured in the presence or absence of FGF-2 for 24 hours. The 
expression of MMP-1 and MMP-13 was increased when FGF-2 was added into the culture, compared 
to untreated control cells (Fig. 3). The expression of cartilage matrix components aggrecan and 
collagen II, on the other hand, was significantly reduced when FGF-2 was added into the culture (Fig. 
3). IL-1 was used as a control compound, and FGF-2 had qualitatively similar but smaller effects than 
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IL-1, which also increased the expression of MMP-1 and MMP-13 and decreased the expression of 
aggrecan and collagen II in human OA chondrocytes (Table 2). 
 
The effects of FGF receptor antagonists AZD4547 and NVP-BGJ398  
Human OA chondrocytes were treated with increasing concentrations of FGFR antagonists AZD4547 
and NVP-BGJ398 in the presence or absence of FGF-2 for 24 h. MMP-1 and MMP-13 protein levels 
in control samples following 24 h incubation were 221.5 ± 77.0 ng per 106 cells, n=5 and 11.0 ± 2.0 
ng per 106 cells, n=5 (Fig. 5), respectively. Both AZD4547 and NVP-BGJ398 decreased the 
production of catabolic factors MMP-1 and MMP-13 in a dose dependent manner (Fig. 4-5). This 
effect was observed at the mRNA (Fig. 4) and protein level (Fig. 5), and interestingly, in the presence 
and absence of exogenous FGF-2.  
Due to the interesting effects of these FGFR antagonists in chondrocytes also when exogenous FGF-
2 was not added into the culture, we decided to examine the FGF-2 production of these cells in 
primary human OA chondrocyte cultures. The cells released FGF-2 1.8 ± 1.0 ng per 106 cells, n=5, 
during 24 h incubation. 
Next, we investigated the effects of AZD4547 and NVP-BGJ398 on the expression of major 
extracellular matrix components aggrecan and collagen II. Both antagonists had a beneficial effect on 
the expression of these extracellular matrix components by up-regulating the production of aggrecan 
and collagen II in a dose dependent manner, in the presence and absence of exogenous FGF-2 (Fig. 
6). Taken together, the FGFR antagonists shifted the balance between catabolic and anabolic 
mediators towards anabolism, showing a beneficial effect on the metabolism of cartilage. 
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Discussion 
FGF-2 belongs to the family of fibroblast growth factors. In the present study we investigated the 
effects of FGF-2 and two commercially available FGFR antagonists on human OA cartilage and 
chondrocytes with the hypothesis that FGF-2 functions as a catabolic mediator and a potential drug 
target. The present results suggests that, in contrast to its growth factor role in some other tissues, 
FGF-2 induces catabolic effects in human OA cartilage and primary human OA chondrocytes by up-
regulating the production of collagenases MMP-1 and MMP-13 and down-regulating the expression 
of cartilage matrix components aggrecan and collagen II. 
Four FGF receptors have been described (29). We investigated the receptor expression profiles in OA 
chondrocytes used in this study and found the expression of FGFR1 to be the highest of the four 
receptors and significantly higher than that of FGFR3. Previously FGFR1 and FGFR3 have been 
found to be the most prominent FGF receptors in normal human articular cartilage (11). In cartilage, 
activation of FGFR1 has been reported to induce mainly catabolic effects (11), whereas activation of 
FGFR3 has been associated principally with anabolic effects (3). Further, FGFR1 expression has been 
reported to be increased and FGFR3 expression decreased in degenerative OA cartilage compared to 
healthy cartilage (9,11), supporting our present results on the receptor expression profiles in OA 
chondrocytes. Surprisingly, unlike in human OA cartilage, in murine knee articular cartilage FGFR2 
and 4 have been shown to be the most prominent receptors (15). In human OA cartilage the role of 
FGFR1 in mediating the effects of FGF-2 is supposed to be pronounced, because it is the most widely 
expressed FGF receptor especially in human OA cartilage, but not in murine cartilage. The 
predominant expression of FGFR2 and 4, and the up-regulation of FGFR3 in response to FGF-2 
treatment in murine articular cartilage may explain why FGF-2 has been reported to have anabolic 
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effects on murine cartilage (15). However at present the precise roles of FGFR2 and FGFR4 are not 
clearly understood. 
As the receptor expression profile in the primary human OA chondrocytes was shifted towards 
catabolic FGFR1, we wanted to explore if this had functional consequences in OA cartilage. The 
results showed that human OA cartilage released FGF-2, MMP-1 and MMP-13 into the culture 
medium at detectable levels. The levels of FGF-2 released from the cartilage samples correlated 
positively with levels of MMP-1 and MMP-13, suggesting a link between the production of FGF-2 
and these catabolic factors in articular cartilage. Next, we aimed to investigate the causality of these 
correlations in primary human OA chondrocyte cultures. FGF-2 up-regulated the production of matrix 
degrading enzymes MMP-1 and MMP-13 and at the same time down-regulated the expression of 
matrix components aggrecan and collagen II. FGF-2 was found to increase MMP-1 and MMP-13 
mRNA levels in chondrocytes and protein levels in the culture supernatant, measured by quantitative 
RT-PCR and immunoassay, respectively. The latter measures total MMP-1 and MMP-13 
concentrations but unfortunately does not distinguish between the pro-form and active protein. These 
findings of the effects of FGF-2 in chondrocyte cell cultures are supported by previous studies 
(7,9,10,30), but there are also contradictory findings indicating a chondroprotective role for FGF-2 in 
human articular cartilage explants (12) and KO mouse models (13-15). These contradicting results 
can be suggested to result from interspecies variation as FGF-2 seems to have species-specific 
functions (15). This does not, however, explain the differing results obtained from human cartilage 
explants (12). One possible explanation for these differing results is that the cartilage samples utilized 
by Sawaji et al. (12) were obtained from non-OA patients, with no initial macroscopic degradation of 
the cartilage. A likely mechanistic explanation for the discrepancies between FGF-2 results are 
different FGF receptor expression profiles between species, cell types and progression stages of OA 
(9,11,15) as discussed above.  
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Since in this study exogenous FGF-2 exerted catabolic and anti-anabolic effects in primary human 
OA chondrocytes, we decided to investigate whether these effects could be counteracted with FGF 
receptor antagonists. Recently described selective FGF receptor antagonists AZD4547 (26) and NVP-
BGJ398 (27) were used. Both compounds have been reported to antagonize FGF receptors 1-3 at 
nanomolar concentrations, with highest selectivity towards FGFR1 (26,27). As hypothesized, these 
antagonists counteracted the effects of FGF-2 in a dose-dependent manner resulting in decreased 
production of MMP-1 and MMP-13 and increased expression of aggrecan and collagen II in the 
presence of exogenous FGF-2. Interestingly, this effect was observed also in the absence of added 
exogenous FGF-2 suggesting that OA chondrocytes produce FGF-2 in amounts involved in the 
pathogenesis of cartilage degradation in OA joints. Therefore we measured the FGF-2 synthesis in 
OA chondrocytes and found the cells to produce FGF-2, and FGF-2 was also released from OA 
cartilage in tissue cultures. FGF-2 has previously been reported to be released also from healthy 
human articular cartilage, where it has been suggested to be sequestered within the extracellular 
matrix by the heparan sulfate proteoglycan perlecan (31). However, it has been unclear whether FGF-
2 is produced by cartilage, or is it produced by other tissues of the joints and diffused via synovial 
fluid into the cartilage. In the present study, we showed that primary chondrocytes from OA patients 
produced FGF-2 in monolayer cell cultures. This result is supported by the findings of Vincent et al. 
showing that porcine chondrocytes produce FGF-2 in alginate bead culture (31). Further, when we 
treated OA chondrocytes with FGFR antagonists the balance of catabolic and anabolic factors was 
beneficially shifted towards anabolism. Therefore, the use of FGFR/FGFR1 antagonists as disease 
modifying OA drugs (DMOADs) is an interesting prospect. This is also supported by recent studies 
with fgfr1 KO mouse models (22). However, as the present promising results are based on in vitro 
data they should be interpreted accordingly and further studies are needed to validate the clinical 
significance of these observations in the pathogenesis of OA. 
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FGF-18 has been shown to signal principally through FGFR3 leading to anabolic effects (3). The 
pharmaceutical company Merck Serono is investigating the effects of an intra-articular recombinant 
FGF-18 drug, sprifermin, on osteoarthritis progression in humans in a Phase II clinical trial and the 
first results were published recently (6). Sprifermin treatment showed dose dependent reductions in 
the loss of total and lateral femorotibial cartilage thickness and volume and joint space narrowing in 
the lateral femorotibial compartment, which was a secondary end point in the study. However, 
sprifermin showed no statistically significant dose response in the primary efficacy end point, which 
was a change in central medial femorotibial compartment cartilage thickness. Considering the 
predominant expression of FGF receptor type 1 in OA cartilage, and the catabolic and anti-anabolic 
functions of FGF-2 observed in the present and previous studies, it could also be beneficial to 
investigate the use of FGF-2 synthesis inhibitors or FGFR1/FGFR antagonists alone or the two former 
also in combination with FGF-18 as a novel drug approach in OA.  
Conclusions 
Currently, OA remains an incurable disease and there is a critical need to develop disease modifying 
drugs for OA (DMOADs) which could shift the balance of catabolic and anabolic responses to favor 
the latter, and enable the prevention, retardation or repair of cartilage destruction. In the present study, 
we found that FGF-2 produced catabolic effects in the OA cartilage. FGF-2 was released from OA 
cartilage in correlation to MMP-1 and MMP-13, and in chondrocyte cultures it enhanced the 
production of MMPs along with inhibitory effect on the de novo synthesis of cartilage matrix 
molecules aggrecan and collagen II. Further, FGF receptor antagonists reversed the catabolic and 
anti-anabolic effects of FGF-2 and, more importantly, had comparable beneficial effects also in the 
absence of exogenous FGF-2 in human OA chondrocytes. 
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FGF receptor antagonists showed a favorable effect on the balance of anabolic and catabolic factors 
produced by human OA chondrocytes supporting the idea that FGF receptor antagonists hold 
therapeutic potential in the treatment of osteoarthritis. 
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 Table 1. Primer and probe sequences and concentrations used in qPCR experiments 
MMP-1 
forward TTGAAGCTGCTTACGAATTTGC 900 nM 
reverse GAAGCCAAAGGAGCTGTAGATGTC 900 nM 
probe CAGAGATGAAGTCCGGTTTTTCAAAGGGA 250 nM 
MMP-13 
forward TGATCTCTTTTGGAATTAAGGAGCAT 300 nM 
reverse GGAACTACTTGTCCAGGTTTCATCAT 900 nM 
probe CCCTCTGGCCTGCTGGCTCATG 150 nM 
AGC1 
forward GCCTGCGCTCCAATGACT 300 nM 
reverse TAATGGAACACGATGCCTTTCA 300 nM 
probe CCATGCATCACCTCGCAGCGGTA 150 nM 
COL2A1 
forward GGCAATAGCAGGTTCACGTACA 50 nM 
reverse CGATAACAGTCTTGCCCCACTT 900 nM 
probe CTGAAGGATGGCTGCACGAAACATACC 150 nM 
GAPDH 
forward AAGGTCGGAGTCAACGGATTT 300 nM 
reverse GCAACAATATCCACTTTACCAGAGTTAA 300 nM 
probe CGCCTGGTCACCAGGGCTGC 150 nM 
MMP-1; matrix metalloproteinase 1, MMP-13; matrix metalloproteinase 13, AGC1; aggrecan 1, 
COL2A1 ; collagen II A1, GAPDH; glyceraldehyde 3-phosphate dehydrogenase 
 
Table 2. IL-1? stimulated the production of MMP-1, MMP-13, aggrecan and collagen II in primary 
human OA chondrocytes 
 MMP-1 MMP-13 Aggrecan Collagen II 
 mRNA protein mRNA protein mRNA mRNA 
control 100 100 100 100 100 100 
IL-1? 1042 ± 268 * 344 ± 92X 632 ± 103 ** 228 ± 32 * 62 ± 9 * 9 ± 1 *** 
 Primary human OA chondrocyte cultures were stimulated with IL-1? (100 pg/ml) for 24 h. MMP-1, 
MMP-13, aggrecan and collagen II mRNA expression was measured by quantitative RT-PCR and 
MMP-1 and MMP-13 production was detected by immunoassay. The mRNA expression levels were 
normalized against GAPDH mRNA levels. N=5 patients for protein production analysis (b, d) and 
n=10 patients for mRNA expression analysis (a, c, e, f). Results are represented as mean ± SEM. One-
way ANOVA was performed and statistical significance is indicated as xp=0.0573, *p < 0.05, **p < 
0.01 and ***p < 0.001. 
IL-1?; Interleukin 1?, MMP-1; matrix metalloproteinase 1, MMP-13; matrix metalloproteinase 13 
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Figure legends 
 
Figure 1. 
Levels of FGF-2 released by human OA cartilage correlated positively with the levels of MMP-1 (a) 
and MMP-13 (b). Cartilage explants from OA patients (n=97) undergoing joint replacement surgery 
were incubated for 42 h and the levels of FGF-2, MMP-1 and MMP-13 released into the culture 
medium were measured by immunoassay. Results are LN transformed to obtain a normal distribution 
and analyzed using Pearson correlation.   
Figure 2. 
FGF receptor expression profiles of primary human OA chondrocytes. Chondrocytes were cultured 
for 24 h and the mRNA expression of FGFR1-4 was detected by quantitative RT-PCR. The mRNA 
expression levels were calculated with the ??Ct method. Results from 3 patients were combined and 
the results are represented as mean + SEM. 
Figure 3. 
FGF-2 enhanced the production of MMP-1 (a, b) and MMP-13 (c, d) and down-regulated the 
expression of aggrecan (e) and collagen II (f) in primary human OA chondrocytes. Chondrocyte 
cultures were stimulated with FGF-2 (200 ng/ml) for 24 h. MMP, aggrecan and collagen II mRNA 
expression was detected by quantitative RT-PCR and MMP production was detected by 
immunoassay. The mRNA expression levels were normalized against GAPDH mRNA levels. Results 
from 5 patients were combined for protein production analysis (b, d) and 10 patients for mRNA 
expression analysis (a, c, e, f). Results are represented as mean + SEM. One-way ANOVA was 
performed and statistical significance is indicated as *p < 0.05, **p < 0.01 and ***p < 0.001.  
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Figure 4 
FGF-2 antagonists AZD4547 and NVP-BGJ398 down-regulated the expression of MMP-1 (a, b) and 
MMP-13 (c, d) in the presence and absence of exogenous FGF-2. Isolated primary human OA 
chondrocytes were treated with increasing concentrations of AZD4547 and BGJ398 (1 - 300 nM) in 
the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. MMP-1 and MMP-13 mRNA 
levels were measured by quantitative RT-PCR, and the results were normalized against GAPDH 
mRNA levels. Results from 2-3 patients were combined. Results are expressed as percentage in 
comparison to untreated control samples. Values are expressed as mean + SEM. Repeated measures 
ANOVA with Bonferroni’s post-test was performed and statistical significance is indicated as *p < 
0.05, **p < 0.01 and ***p < 0.001 compared to control or FGF-2 treated samples. 
Figure 5 
FGF-2 antagonists AZD4547 and NVP-BGJ398 down-regulated the production of MMP-1 (a, b) and 
MMP-13 (c, d) expression in the presence and absence of exogenous FGF-2. Isolated primary human 
OA chondrocytes were treated with increasing concentrations of AZD4547 and BGJ398 (1 - 300 nM) 
in the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. MMP-1 and MMP-13 protein 
levels in the culture media were measured by immunoassay. Results from 2-3 patients were 
combined. Results are expressed as percentage in comparison to untreated control samples. Values 
are expressed as mean + SEM. Repeated measures ANOVA with Bonferroni’s post-test was 
performed and statistical significance is indicated as *p < 0.05, **p < 0.01 and ***p < 0.001 compared 
to control or FGF-2 treated samples. 
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Figure 6 
FGF-2 antagonists AZD4547 and NVP-BGJ398 up-regulated the expression of aggrecan (a, b) and 
collagen II (c, d) expression in the presence and absence of exogenous FGF-2. Isolated primary 
human OA chondrocytes were treated with increasing concentrations of AZD4547 and BGJ398 (1 - 
300 nM) in the presence and absence of exogenous FGF-2 (200 ng/ml) for 24 h. Aggrecan and 
collagen II mRNA levels were measured by quantitative RT-PCR, and the results were normalized 
against GAPDH mRNA levels. Results from 3 patients were combined. Results are expressed as 
percentage in comparison to untreated control samples. Values are expressed as mean + SEM. 
Repeated measures ANOVA with Bonferroni’s post-test was performed and statistical significance 
is indicated as *p < 0.05, **p < 0.01 and ***p < 0.001 compared to control or FGF-2 treated samples. 
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